WO1995031459A1 - Morpholino-subunit combinatorial library and method - Google Patents

Morpholino-subunit combinatorial library and method Download PDF

Info

Publication number
WO1995031459A1
WO1995031459A1 PCT/US1995/006041 US9506041W WO9531459A1 WO 1995031459 A1 WO1995031459 A1 WO 1995031459A1 US 9506041 W US9506041 W US 9506041W WO 9531459 A1 WO9531459 A1 WO 9531459A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligomer
morpholino
subunit
library
oligomers
Prior art date
Application number
PCT/US1995/006041
Other languages
French (fr)
Inventor
James E. Summerton
Dwight D. Weller
Original Assignee
Antivirals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antivirals Inc. filed Critical Antivirals Inc.
Priority to AU24385/95A priority Critical patent/AU2438595A/en
Publication of WO1995031459A1 publication Critical patent/WO1995031459A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/02—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/682—Signal amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds

Definitions

  • the present invention relates to a combinatorial library formed by sequences of morpholino subunit struc ⁇ tures, and to a method of generating novel binding compounds using the library.
  • Ligands discovered by screening libraries of this type may be useful in mimicking or blocking natural ligands, or interfering with the naturally occurring interactions of a biological target. They can also provide a starting point for developing related molecules with more desirable properties, e.g., higher binding affinity.
  • Combinatorial libraries of the type useful in this general application may be formed by a variety of solution- phase or solid-phase methods in which mixtures of different subunits are added stepwise to growing oligomers, until a desired oligomer size is reached.
  • a library of increasing complexity can be formed in this manner, for example, by pooling multiple choices of reagents with each additional subunit step (Houghten, 1991; 1993c).
  • the library may be formed by solid- phase synthetic methods in which beads containing different-sequence oligomers that form the library are alternately mixed and separated, with one of a selected number of subunits being added to each group of separated beads at each step.
  • each bead contains only one oligomer specie, allowing the beads themselves to be used for oligomer screening (Furka, 1991; Lam, 1991, 1993; Zuckermann; Sebestyn) .
  • Still another approach that has been suggested involves the synthesis of a combinatorial library on spatially segregated arrays (Fodor) . This approach is generally limited in the number of different library sequences that can be generated. Since the chance of finding useful ligands increases with the size of the combinatorial library, it is desirable to generate libraries composed of large numbers of different-sequence oligomers.
  • oligonucleotides for example, a library having 4-base variability at 8 oligomer residue positions will contain as many as 4 8 (65,536) different sequences. In the case of a polypeptides, a library having 20-amino acid variability at six residue positions will contain as many as 20 6 (64,000,000) different species. Because each different-sequence specie in a large- number library may present in small amounts, one of the challenges in the combinatorial library selection procedure is isolating and determining the sequence of specie(s) that have the desired binding or other selected properties.
  • the combinatorial library consists of oligonucleotides
  • this problem may be solved by amplifying the isolated sequence, e.g., by polymerase chain reaction methods.
  • polymerase chain reaction methods In the case of polypeptide libraries, other methods must be employed.
  • the library has been formed by pooling multiple choices of reagents during synthesis, a pool which is shown to have desired properties is resynthesized iteratively with lower and lower complexity until a single sequence compound is identified.
  • each bead represents one oligomeric specie
  • the library sequences e.g., random peptide sequences
  • a sequenceable tag e.g., an oligonucleotide sequence
  • each oligomer in the library is associated with a distinctive sequenceable tag.
  • a related approach has been to construct combinatorial libraries on beads that are themselves tagged with distinctive tagging molecules at each successive step in oligomer synthesis. Once an oligomer with desired binding properties is identified, the bead to which the oligomer is attached can be "read” to identify the oligomer sequence in terms of a sequence of tagging molecules (Ohlmeyer) .
  • polypeptide libraries these also can be synthesized readily by known solution or solid-phase methods, and the possibility of 20 (or more) different side chains at each oligomer position greatly expands the potential variability of the library.
  • screened polypeptides may be relatively difficult to sequence at the low oligomer concentrations that are likely to be present.
  • polypeptide compounds may be susceptible to protease digestion in vivo.
  • a combinatorial library should be easy to synthesis by stepwise solution-phase or solid-phase methods, should allow for a large number of different subunits at each residue position, should provide a broad range of structural diversity, and should be readily sequenceable, once a library oligomer with desired binding or other screened property is identified, and should be generally stable in living systems.
  • the invention includes, in one aspect, a combinatorial library of non-biological oligomers formed predominantly of morpholino subunit structures of the form:
  • the oligomer bases in the library include a combination of nucleobase side chains, i.e., purines and/or pyrimidines, and non-nucleobase side chains, such as non-nucleobase aromatic side chains, aliphatic side chains, and mixed aromatic/aliphatic side chains.
  • the oligomers are effective to hybridize, by Watson-Crick base pairing, to one of the oligonucleotide oligomers in combinatorial library of random sequence oligonucleotides;
  • the oligomers in the library may also have different sequences of linkages, or be composed of the same linkages.
  • One preferred linkage is a 3-atom carba ate or 3-atom phosphorodiamidate linkage.
  • the oligomers may also include branched structures, in which one or more of the subunit structures forming an oligomer is linked to multiple subunits.
  • the oligomers in the library may be formed on a plurality of particles, such as macroporous particles, where each particle has a surface coating of molecules containing one of the base-sequences in the library.
  • the oligomer molecules are preferably attached to the particle through cleavable linkages, e.g., chemically or photolytically cleavable linkages.
  • the particles may be acroreticular particles having selected sizes in the 40- 200 ⁇ m range, where the oligomers are coupled to the particles through cleavable linkages.
  • the oligomer molecules on each particle may represent a family of different-length oligomers having a common sequence from one oligomer end, but different termination subunit structures at the opposite oligomer end.
  • the invention includes a method of generating an oligomer compound capable of interacting specifically with a selected macromolecular ligand.
  • the method includes contacting the receptor with a combinatorial library of oligomers of the type described above, isolating oligomer molecules that binds specifically to the receptor, and determining the sequence of bases in the isolated oligomer molecules.
  • the determining step includes reacting the isolated oligomers with a combinatorial library of oligonucleotides, under conditions effective to produce hybridization between the isolated oligomer molecules and complementary-base oligonucleotides, and determining the sequence of the oligonucleotides hybridized to the isolated oligomer molecules.
  • the particle containing the desired binding molecules is isolated, e.g., by binding to a solid support, and oligomers on the particles are then sequenced, e.g., by release of the oligomers and micro mass spectrometry of the released oligomers.
  • particle(s) having surface-bound receptor may be identified by reacting the particles with fluorescent-labeled anti-receptor antibodies, or by exploiting the greater density of the particles with surface-bound receptor.
  • a polymer composition assembled predominantly of morpholino subunit structures of the form:
  • the invention includes polymer composition assembled predominantly from morpholino subunit structures of the form:
  • Fig. 1 shows a subunit of an oligomer formed of morpholino subunit structures joined by linkages L;
  • Fig. 2 shows a morpholino subunit structure used in the Fig. 1 oligomer
  • Fig. 3 illustrates the conversion of a ribonucleotide to a morpholino subunit structure
  • Fig. 4 shows the conversion of glucose to a morpholino subunit structure
  • Figs. 5A-5E shows representative X, purine and pyrimidine nucleobase side chains (3A) , modified nucleobase side chains (3B) ; aromatic side chains (3C) , aliphatic side chains (3D, and mixed aromatic/aliphatic side chains (3E), where the X, side chains are shown attached to the 1' morpholino ring position in Fig. 1;
  • Fig. 6 shows stereoche ical options for X, and linkage atoms Y in a morpholino subunit structure
  • Fig. 7 illustrates a variety of activated subunit structures useful in forming the oligomers of the invention
  • Fig. 8 illustrate compounds which may be converted to morpholino subunit structures during oligomer assembly
  • Figs. 9A and 9B illustrate methods for the conversion of ribose and glucose compounds, respectively, to morpholino subunit structures during oligomer assembly
  • Fig. 10 illustrates orientation about the X j bond in morpholino subunit structures
  • Fig. 11 illustrates rotational freedom about the amide linkage in selected tertiary amine linkages
  • Figs. 12A and 12B show representative one-atom linkages in oligomers of the invention
  • Figs. 13A and 13B illustrates the syntheses of oligomers having one-atom linkages between morpholino subunit structures
  • Fig. 14 shows representative two-atom linkages in oligomers of the invention
  • Fig. 15 shows representative three-atom linkages in oligomers of the invention
  • Fig. 16 shows representative four-atom linkages in oligomers of the invention
  • Fig. 17 shows a portion of a branched oligomer formed in accordance with another embodiment of the invention
  • Fig. 18 illustrates the synthesis of the branched portion of the oligomer shown in Fig. 17;
  • Figs. 19A-19C show three different cleavable linkers used in attaching a morpholino oligomer to a tether bound to a particle surface;
  • Fig. 20 shows a portion of a bead having a surface coating of same-sequence oligomer molecules;
  • Fig. 21 illustrates a portion of a bead surface having a family of same-sequence, different-length oligomer molecules;
  • Fig. 22 illustrates a solid-phase method for isolating a particle carrying a surface coating of oligomer molecules that bind to a receptor attached to a solid support
  • Figs. 23A-23D illustrate various solution-phase methods for selecting particles carrying a surface coating of oligomer molecules that bind to a receptor attached to a solid support (23A) , by first binding receptor to a particle having the desired oligomer sequence (23B) , and identifying particle(s) having bound receptor by further reacting the particle with fluorescent-labeled anti- receptor antibody (23C) , or by separating particle with bound receptor on the basis of its increased density (23D) .
  • a "morpholino subunit structure” refers to a morpholino structure of the form:
  • a “side chain” refers to one of several different X- groups that may be carried on a morpholino subunit structure
  • a "subunit” in an oligomer includes a subunit structure and one of its associated linkages to an adjacent subunit structure. That is, the oligomer is composed of linked subunits, which in turn are composed of subunit structures and associated linkages.
  • An "oligomer” refers to a polymer composed of typically between about 4- 15 subunits.
  • the oligomers of the present inventions are formed of morpholino subunit structures that are linked together by linkages of one to four atoms long joining the morpholino nitrogen of one subunit structure to the 4' cyclic carbon of an adjacent subunit structure. Although morpholino subunit structures are the predominant subunit form in the oligomers, other subunit structures may also be employed.
  • sequence of side chains in an oligomer refers to the sequence of individual side chains on successive subunit structures in an oligomer, on progressing from one end of the oligomer to the other.
  • sequence of linkages in an oligomer refers to the sequence of individual linkages linking successive subunit structures in an oligomer, on progressing from one end of the oligomer to the other.
  • a “combinatorial library of oligomers” refers to a library of oligomer molecules containing a large number, typically between 10 3 and 10 7 different-sequence oligomers, typically defined by a different sequence of side chains, or a combination of different sequences of side chains and linkages. Each sequence in a library is preferably represented by a plurality, e.g. , 10 lu -10 12 molecules of the same sequence.
  • a “branched oligomer” refers to an oligomer having one or more morpholino subunit structures that are covalently attached to a linkage that itself directly links two additional morpholino subunit structures in the oligomer.
  • the sequence of side chains in a branched oligomer refers to the sequence of side chains in the longest chain of the oligomer, with branched side chains being indicated in parenthesis at the linkage position to which the branch is joined.
  • an oligomer sequence of the form: X 1 X 2 X 3 X 4 (X 4.1 X 4.2 )X 5 X 6 refers to an eightmer having the linear sequence of sidechains X,X 2 X 3 X 4 X 5 X 6 , and a branched sequence of side chains X 4 . ) X 4 . 2 on a two-subunit chain attached to the linkage between the fourth and fifth subunit structures in the linear chain.
  • a "nucleobase” side chain is a purine or pyrimidine side chain attached to the morpholino moiety through the N9 of the purine or the Nl of the pyrimidine.
  • a "non-nucleobase aromatic" side chain is a substituted or unsubstituted aromatic side chain that is not a purine or pyrimidine.
  • a "mixed aromatic/aliphatic" side chain is an aromatic side chain substituted with an aliphatic side chain.
  • a "receptor” is a macromolecule capable of specifically interacting with ligand molecule, including oligomers of the inventions. Binding of the ligand to the receptor is typically characterized by a high binding affinity, i.e., K m >10 s , and is intended to affect, e.g., inhibit, the function of the receptor in its normal biological setting.
  • the receptor is also referred to herein as a target structure.
  • the invention includes, in one aspect, a combinatorial library of oligomers having the general form shown in Fig. 1.
  • the oligomers are formed from morpholino subunit structures of the form shown in Fig. 2, where the subunit structures are linked together by linkages L one to four atoms long joining the morpholino nitrogen of one subunit structure to the 4' cyclic carbon of an adjacent subunit structure.
  • the ⁇ groups or side chains in the oligomers are nucleobase or non-nucleobase X groups, as will be described below.
  • Each morpholino subunit structure contains a morpholino backbone moiety, which allows linking the subunit structure to other subunit structures in a defined order, and a side chain X'.
  • These morpholino subunit structures have the general structure shown in Fig.
  • X;, the side chain is hydrogen or an organic substituent, which may be in a protected form
  • Y which may be in an activated or protected form, is a group which allows coupling of the morpholino subunit to the morpholino nitrogen or Z group of another morpholino subunit, or other structure
  • Z is hydrogen, a protective group, or other group, which may be in an activated or protected form, which is suitable for coupling to the Y group of another morpholino subunit or other structure
  • X and Y substituents have defined stereochemical orientations.
  • Morpholino subunit structures can be prepared from ribonucleosides and related substituted furanosides, as illustrated in Fig. 3 and described in Example 1, and from substituted glucose and related hexopyranoside ⁇ , as illustrated in Fig. 4 and described in Example 2.
  • FIGs. 5A-5E illustrate representative types of side chains of morpholino subunits which can be prepared from natural products and simple chemical reagents.
  • Fig. 5A shows representative nucleobase side chains.
  • Example 3 describes synthetic routes to such structures.
  • Fig. 5B shows a number of modified nucleobase side chains modified by addition of R groups at various ring positions, as indicated.
  • R is preferably an aliphatic group, such as methyl.
  • Example 4 describes synthetic routes to nucleobases modified at one or more such sites.
  • Fig. 5C shows representative, aromatic, non-nucleobase side chains.
  • X is OH or OR, where R is a lower alkyl, or a primary, secondary or tertiary amine.
  • Y and Z may be any of a variety of small groups, such as CN, halogen, N0 2 , OH, alkoxy, aldehyde, and amine groups.
  • Examples 5A-5E disclose methods for preparing morpholino subunit structures with exemplary non-nucleobase aromatic side chains.
  • morpholino subunit structures with aliphatic side chains, as shown in Fig. 5D, where the R groups may be branched or unbranched alkanes, alkenes, or alkynes.
  • R groups may be branched or unbranched alkanes, alkenes, or alkynes.
  • Exemplary morpholino subunits having these types of side chains are described in Examples 5F-5I.
  • the side chains may be mixed aromatic/aliphatic groups, such as shown in Fig. 5E.
  • the stereochemistry of the X side chain about the 1' carbon of the morpholino moiety can be selected to be either alpha or beta, and the stereochemistry of the Y group about the 4' carbon of the morpholino moiety can also be selected to be either alpha or beta, as illustrated in Fig. 6.
  • Basic synthetic strategies for achieving these selected stereochemical options are illustrated in Example 6.
  • Morpholino oligomers are assembled predominantly by linking the Y group of one morpholino subunit structure to the morpholino nitrogen or Z group of another morpholino subunit structure (Fig. 2) , where one of these groups is nucleophilic and the other is electrophilic.
  • the resulting intersubunit linkage, L should be stable to conditions of synthesis and any required deprotection steps, as well as stable under the conditions of use.
  • a preferred assembly method is to use subunit structures in which the nucleophilic moiety is in a protected form (often protected with a trityl group) , and the electrophilic moiety is in an activated form, or is activated in situ just before or during the coupling step.
  • Fig. 7 illustrates a number of representative morpholino subunits so configured for oligomer assembly, and Example 7 describes their preparation.
  • morpholino oligomers can also be assembled by a method in which the morpholino backbone moieties are formed in the course of oligomer assembly.
  • Fig. 8 illustrates a number of representative compounds suitable for this purpose, and Example 8 describes their synthesis. Key structural characteristics of the backbone moiety of any such compound include a primary aliphatic amine moiety and two or more vicinal hydroxyls.
  • This section describes methods for preparing morpholino oligomers of the type used in the invention, and the spatial and geometric considerations important in polymer construction.
  • the diversity of spatial arrangements of the side chains in a library of morpholino oligomers can be increased appreciably by use of nucleobase and similar side chains which are structured so as to control their orientation about the bond between the side chain and the 1' atom of the morpholino backbone moiety.
  • the morpholino backbone moiety exists predominantly in a chair conformation, with the X and Y groups positioned equatorial.
  • pyrimidines and related side chains which contain a bulky group at the 2 position and a hydrogen at the 6 position exist almost exclusively in the anti conformation about the X-l' bond.
  • purines and related side chains which contain a hydrogen at the 8 position can exist in either the syn or anti conformation about the X-l' bond.
  • purines and related side chains which contain a bulky group at the 8 position exist predominantly in the syn conformation about the X-l' bond.
  • a key objective is to prepare an oligomer library containing a collection of molecules, each of which has a definable spatial arrangement of side chains.
  • certain linkage constraints need to be considered. For example, if a bond has a high barrier to rotation, resulting in two distinct rotomers, and both rotomers are present at significant concentrations, then a given molecular specie containing such linkages would be expected to contain 2" distinct, but slowly interconverting conformations, where n is the number of rotomer-generating restricted-rotation bonds in that oligomer. This results in a diverse collection of rotomers, only one of which has the desired spatial arrangement of side chains.
  • tertiary amides and related groups containing a carbonyl linked to a nitrogen containing two alkyl groups are well known to exhibit two distinct rotomer forms which interconvert only very slowly at physiological temperatures.
  • amides containing the dialkyl nitrogen of proline have been reported to have a T, /2 of rotation of many hours at 37°C, and the temperature of coalescence (Tc) , determined by nuclear magnetic resonance, has been found to be 114°C.
  • tertiary amide intersubunit linkages to the ring nitrogen of the morpholino backbone moiety are now known to be acceptable linkages for a variety of morpholino oligomers.
  • Novel intersubunit linkages of this type which heretofore appeared to be unacceptable on the basis of previously available information, are illustrated in structure 1 of Fig. 12, structure 4 of Fig. 14, structure 2 of Fig. 15, and structure 2 of Fig. 16.
  • oligomers containing one-atom linkages may be constructed by converting the last-added subunit to a morpholino group during oligomer synthesis, as illustrated in Fig. 9 for ribose and glucose subunits. The methods of synthesis are detailed in Example 10.
  • D. Forming Oligomers with Two-Atom Linkages Two-atom-length linkages afford oligomer structures with greater conformational freedom than those with one- atom linkages. Exemplary two-atom linkages, shown in Fig. 14, can be formed by the general methods illustrated in Fig. 13 and described in Example 9, or by the general method illustrated in Fig. 9 and described Example 10.
  • Fig. 15 illustrates and Example 11 describes methods of forming representative three-atom-length linkages between morpholino subunits. Additional methods are described in co-owned U.S. Patent Nos. 5,235,033 and 5,185,444. Such linkages properly space and position suitable nucleobase side chains for Watson/Crick binding to complementary single-stranded oligonucleotides, and to suitable complementary morpholino oligomers. Further, incorporation of a relatively rigid carbamate or thiocarbamate intersubunit linkage (structure 1 of Fig. 15) largely precludes stacking of adjacent nucleobase side chains in aqueous solution, resulting in substantial hydrophobic character for such nucleobase-containing oligomers.
  • incorporation of relatively flexible sulfonyl, and particularly phosphoryl linkages affords good stacking of adjacent nucleobase side chains in aqueous solution, resulting in generally good water solubility for many such nucleobase-containing oligomers.
  • non-morpholino subunits can be introduced into the morpholino-subunit oligomers, either in linear or branched portions thereof, by selecting subunit structures having suitable donor and acceptor groups, and incorporating these subunits into the oligomer by the general coupling methods described herein.
  • Utilization of one or more branches in an oligomer can substantially increase the spatial diversity of its side chains relative to unbranched oligomers.
  • One or more branches in an oligomer also serves to increase structural complexity by positioning a greater number of side chains in a small area, resulting in an increased likelihood of multiple interactions with a suitable target structure.
  • Fig. 17 shows a portion of a morpholino-subunit oligomer having a branch linkage at which a 1-N subunit branch extends from a dominant linear portion of the oligomer (the longest linear chain in the oligomer) .
  • the branch oligomers may be formed by a variety of methods, typically by employing a branched structure which provides two nitrogens, each of which can be reacted with an activated subunit, as illustrated in Fig. 18.
  • Example 13 describes the preparation of several such in-line type branches.
  • Example 14 describes the synthesis of branched oligomers with hub branches.
  • Example 15 describes the covalent joining of branched ends.
  • the libraries are constructed to contain oligomers having a large number of different sidechain sequences and, optionally, linkage sequences.
  • the oligomers making up the library include subunit structures with at least three, and typically 5-20 different side chains, and at least about 1,000 different side chain sequences.
  • the library contains 10 4 to 10 7 different sequences, which may include different sidechain ⁇ and different linkages.
  • Each different-sequence specie in the library preferably exists in multiple copies, preferably IO 10 or more where microsequencing is employed to determine oligomer sequence.
  • Subunits with the same X side chain but different Y and/or Z groups constitute different subunits, since changing the Y or Z moiety generally alters the relative spatial arrangement of the side chain in the oligomer.
  • subunits with the same X side chain and the same Y and Z, but with differing stereochemistry about the X and/or Y groups also constitute different subunits since changing the stereochemistry generally affords a substantial alteration of the spatial arrangement of the side chain in the oligomer.
  • hundreds of different subunits can be readily prepared, in contrast to the four nucleotide subunits of enzymatically-prepared oligonucleotides and the 20 amino acids of biologically- generated peptides.
  • Combinatorial libraries of the type used in the invention may be formed by a variety of solution-phase or solid-phase methods in which subunits are added stepwise to growing oligomers, until a desired oligomer size is reached, as outlined below.
  • the library is formed by solid-phase synthetic methods in which beads containing different-sequence oligomers that form the library are alternately mixed and separated, with one of a selected number of subunits being added to each group of separated beads at each step.
  • Each bead in the resultant library contains only one oligomer specie, allowing a single bead, once identified as containing the desired binding oligomer sequence, to provide oligomer for sequence identification.
  • One preferred particle or bead for use in library construction is a macroporous bead having a density of between 1 and 1.3, and a size of about 20-200 ⁇ m.
  • the particle which is shown fragmentarily at 30, is preferably derivatized with a separator chain or tether, such as tether 32, having a cleavable linkage 34 adjacent its distal or free end, such as detailed in Example 16.
  • Highly crosslinked macroporous polystyrene particles (buoyant density 1.05 g/cm 3 ) are particularly suited for use in preparing such oligomer-particles, and commercially available polystyrene particles with amine, hydroxyl, or carboxyl moieties covering their surfaces provide suitable sites for linking tethers and dyes or fluorescent groups.
  • Polyethylene glycols and polypropylene glycols preferably with average molecular weights in the range of 400 to 6000, serve as effective tethers.
  • Use of higher molecular weight tethers ( > 1000 MW) typically afford oligomer-particles with higher target binding capacities in the typical case where the target structure is relatively large, for example proteins, which generally range from 30 to 100 angstroms in diameter.
  • the selectively cleavable anchor between the tether and the oligomer should be stable to conditions used for subunit coupling, deprotection of termini, deprotection of side chains, and the aqueous conditions used for assessment of target binding.
  • the linker should also be easily and selectively cleavable under simple conditions. Three linkages which satisfy these criteria are: disulfide (cleavable with mercaptoethanol) ; derivatives of 4- hydroxymethyl-3-nitro-benzoic acid (cleavable with 350 n light) ; and vicinal alcohols (cleavable with periodate) , as illustrated in Figs. 19A-19C.
  • Macroporous particles each containing many femptomoles to a few picomoles of functional sites on its surfaces, and preferably having a buoyant density appreciably less than that of the target structure, are reacted to add to the surface a water soluble tether ending in a selectively cleavable anchor.
  • Remaining sites on the particle surfaces may be reacted with a suitable dye or fluorescent group, or dye or fluorescent material may be incorporated within the particle matrix during its polymerization.
  • a suitable dye or fluorescent group or dye or fluorescent material may be incorporated within the particle matrix during its polymerization.
  • Such label is desirable to improve visualization of the oligomer-particles in the course of assessing for target binding.
  • Each portion of particles is than reacted with a different subunit of the subunit set, such as subunit structure 36 in Fig. 20. After coupling, all portions of particles are combined, mixed thoroughly, washed, and treated to deprotect the oligomer termini.
  • This subunit addition cycle comprising distribution of particles into separate portions, coupling each portion with a different subunit, recombining, mixing, washing, and deprotection of the oligomer termini, is repeated until the desired number of subunits have been added to give a complete library of oligomers covalently bound to the particles.
  • Example 16 describes representative procedures for preparing such oligomer-particles.
  • One particle in a completed library is illustrated in Fig. 20.
  • the particle shown fragmentarily at 38, contains a plurality of oligomer molecules, such as molecules 40, each having the oligomer sequence ABCDEFGH, representing the sequence of eight different subunit side chains.
  • each oligomer molecules is attached to the particle through a tether, such as tether 42, containing a cleavable linker, such as linker 44.
  • Methods for forming library beads of the type just described are given in Example 16.
  • the particle shown fragmentarily at 46, contains a plurality of oligomer molecules, such as molecules 48, each having a portion of the sequence ABCDEFGH (including some molecules containing the entire sequence ABCDEFGH) , of an oligomer having this side chain sequence.
  • the oligomer molecules are each attached to the particle through a tether, such as tether 50, containing a cleavable linkage, such as linkage 52.
  • a mixture of activated subunits when coupling a given subunit with a particular portion of particles a mixture of activated subunits is used wherein a defined fraction in the mixture (50% to 90%) contains a protective group which, after coupling, can be cleaved to allow coupling of a subsequent subunit in the next subunit addition cycle.
  • the remaining fraction of subunit in the mixture (10% to 50%) is capped with a group which precludes coupling in subsequent subunit addition cycles.
  • each oligomer-particle will contain a family of oligomer species, this family comprising capped oligomers ranging from 1 to N-l subunits, and an uncapped oligomer of N subunits.
  • an acetyl cap is convenient. If it is desirable to remove the cap prior to use in the target binding assessment, a trifluoroacetate cap can be used. This group is removed during the treatment with ammonium hydroxide typically used for deprotecting side chains. In using this method of generating families of oligomers on a single particle, when branched oligomers are prepared, the method can lead to ambiguities in sequence information generated in the final mass spectral analysis. Such ambiguities arise because truncation can occur independently in each of the branches.
  • a strategy to remove most, and often all of this sequence ambiguity is to incorporate a dual-mass cap in those oligomers which are truncated in the first- synthesized branch.
  • One representative dual-mass scheme which is easily assessed in the mass spectral sequencing step entails utilizing a mixture of acetyl and benzoyl capped subunits in the subunit mixtures used for the first- synthesized branch of a branched oligomer, while using just the acetyl cap for subunit mixtures used for all other subunits additions. This affords a mass series in which each oligomer truncated in the first-synthesized branch is distinguished by dual masses, separated by 62 mass units.
  • Another dual-mass scheme entails using a mixture of acetyl and trifluoroacetyl capped subunits for the first- synthesized branch, and just trifluoroacetyl capped subunits for subunit mixtures used for all other subunit additions.
  • the trifluoroacetyl moieties are cleaved by treatment with ammonia. This affords a mass series in which each oligomer truncated in the first-synthesized branch is distinguished by dual masses, separated by 42 mass units.
  • the combinatorial libraries described above are used to select one or more oligomer species in the library that demonstrate a specific interaction with a selected receptor.
  • the receptor is any biological receptor of interest, that is, one for which it is desired to identify a oligomer (ligand) that binds specifically to the receptor, to affect the functioning of the receptor in its normal physiological setting.
  • the receptor may be an enzyme, where the oligomer is able to bind to the active site of the enzyme or otherwise inhibit the action of the enzyme on a normal substrate.
  • the receptor may be a cell receptor protein, such as an ion channel or other transport receptor protein, or a receptor site for a hormone or other cell effector, or a receptor site for binding of pathogenic bacteria or viruses to a cell surface.
  • the receptor protein may be associated with isolated cells with culture cells, with biological membrane particles isolated from tissues, with cells which are transformed to produce the receptor recombinantly, or with isolated cell receptors.
  • Receptor proteins of this type, and expressed or isolated in a variety of forms, have been described in the literature, such as that cited above.
  • the receptor is an antibody or antibody fragment, where it is desired to identify an "artificial" epitope ligand that binds specifically and with high affinity to the antibody.
  • the library of oligomers is screened for oligomer (ligand) molecules that bind specifically and with high affinity, e.g., with a binding constant K B greater than 10 6 M, to the receptor.
  • receptor molecules such as molecules 54
  • Attachment may be by way of covalent or noncovalent attachment of an isolated receptor to the surface.
  • the solid surface may be cells having surface-bound receptor, or the cells themselves may be anchored on a solid support. Methods for attaching proteins or cells to a solid support are well known.
  • the support is contacted with the library oligomers, i.e., the different-sequence oligomer molecules making up the oligomer library, under conditions that allow binding of only one or a few oligomer species to the receptor.
  • the binding conditions e.g., salt concentration, pH and/or temperature may be selectively varied, according to standard methods, to ensure that only the highest-affinity oligomer species are bound to the receptor.
  • the library is constructed as above to include a library of particles, each containing multiple copies of the same-sequence oligomer.
  • the particles are reacted with support-bound receptors under conditions which promote binding to the solid surface of library particles, indicated at 58, that carry high-affinity ligands, such as oligomers 60, for the receptor.
  • the solid surface is washed to remove unbound or less tightly bound particles, and the one or more remaining bound particles are then analyzed, according to methods described below, to determine the sequence of the high-affinity oligomers.
  • Figs. 22A-22D illustrate various solution-phase methods for identifying desired library oligomer sequence(s).
  • a library particle 62 carrying molecules, such as molecules 64, having one of the library sequences is reacted with the receptor 66 in solution phase, under conditions which lead to receptor binding to high-affinity library particles, as illustrated in Fig. 23B.
  • the particles with bound receptor may be further reacted with reported-labeled antibody 68 specific against the receptor molecules, to label the desired library particle( ⁇ ) with a suitable reporter, such as a fluore ⁇ cent label, a ⁇ indicated in Fig. 23C.
  • the labeled particles may be removed by micromanipulation, e.g., under fluorescent microscopy, or using standard cell sorting methods to isolated reporter-labeled particles.
  • the particle density may be so selected that binding of receptor protein to the particles increases the particle den ⁇ ity sufficiently to separate receptor- bound particles on the basis of differential density, as illustrated in Fig. 23D.
  • the figure shows a receptor-bound particle being separated by centrifugation or particle settling in a medium 70 who ⁇ e den ⁇ ity is intermediate between the den ⁇ ity of particles 72 that do not contain bond receptor, and those, such a ⁇ particle 62, that do.
  • a preferred type of particle for density separation which has desired density and solvent-re ⁇ istance properties is macroporous polystyrene particles in the size range of 20 to 200 microns in diameter.
  • macroporous particles which are used for ion exchange chromatography, can be obtained which have large surface to mass ratios, suitable pore sizes (in the range of 400 to 1000 angstroms) , and which have surfaces containing covalently linked amine, hydroxyl, or carboxyl groups, which provide convenient sites for anchoring oligomers.
  • the library particles such as polymeric particles having particle sizes in the 0.5-2 ⁇ m range, are reacted with the cells under conditions that promote ligand- ⁇ pecific receptor surface binding, followed by one or more cell washes, to remove unbound particles, and release of bound particle(s) from the washed cells.
  • the oligomer library may be formed of oligomer molecules having (i) nucleobase side chains and (ii) intersubunit linkages that allow Watson-Crick ba ⁇ e pairing between the nucleobases the bases of complementary- base sequence oligonucleotides.
  • the isolated oligomer molecules are reacted with a combinatorial library of oligonucleotide ⁇ , under hybridization condition ⁇ that permit complementary ⁇ trand hybridization between the selected oligomer molecules and same-sequence oligonucleotide molecules.
  • the bound oligonucleotide molecules are then released, made double stranded, amplified, e.g., by polymerase chain reaction, and sequenced according to standard methods. The sequence obtained corresponds then to the side-chain sequence of the isolated oligomer molecules.
  • Both the library oligomer molecules and the random- sequence oligonucleotides may have known-sequence oligonucleotide end segments to enhance hybridization between the two. If the oligomers are designed to contain a mixture of nucleobases and either modified nucleobases or non-nucleobase sidechains, the stringency of the hybridization conditions may be reduced, to allow some non- pairing with oligomer bases. Sequencing the bound oligonucleotides would be effective to reconstruct the oligomer ⁇ equence in ⁇ ome, but not all, ⁇ ubunit po ⁇ itions.
  • each particle containing only one oligomer sequence
  • the isolated particles are treated to release the attached oligomer molecules, and the release molecules are sequenced, e.g., by micro ma ⁇ s spectrometry, ⁇ uch as detailed in Example 17 below.
  • each particle provides sufficient oligomer material for microsequencing, to avoid the problem of sequencing mixed- sequence oligomers derived from different beads.
  • the library particles are prepared to contain a family of different- length, same-sequence oligomer molecules, as described above. After cleavage of the family of oligomers from an isolated particle surface, sinapinic acid i ⁇ added and the material i ⁇ placed under reduced pressure to remove volatile material, and then in ⁇ erted into a ma ⁇ s spectrometer, preferably a laser-desorption time-or-flight mass spectrometer.
  • a ma ⁇ s spectrometer preferably a laser-desorption time-or-flight mass spectrometer.
  • oligomers having that ⁇ equence, and ⁇ ize ⁇ ranges from 1 to N subunits may be prepared to determine the oligomer length that affords highe ⁇ t binding affinity, or which provide ⁇ the best compromise between high binding affinity and length.
  • oligomer libraries can be prepared as described earlier, but cleaved from the support before testing.
  • testing is carried out with oligomer free in solution, one can asse ⁇ s for a broader range of activities than just target binding, such a ⁇ inhibition or activation of enzymes, blocking of binding of ligands, etc.
  • Screening of these oligomers free in solution, along with an iterative selection and synthesis proces ⁇ for the systematic identification of oligomers having a desired biological activity can be carried out by methods modeled after those reported by Houghten, et al . (Nature 354 84 (1991)) .
  • the combinatorial library is easy to synthesis by stepwise solution-pha ⁇ e or ⁇ olid-pha ⁇ e method ⁇ , with the morpholino ⁇ ubunit ⁇ tructure ⁇ making up the oligomer ⁇ being preformed or formed during ⁇ tepwise synthesis.
  • the ability to construct ⁇ ubunit structures with a wide range or nucleobase, modified nucleobase, aromatic, aliphatic, and mixed base side chains allows the construction of libraries having virtually any desired degree of complexity.
  • the po ⁇ sible complexity of the libraries is further enhanced by the stereochemical variations, and variations in linkages that are possible, as well as the ability to construct branched oligomers.
  • the oligomer ⁇ may be readily screened for a desired interaction with a selected receptor, e.g., according to binding affinity.
  • the invention provides a variety of methods for isolating library particle ⁇ containing de ⁇ ired oligomer ligand ⁇ , a ⁇ well a ⁇ ⁇ imple method ⁇ for determining oligomer ⁇ equence ⁇ .
  • Tr trityl (triphenylmethyl)
  • DMT 4, 4'-dimethoxytrityl
  • CBz phenylmethyl) oxycarbonyl
  • Boc ( 1 , 1- dimethyl ) ethyloxycarbonyl
  • FMOC ( 9 - fluoreny Imethy 1 ) oxycarbonyl
  • TBDMS tert- butyldimethylsilyl
  • TBDPS tert-butyldiphenylsilyl
  • Ac acetate
  • Bz benzoate
  • DBU 1, 8-diazabicyclo[5.4.0]undec- 7-ene
  • NMP l-methyl-2-pyrolidinone.
  • ribo uransoide ⁇ and the corresponding acylating agents are cytidine and benzoyl chloride; adenosine and benzoyl chloride; guano ⁇ ine and the e ⁇ ter formed from 1-hydroxybenzotriazole and phenylacetyl chloride (Ben ⁇ eler and McLaughlin) .
  • the FMOC group may be introduced by the method of Heikkila and Chattopadhyaya.
  • Alcohols may be protected by reaction with benzoyl chloride or a substituted benzoyl chloride, eg, anisoyl chloride, in pyridine to form the ester.
  • the hydroxyl group is silylated with t-butyldiphenyl ⁇ ilyl chloride and imidazole in DMF.
  • p-toluenesulfonic acid (or other arylsulfonic acid) may be used in place of 6N HCl in the reduction step.
  • a crystalline salt of the morpholino derivative and the sulfonic acid is obtained which may be filtered off and used in the next step.
  • This method is especially effective for morpholino derivatives of uridine, N-4 benzoylcytidine and N-2 phenylacetylguanosine.
  • the crude residue, or sulfonate ⁇ alt, from the morpholino ring ⁇ ynthe ⁇ is is su ⁇ pended in DMF (2L) and treated with triethylamine (10 mole ⁇ ) and evaporated to near dryne ⁇ .
  • the re ⁇ idue i ⁇ again suspended in DMF (2L) and treated with triethylamine (4 moles) and trityl chloride (2 moles) while the temperature is maintained at 10 degrees C.
  • the reaction is vigorously ⁇ tirred for 15 inute ⁇ at room temperature, then quenched by the addition of piperidine (1 mole) . After 5 minutes, the reaction is poured into 20L of a one to one water/satd NaCL solution.
  • the solids are collected, washed with water, and dissolved in 2L of 20% methanol/chlorofor .
  • To thi ⁇ is added 2L of 20% isopropanol/chloroform and the mixture washed con ⁇ ecutively with water, 5% ⁇ odium bicarbonate, and brine.
  • the organic layer i ⁇ dried over ⁇ odium ⁇ ulfate, filtered, and evaporated to provide crude N-tritylmorpholino subunit.
  • the ⁇ ubunit may be purified by silica gel chromatography.
  • base sen ⁇ itive amine protecting groups may be incorporated, for example, 9- fluorenylmethylcarbonyl (using FMOC chloride in pyridine/DMF and quenching with water) .
  • the compound is di ⁇ olved in methanol or methanol/DMF mixture containing 4 molar equivalent ⁇ of acetic acid and 2 molar equivalent ⁇ of ⁇ odium acetate. Cerric ammonium nitrate (2 molar equivalent ⁇ ) i ⁇ added and the reaction ⁇ tirred at room temperature for 1-24 hours. After evaporation of the solvent ⁇ the morpholino nitrogen may be protected a ⁇ in the general Example.
  • the morpholino ring is constructed as in Example IB with the sole exception that 2.2 moles of sodium periodate are used in the oxidation step.
  • Example IC The morpholino ring nitrogen is protected as in Example IC.
  • Example 3 Preparation of Subunits with Nucleobase Side Chains
  • the example illustrate the u ⁇ e of the D- ⁇ ugar ⁇ .
  • the enantiomeric subunits may be obtained by employing the corresponding L-sugars.
  • Uracil is bi ⁇ -trimethyl ⁇ ilylated according to the procedure of Niedballa and Vorbruggen.
  • a wide variety of other 5- ⁇ ub ⁇ tituted uracil ⁇ (halo, alkynyl, alkyl, alkenyl, nitro) may be prepared in thi ⁇ manner. In some case ⁇ the use of acetonitrile in the Hilbert-Johnson reaction is advantageous.
  • N-6-Benzoyl-9-(2,3,4,6-tetra-O-acetyl- ⁇ -D- glucopyrano ⁇ yl) adenine (Lichtenhaler, et al . ) i ⁇ treated with 2:1 ammonium hydroxide/DMF at 45 degree ⁇ C for 15 hour ⁇ to give 9- (/3-D-glucopyrano ⁇ yl)adenine 33.1a (Xi ⁇ - adenin-9-yl) .
  • a more direct method for the conversion of the glucoside into the morpholino subunit employs the selective O-deacylation procedure of Rammler and Khorana on
  • Example 4 Preparation Subunit ⁇ with Modified Nucleoba ⁇ e Side Chains
  • a variety of pyrimidines, purines, and their analog ⁇ may be converted into the corresponding ribofuranoside ⁇ and hexopyrano ⁇ ides by the methods of Niedballa and Vorbruggen and by the method ⁇ of Lichtenhaler, et al .
  • the ⁇ e may be further processed to morpholino subunit ⁇ a ⁇ per the example ⁇ below.
  • hypoxanthine morpholino subunit from Example 3E i ⁇ treated with 1.1 equivalent ⁇ of ⁇ odium hydride in DMF followed by methyl iodide to produce the 1,8- dimethylhypoxanthine morpholino subunit 32.2b ( ⁇ -Nl- methylhypoxanthin-9-yl) .
  • the use of other alkyl groups allow ⁇ the formation of other 1-alkyated hypoxanthine ⁇ ubunit ⁇ .
  • Example 4F i ⁇ treated with 1.1 equivalents of sodium hydride in DMF followed by methyl iodide to produce the
  • Example 41 J. 8-Methylthio-N2-phenylacetylguanine as Side Chain
  • the 8-bromoguanine derivatives in Example 41 are converted into the 8-methylthio species by reaction with sodium thiomethoxide in DMF.
  • the 8-bromoadenine and 8- bromohypoxanthine specie ⁇ may be ⁇ i ilarly converted.
  • Methyl 4 (5) -methylimidazole-5 (4) -carboxylate is silylated and reacted with an equimolar amount of 1,2,3,4, 6-penta-0-acetyl-3-D-glucopyranose by the method of Cook, et al . , using at least 1.44 mole of stannic chloride per mole sugar yields the acetylated sugar.
  • Methanolysis with ⁇ odium methoxide in methanol provide ⁇ methyl 5-methyl- 1- (0-D-glucopyrano ⁇ yl) imidazole-4-carboxylate 33.
  • Alkyl a ⁇ Side Chain The methods below may be used to prepare a wide variety of alkyl or aralkyl (for example, benzyl or phenethyl) sub ⁇ tituted morpholino subunits.
  • This compound may also be prepared by application of the procedure ⁇ in Example 4Glb to L-mannose.
  • the ⁇ econdary alcohol ⁇ may by oxidized to ketone ⁇ which may be reacted again with any of a large variety of Grignard or organolithium reagent ⁇ to provide tertiary alcohol ⁇ .
  • the ⁇ e typically do not require protection and the final ⁇ ubunit may be prepared by hydrogenoly ⁇ i ⁇ .
  • TBDPS group i ⁇ removed with tetrabutylammonium fluoride.
  • the alcohol i ⁇ converted into the aldehyde with diisopropylcarbodiimide in DMSO containing a small amount of pyridinium methane ⁇ ulfonate.
  • the aldehyde may be reacted with any of a large variety of Wittig reagent ⁇ (Maercker) to produce alkene ⁇ .
  • Subunit ⁇ 34.2-34.4 with aliphatic ⁇ ide chain ⁇ containing carbon-carbon double bonds are prepared in a similar fashion.
  • the acids prepared in part I above are reacted with diisopropylcarbodiimide and morpholino in dichloromethane to produce the morpholino amide. Conversion to the subunit follows hydrogenolytic cleavage of the carba ate and acetal with Pd on charcoal. Other amides may be prepared by use of ammonia or other amines.
  • the alcohol is converted into an aldehyde with diisopropylcarbodiimide in DMSO containing a ⁇ mall amount of pyridinium methane ⁇ ulfonate.
  • the resulting amine is protected a ⁇ in the general Example ⁇ and the acetal cleaved by hydrogenoly ⁇ is.
  • ketones prepared in Example 4G5 may be employed a ⁇ starting material ⁇ for the production of more amine ⁇ species.
  • Example ⁇ 3 and 4 above generally illu ⁇ trate the preparation of morpholino ⁇ ubunits with nucleobase or modified nucleobase side chains with group ⁇ R and Y in figure 6 both in the ⁇ po ⁇ ition (figure 34.1) .
  • Thi ⁇ derive ⁇ principally from the u ⁇ e of D-gluco ⁇ e or D- galacto ⁇ e or D-ribo ⁇ e and their derivatives a ⁇ precur ⁇ or ⁇ .
  • corre ⁇ ponding L- ⁇ ugar ⁇ are employed.
  • the sulfonic acid is isolated as its triethylamonium salt by extraction into chloroform from water saturated with triethylamine hydrochloride.
  • the salts of sulfonic acids can be easily chromatographed on silica gel using triethylamine/methanol/chloroform ixture ⁇ if the ⁇ ilica i ⁇ first pre-eluted with 2% triethylamine in chloroform.
  • Retritylation may be collected by hydrogenolysi ⁇ with Pd on charcoal to remove the carba ate followed by tritylation by the general procedure.
  • the acid ⁇ alt from the previous example is activated by treatment with dii ⁇ opropylcarbodiimide in dichloromethane containing p-nitrophenol containing 1 equivalent of pyridinium p-toluene ⁇ ulfonate.
  • the crude salt is di ⁇ olved in dichloromethane/pyridine and treated with 3 equivalents of dimethoxytrityl chloride.
  • the solvent ⁇ are evaporated and the re ⁇ idue taken up in 1:1 methanol/acetic acid to cleave the DMT group on the nitrogen.
  • the solvents are removed, the residue dis ⁇ olved in dichloromethane, wa ⁇ hed with water, ⁇ odium bicarb ⁇ olution and brine.
  • the salt ⁇ of ⁇ ulfamic acid ⁇ can be easily chromatographed on silica gel using triethylamine/methanol/chloroform mixture ⁇ if the silica i ⁇ fir ⁇ t pre-eluted with 2% triethylamine in chloroform.
  • the amine is sulfated by treatment with SO,/pyridine complex (with excess pyridine) in di ethylformamide (DMF) .
  • DMF di ethylformamide
  • the salt ⁇ of ⁇ ulfamic acid ⁇ can be ea ⁇ ily chromatographed on si l ica gel using triethylamine/methanol/chloroform mixtures if the silica is first pre-eluted with 2% triethylamine in chloroform.
  • the dimethyla inodichlorophosphate u ⁇ ed in the above procedure wa ⁇ prepared a ⁇ follows: a suspen ⁇ ion containing 0.1 mole of dimethylamine hydrochloride in 0.2 mole of pho ⁇ phorou ⁇ oxychloride wa ⁇ refluxed for 12 hour ⁇ and then distilled (boiling point is 36°C at 0.5 mm Hg) .
  • the re ⁇ ulting secondary amine i ⁇ reacted with i ⁇ oamyl nitrite and the N-nitro ⁇ o ⁇ pecies reduced with hydrogen over Pd on charcoal or Zn in acetic acid.
  • the amino group may be protected as the benzhydryl carbamate by the method of Hiskey and Adam ⁇ or a ⁇ the Boc carbamate u ⁇ ing ditertbutyl dicarbonate.
  • Other activated ⁇ pecies may be prepared using thiocarbonyldiimidazole or N,N-dimethylaminopho ⁇ phoryl chloride a ⁇ de ⁇ cribed in the preceeding example ⁇ .
  • Ribofurano ⁇ ide ⁇ may be converted into their 5'-amino derivatives by reaction with triphenylphosphine, sodium or lithium azide and carbon tetrabromide in DMF (Yamamato) , followed by reduction with either triphenyl phosphine/ammonia or with hydrogen over Pd on charcoal.
  • 6'-Aminohexopyrano ⁇ ide ⁇ 8.4 Hexopyranosides may be converted into their 6'-amino derivatives by the procedure in Example 8A or by the following procedure.
  • the glycoside is treated with dimethoxytrityl chloride in pyridine to selectively protect the primary alcohol.
  • the remaining hydroxy groups are protected by reaction with t-butyldimethylsilyl chloride in DMF containing imidazole.
  • the dimethoxytrityl group i ⁇ cleaved by treatment with zinc bromide in nitromethane at room temperature (K ⁇ ter, et al ) .
  • the free 6'-alcohol is converted into the 6'-amino derivative by reaction with triphenylpho ⁇ phine, ⁇ odium or lithium azide and carbon tetrabromide in DMF (Yamamato) , followed by reduction with either triphenyl pho ⁇ phine/ammonia or with hydrogen over Pd on charcoal.
  • the ⁇ ilyl group ⁇ are removed by treatment with HF/pyridine of tetrabutylammonium fluoride in THF.
  • Ribofurano ⁇ ide ⁇ may be converted into their 5'-0-amino derivatives by the following procedure.
  • the glycoside is treated with dimethoxytrityl chloride in pyridine to selectively protect the primary alcohol.
  • the remaining hydroxy group ⁇ are protected by reaction with t- butyldimethylsilyl chloride in DMF containing imidazole.
  • the dimethoxytrityl group is cleaved by treatment with zinc bromide in nitromethane at room temperature (K ⁇ ster, et al ) and the primary alcohol converted into the de ⁇ ired aminoxy ⁇ pecies using N-hydroxyphthalimide by the procedure of Vas ⁇ uer, et al .
  • the ⁇ ilyl group ⁇ are removed by treatment with HF/pyridine of tetrabutylammonium fluoride in THF.
  • the morpholino nitrogen of a subunit, or the terminal subunit in an oligomer contains an acid labile group such a ⁇ the trityl group
  • deprotection is performed with mild acid.
  • Representative acid mixtures which are ⁇ uitable include 10% cyanoacetic acid in 4:1 dichloromethane/acetonitrile, 7% formic acid in dichloromethane, and 2.5% cyanoacetic acid in 7:93 trifluoroethanol/dichloro ethane.
  • a 20-50% solution of trifluoroacetic acid in dichloromethane may by employed.
  • the acid is removed by precipitation of the deprotected subunit in ether if the reaction i ⁇ done in homogeneou ⁇ solution, or by washing with the appropriate rinse solvent if solid phase methods are employed.
  • the morpholino nitrogen of a subunit, or the terminal subunit in an oligomer contains a base labile group such as the FMOC group
  • deprotection is performed with mild base.
  • Representative base reagents which are suitable include 1-10% DBU/DMF, 10% N- methylpyrrolidine/DMF, and 2-20% piperidine/DMF.
  • the excess reagent, dibenzofulvene, and derived by product ⁇ are removed by precipitation of the deprotected ⁇ ubunit in ether if the reaction i ⁇ done in homogeneous solution, or by wa ⁇ hing with the appropriate rin ⁇ e solvent if solid pha ⁇ e method ⁇ are employed.
  • Coupling to a morpholino ⁇ ubunit require ⁇ that the morpholino nitrogen be present in the uncharged state. This may be achieved as follow ⁇ .
  • a mild ba ⁇ e ⁇ uch as triethylamine, diisopropylethyla ine, or dii ⁇ opropylaminoethanol (or it ⁇ ethers or ester ⁇ ) is employed to neutralize residual charge produced in acidic deprotections and/or to maintain any unreacted morpholino nitrogen in the neutral ⁇ tate during the coupling reaction.
  • Example 7C The nitrophenyl e ⁇ ter formed in Example 7C, is dissolved in DMF or NMP (containing 0.2-0.4 molar of an appropriate base, ⁇ uch as methyl diisopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric species with an uncharged morpholino nitrogen produced as in Example 9A.
  • DMF or NMP containing 0.2-0.4 molar of an appropriate base, ⁇ uch as methyl diisopropylaminoethyl ether
  • Example 7G The nitrophenyl ester formed in Example 7G, is dissolved in DMF or NMP (containing 0.2-0.4 molar of an appropriate base, such as methyl diisopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric ⁇ pecies with an uncharged morpholino nitrogen produced as in Example 9A. )
  • DMF or NMP containing 0.2-0.4 molar of an appropriate base, such as methyl diisopropylaminoethyl ether
  • Oligomer may be a ⁇ embled by con ⁇ truction of the morpholino ring from a dialdehyde and a primary amine.
  • the coupling i ⁇ performed a ⁇ follows.
  • the 5'- aminoribofuranoside or 6'-aminohexopyranoside from Example 8 is protected on the amine with trityl as in the general procedure.
  • the molecule is di ⁇ olved or suspended in methanol and treated with periodate as per the general procedure in Examples 1 or 2.
  • dialdehyde ⁇ o formed i ⁇ To the dialdehyde ⁇ o formed i ⁇ added a second 5'-aminoribofuranoside or 6'- aminohexopyrano ⁇ ide followed by ⁇ odium cyanoborohydride and the pH i ⁇ maintained between 4.5 and 6.5.
  • a particularly advantageou ⁇ method for the ⁇ ynthe ⁇ i ⁇ of oligomers by this method involve ⁇ fixing the the amino group of the fir ⁇ t aminoglyco ⁇ ide to a ⁇ olid support by a cleavable anchor, as in Example 16 below, and performing the oxidation and reductive amination ⁇ teps on the solid support.
  • Example 71 The nitrophenyl e ⁇ ter formed in Example 71, i ⁇ di ⁇ olved in DMF or NMP (containing 0.2-0.4 molar of an appropriate ba ⁇ e, ⁇ uch a ⁇ methyl dii ⁇ opropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric ⁇ pecie ⁇ with an uncharged morpholino nitrogen produced as in Example 9A.
  • DMF or NMP containing 0.2-0.4 molar of an appropriate ba ⁇ e, ⁇ uch a ⁇ methyl dii ⁇ opropylaminoethyl ether
  • Thi ⁇ linkage is prepared from the nitrophenyl carbonate formed in Example 7J and the morpholino- deprotected subunit ⁇ /oligomer formed a ⁇ in Example 9A.
  • the coupling follows the method of Summerton and Weller (US patent 5,034,506)
  • This linkage is prepared from the ⁇ ulfamoyl chloride ⁇ produced in Example ⁇ 7M or 7N and the morpholino deprotected ⁇ ubunit ⁇ /oligomer formed a ⁇ in Example 9A.
  • the coupling follows the method of Summerton and Weller (US patent 5,034,506)
  • Example 7S The nitrophenyl ester formed in Example 7S, is di ⁇ olved in DMF or NMP (containing 0.2-0.4 molar of an appropriate ba ⁇ e, ⁇ uch a ⁇ methyl diisopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric species with an uncharged morpholino nitrogen produced as in Example 9A.
  • DMF or NMP containing 0.2-0.4 molar of an appropriate ba ⁇ e, ⁇ uch a ⁇ methyl diisopropylaminoethyl ether
  • Example 7T The nitrophenyl ester formed in Example 7T, is dis ⁇ olved in DMF or NMP (containing 0.2-0.4 molar of an appropriate ba ⁇ e, ⁇ uch a ⁇ methyl diisopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric ⁇ pecie ⁇ with an uncharged morpholino nitrogen produced a ⁇ in Example 9A.
  • DMF or NMP containing 0.2-0.4 molar of an appropriate ba ⁇ e, ⁇ uch a ⁇ methyl diisopropylaminoethyl ether
  • Thi ⁇ linkage i ⁇ prepared from the nitrophenyl carbonate formed in Example 7Q i ⁇ di ⁇ solved in DMF or NMP (containing 0.2-0.4 molar of an appropriate base, such as methyl dii ⁇ opropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric ⁇ pecie ⁇ with an uncharged morpholino nitrogen produced a ⁇ in Example 9A.
  • an appropriate base such as methyl dii ⁇ opropylaminoethyl ether
  • the triamine is reacted with one equivalent of triamine and the terminally reacted monotritylated species isolated by chromatography on alumina.
  • the diamine is now reacted with FMOC chloride, followed immediately by sulfation in pyridine with the sulfur trioxide/pyridine complex.
  • the salts of the sulfamic acid ⁇ can be ea ⁇ ily chromotographed on ⁇ ilica gel u ⁇ ing triethylamine/methanol/chloroform mixture ⁇ if the ⁇ ilica i ⁇ fir ⁇ t pre-eluted with 2% triethylamine in chloroform.
  • ⁇ olution i ⁇ allowed to come to room temperature and then washed with aqueou ⁇ NaHCO,, dried, and chromatographed on ⁇ ilica gel eluting with a mixture of chloroform and acetone to give the desired sulfamoyl chloride.
  • the sulfamate can be coupled to an amino group or morpholino amine in the same fa ⁇ hion in which an activated ⁇ ubunit may be coupled (Examples 9-12) .
  • cleavage of the trityl group allows construction of the oligomeric branche ⁇ by ⁇ equential coupling of ⁇ ubunits.
  • the second branch may now be synthesized using by sequential coupling of subunits.
  • cleavage of the trityl group allow ⁇ construction of the oligomeric branch by sequential coupling of subunit ⁇ .
  • the first branch i ⁇ complete, it is capped and the molecule treated with 10% DBU/DMF to remove the FMOC group.
  • the second branch may now be ⁇ ynthe ⁇ ized u ⁇ ing by ⁇ equential coupling of subunits.
  • Additional subunits may be introduced by detrityalation and repetition of the coupling. Following introduction of the final subunit, the chain is detritylated and capped with acetic anhydride. The nitrophenethyl e ⁇ ter i ⁇ cleaved by treatment with 10% DBU/DMF. The free acid i ⁇ coupled with N-trityl piperazine prepared below u ⁇ ing dii ⁇ opropylcarbodiimide in dichloromethane. Sububit ⁇ may be introduced by detritylation and coupling a ⁇ above. When this chain is finished it i ⁇ capped with acetic anhydride.
  • the o-nitrobenzyl e ⁇ ter is cleaved by irradiation with 320 nm light.
  • sububit ⁇ may be introduced by detritylation and coupling a ⁇ above.
  • the free acid i ⁇ coupled to ⁇ ubunit ⁇ or preformed oligomer ⁇ , at the free morpholino nitrogen (produced by detritylation and neutralization as described in Example 9) , u ⁇ ing dii ⁇ opropylcarbodiimide in dichloromethane.
  • the nitrophenethyl e ⁇ ter i ⁇ cleaved by treatment with 10% DBU/DMF.
  • the o- nitrobenzyl e ⁇ ter is cleaved by irradiation with 320 nm light.
  • the free acid is coupled to ⁇ ubunit ⁇ or preformed oligomer ⁇ , at the free morpholino nitrogen, u ⁇ ing dii ⁇ opropylcarbodiimide in dichloromethane. It ⁇ hould be recognized that the acid may be employed in ⁇ olid pha ⁇ e synthesis by coupling to a growing chain on a solid ⁇ upport. The two e ⁇ ters which may each be selectively deprotected are reacted ⁇ equentially with ⁇ ubunits or oligomers.
  • N-tritylpiperazine i ⁇ reacted with FMOC chloride The trityl group i ⁇ removed by the method in Example 9, and the free piperazine nitrogen reacted with an activated ⁇ ubunit by the method above. A ⁇ many ⁇ ubunits as desired may be introduced by the method in Example 14A above. Following end capping of thi ⁇ chain, the FMOC group i ⁇ cleaved u ⁇ ing 10% DBU/DMF. The free piperazine nitrogen i ⁇ reacted with an activated subunit by the method above. As many ⁇ ubunits as desired may be introduced by the method in Example 14A above.
  • the disulfide is cleaved using dithiothreitol in mildy ba ⁇ ic aqueou ⁇ ⁇ olution.
  • the oligomeric dithiol is separated from the reagents by passage over a column of chromatographic grade polypropylene and eluting with an acetonitrile in dilute aqueous acetic acid.
  • ⁇ upport ⁇ are ⁇ uitable for solid phase synthe ⁇ i ⁇ of oligomer ⁇ : aminomethyl poly ⁇ tyrene re ⁇ in, 1% divinylbenzene cro ⁇ linked, 200-400 mesh, 0.5-1.5 mmoles N per gram (Sigma Chemical CO.
  • poly ⁇ tyrene re ⁇ in 1% divinylbenzene cros ⁇ linked, grafted with polyethylene glycol, primary amino terminated, 0.1-0.3 mmoles N per gram (TentaGel, Rapp Polymere, Germany)
  • custom- ⁇ ynthe ⁇ ized macroporou ⁇ poly ⁇ tyrene 8% divinylbenzene cro ⁇ linked, functionalized with 1, 12-diaminododecane, with particle ⁇ ize ⁇ in the range of 50-80 micron ⁇ in diameter, and with pore ⁇ izes approximately 700 ⁇ .
  • Anchor ⁇ The following anchors are employed for solid phase oligomer synthe ⁇ i ⁇ :
  • Bio-Spin Di ⁇ posable Chromatography Column cat # 732-6008, whose frit has been replaced with a new frit (Isolab Quik- Sep Disc # D-4301) .
  • the resin i ⁇ treated with DMF for 1-12 hour ⁇ , during which time it is placed in a aspirator vacuum to remove trapped air, and gently agitated to break up clump ⁇ .
  • Sufficient tether i ⁇ added ⁇ o a ⁇ to react 5-50% of the free amine ⁇ on the re ⁇ in surface. After 12-48 hours at 45 degrees C the solvents are drained and the resin washed with DMF.
  • the resin is washed with dichloromethane, then 5% diisopropylethylamine in dichloromethane.
  • the anchor is di ⁇ olved in DMF or NMP (containing 0.2-0.4 molar of an appropriate ba ⁇ e, ⁇ uch a ⁇ methyl dii ⁇ opropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the re ⁇ in containing the deprotected tether for 2-48 hour ⁇ at room temperature. The re ⁇ in i ⁇ thoroughly washed with DMF.
  • a mixture of activated subunits prepared in Example 7 is coupled to the end of the growing chain by the procedures defined in Example ⁇ 9-12. It i ⁇ critical, in order to achieve roughly equimolar amount ⁇ of the individual oligomer ⁇ , that the concentration ⁇ of each activated subunit in the reaction be adjusted so that the rate of coupling for each ⁇ ubunit will be a ⁇ nearly the same as pos ⁇ ible.
  • the coupling rate ⁇ for the activated subunit are determined in solution, by reaction with a monomeric morpholino subunit.
  • Example 16E1 Preparation of a mixed backbone oligomer.
  • the method of Example 16E1 i ⁇ employed, but activated ⁇ ubunits other than morpholino ⁇ pecie ⁇ are employed.
  • Boc-alanine may be converted into i ⁇ p-nitrophenyl ester using diisopropylcarbodiimide in dichloromethane. It is u ⁇ ed a ⁇ an activated ⁇ ubunit in the repetitive ⁇ teps outlined in the method of example 16E1.
  • the oligomer so produced has a mixed morpholino-peptide backbone.
  • Example 16E1 i ⁇ employed with the following difference ⁇ .
  • a macroporou ⁇ re ⁇ in is treated with tether, then anchor.
  • Two additional ⁇ tep ⁇ , a and e below, are incorporated into each cycle to produce the following ⁇ equence:
  • the resin is di ⁇ tributed, in equal portion ⁇ , into a number of ⁇ ynthesi ⁇ column ⁇ that i ⁇ the same as the number of subunit ⁇ species desired to couple in step e.
  • the resin is recombined.
  • an oligomer family which consi ⁇ ts of activated subunit ⁇ derived from the following ⁇ et of ⁇ ubunit ⁇ :
  • the synthe ⁇ i ⁇ cycle i ⁇ then preformed with each column receiving a ⁇ ingle activated ⁇ ubunit ⁇ pecie ⁇ (prepared by the method ⁇ in Example 7, from the ⁇ ubunit ⁇ in the list above) for the coupling step.
  • the resin is recombined and distributed into five new solid phase synthesi ⁇ column ⁇ for the ⁇ econd ⁇ ynthe ⁇ is cycle, where again, each column recieves a ⁇ ingle activated ⁇ ubunit ⁇ pecie ⁇ .
  • Example 7 These are then individually activated by the methods in Example 7 and individually mixed with the corresponding activated, but still tritylated, subunit ⁇ with the ⁇ ame Xi group.
  • the ⁇ ynthe ⁇ i ⁇ i ⁇ then performed exactly as described in Example 16F1 with the ⁇ e five mixture ⁇ of capped and tritylated activated subunit specie ⁇ .
  • the resin containing the detritylated chain is treated with 7% formic acid in dichloromethane.
  • the extent of formylation i ⁇ controlled by the length of the treatment For example, to achieve a 2.5% conver ⁇ ion to formylated chain ⁇ require ⁇ one hour with thi ⁇ reagent.
  • the cleavage of trityl may be done with formic acid/dichloromethane mixtures a ⁇ de ⁇ cribed in example 9A. In ⁇ tead of immediately wa ⁇ hing the re ⁇ in after detritylation, to remove the acidic reagent, the reaction i ⁇ continued to promote the formylation of the morpholino nitrogen.
  • Anchor from 16B3 is cleaved by iradiation of the resin with light of 350 nm. Wavelengths shorter than
  • 300 nm are are excluded by a pyrex filter.
  • the anchor i ⁇ then cleaved by the method in Example 16H u ⁇ ing 2 uL of reaction solution.
  • the reaction mixture is combined with a mixture of ⁇ inapinic acid and aqueou ⁇ acetonitrile (4 part ⁇ ) .
  • the ⁇ olution i ⁇ then introduced onto the probe of a Matrix A ⁇ sisted Laser Desorption Time Of Flight (MALDE- TOF) mas ⁇ ⁇ pectrometer.
  • MALDE- TOF Matrix A ⁇ sisted Laser Desorption Time Of Flight
  • the oligomer-particles preferably contain an intense dye or fluore ⁇ cent material to facilitate vi ⁇ ualization of individual particle ⁇ .
  • Each particle ⁇ i ⁇ preferably prepared to contain a ⁇ ingle family of N- ⁇ ubunit oligomer ⁇ pecie ⁇ , and together the collection of particle ⁇ in a given preparation contain the full library of oligomer specie ⁇ .
  • the oligomer-particle library preparation i ⁇ mixed with a suitable concentration of target in a solution having a den ⁇ ity greater than that of the oligomer-particle, but le ⁇ than that of an oligomer-particle/target complex.
  • Sucro ⁇ e ⁇ olution ⁇ are generally convenient for this purpose.
  • the ⁇ olution i ⁇ allowed to ⁇ tand for a period of time, whereupon any oligomer-particle/target complex which form ⁇ will settle to the bottom of the container. If the particles are quite small (e.g., 20 to 30 microns in diameter) or the buoyant density differential between the ⁇ olution and the oligomer-particle/target is small, then centrifugation can be used to ⁇ peed the ⁇ ettling of complexed particle ⁇ .
  • the oligomer-particle preparation i ⁇ mixed with a ⁇ uitable concentration of target in a solution containing a density-gradient-forming component, such as metrizamide, Centrifugation in an ultracentrifuge then generally rapidly ⁇ eparate ⁇ oligomer-particle ⁇ from any oligomer-particle/target complex which may have formed.
  • a density-gradient-forming component such as metrizamide

Abstract

A method of generating a compound capable of interacting specifically with a selected macromolecular ligand is disclosed. The method involves contacting the ligand with a combinatorial library of oligomers composed of morpholino subunits with a variety of nucleobase and non-nucleobase side chains. Oligomer molecules that bind specifically to the receptor are isolated and their sequence of base moieties is determined. Also disclosed is a combinatorial library of oligomers useful in the method and novel morpholino-subunit polymer compositions.

Description

MORPHOLINO-SUBUNIT COMBINATORIAL LIBRARY AND METHOD
1. Field of the Invention The present invention relates to a combinatorial library formed by sequences of morpholino subunit struc¬ tures, and to a method of generating novel binding compounds using the library.
2. References
Adlington, et al . , J . Chem . Soc . , Chem . Commun . 944 (1983) .
Barbas, C.F., et al . , Proc Nat Acad Sci , USA 89(10) :4457 (1992) . Dooley, C.T., et al . , Proc Nat Acad Sci , USA 90(22) : 10811 (1993a) .
Dooley, C.T., et al . , Life Sci , 5_2(18) :1509 (1993b). Ecker, D.J., et al . , Nuc Acids Res 2.1(8): 1853 (1993). Eichler, J, et al . , Biochemistry .32.(41) : 11035 (1993) . Fodor, S.P., et al . , Science 251:767-773 (1991).
Furka, A., et al . , 14th International Congress on Biochemistry 5_:47, Prague, Czechoslovakia, July 10-15, 1988a.
Furka, A., et al . , 10th International Congress on Biochemistry 5 : 288, Prague, Czechoslovakia, August 15-19, 1988b.
Furka, A., et al . , Int . J . Pept . Protein Res . 3.7:487- 493 (1991) .
Houghten, R.A., et al . , NIDA Res Monograph 134 :66 (1993a) .
Houghten, R.A. , Gene 132(1) :7 (1993b) . Houghten, R.A., and Dooley, C.T., Bioorg . Med . Chem . Lett . 3:405-412 (1993c) .
Houghten, R.A., et al . , Biotechniqueε 13 (3) :412 (1992) .
Houghten, R.A. , et al . , Nature (London) 3_5_4:84-86 (1991) .
Jung, G., and Beck-Sickinger, A.G., Angew . Chem . Int . Ed . Eng . 31:367-383 (1992). Koppel and Robins, J . Org . Chem . 22:1459 (1958) .
Kramer, A., et al . , Pept Res ϋ(6) : 314 (1993) .
Lam, K.S., et al . , Nature (London) 354:82-84 (1991).
Lam, K.S., et al., Bioorg . Med . Chem . Lett . 2:419-424 (1993) .
Ohlmayer, M.H., et al . , Proc Nat Acad Sci, USA 90(23) :10922 (1993) .
Pavia, M.R. , et al . , Bioorg . Med . Chem . Lett . 2:387- 383 (1993). Pinilla, C. , et al . , Gene 128(1) :71 (1993).
Pinilla, C. , et al . , Biotechniques 12(6) :901 (1992).
Sebestyen, F., et al . , Bioorg . Med . Chem . Lett . 2:413- 418 (1993) .
Zuckermann, R.N., et al . , Int . J . Pept . Protein Res . 0:498-507 (1992) .
3. Background of the Invention
There is current widespread interest in using combinatorial libraries of random-sequence oligonucleotides, polypeptides, or synthetic oligomers to search for biologically active compounds (Kramer; Houghten, 1993a-1993c, 1992, 1991; Ohlmeyer; Dooley, 1993a-1993b; Eichler; Pinella, 1993, 1992; Ecker; and Barbas) . Ligands discovered by screening libraries of this type may be useful in mimicking or blocking natural ligands, or interfering with the naturally occurring interactions of a biological target. They can also provide a starting point for developing related molecules with more desirable properties, e.g., higher binding affinity. Combinatorial libraries of the type useful in this general application may be formed by a variety of solution- phase or solid-phase methods in which mixtures of different subunits are added stepwise to growing oligomers, until a desired oligomer size is reached. A library of increasing complexity can be formed in this manner, for example, by pooling multiple choices of reagents with each additional subunit step (Houghten, 1991; 1993c). Alternatively, the library may be formed by solid- phase synthetic methods in which beads containing different-sequence oligomers that form the library are alternately mixed and separated, with one of a selected number of subunits being added to each group of separated beads at each step. An advantage of this method is that each bead contains only one oligomer specie, allowing the beads themselves to be used for oligomer screening (Furka, 1991; Lam, 1991, 1993; Zuckermann; Sebestyn) . Still another approach that has been suggested involves the synthesis of a combinatorial library on spatially segregated arrays (Fodor) . This approach is generally limited in the number of different library sequences that can be generated. Since the chance of finding useful ligands increases with the size of the combinatorial library, it is desirable to generate libraries composed of large numbers of different-sequence oligomers. In the case of oligonucleotides, for example, a library having 4-base variability at 8 oligomer residue positions will contain as many as 48 (65,536) different sequences. In the case of a polypeptides, a library having 20-amino acid variability at six residue positions will contain as many as 206 (64,000,000) different species. Because each different-sequence specie in a large- number library may present in small amounts, one of the challenges in the combinatorial library selection procedure is isolating and determining the sequence of specie(s) that have the desired binding or other selected properties. Where the combinatorial library consists of oligonucleotides, this problem may be solved by amplifying the isolated sequence, e.g., by polymerase chain reaction methods. In the case of polypeptide libraries, other methods must be employed. In one approach, where the library has been formed by pooling multiple choices of reagents during synthesis, a pool which is shown to have desired properties is resynthesized iteratively with lower and lower complexity until a single sequence compound is identified.
Where the library oligomers have been formed on beads, and each bead represents one oligomeric specie, it may be possible to conduct microscale sequencing on the oligomers contained on a single isolated bead.
In another approach, the library sequences, e.g., random peptide sequences, are cosynthesized with a sequenceable tag, e.g., an oligonucleotide sequence, attached to the library sequence oligomer. That is, each oligomer in the library is associated with a distinctive sequenceable tag. Once an oligomer with the desired selection properties is identified, its sequence can be determined by determining the corresponding sequence of the sequenceable tag (Brenner; Kerr) .
A related approach has been to construct combinatorial libraries on beads that are themselves tagged with distinctive tagging molecules at each successive step in oligomer synthesis. Once an oligomer with desired binding properties is identified, the bead to which the oligomer is attached can be "read" to identify the oligomer sequence in terms of a sequence of tagging molecules (Ohlmeyer) .
Another basic consideration in the generation of desired compounds by screening combinatorial libraries is the nature of the selected compound itself. Polynucleotide libraries are relatively easy to generate and can sequenced at low concentrations, but have two basic disadvantages. First, the molecular variation in the library is limited by the relatively few bases that are employed, typically the standard four bases/oligomer position. Secondly, even if an active compound is identified, the compound may have pharmacological limitations due to its susceptibility to nuclease digestion.
In the case of polypeptide libraries, these also can be synthesized readily by known solution or solid-phase methods, and the possibility of 20 (or more) different side chains at each oligomer position greatly expands the potential variability of the library. However, as indicated above, screened polypeptides may be relatively difficult to sequence at the low oligomer concentrations that are likely to be present. Further, polypeptide compounds may be susceptible to protease digestion in vivo. Ideally, then, a combinatorial library should be easy to synthesis by stepwise solution-phase or solid-phase methods, should allow for a large number of different subunits at each residue position, should provide a broad range of structural diversity, and should be readily sequenceable, once a library oligomer with desired binding or other screened property is identified, and should be generally stable in living systems.
4. Summary of the Invention
The invention includes, in one aspect, a combinatorial library of non-biological oligomers formed predominantly of morpholino subunit structures of the form:
Figure imgf000007_0001
where (i) the structures are linked together by linkages "L" one to four atoms long joining the morpholino nitrogen of one subunit structure to the 4' cyclic carbon of an adjacent subunit structure, and X, is a purine or pyrimidine side chain, a non-nucleobase aromatic side chain, an aliphatic side chain, and/or a mixed aromatic/aliphatic side chain. At least 3 of the side chains X, are variable, and the library includes at least about 1,000 different side chain sequence oligomers.
In one general embodiment, the oligomer bases in the library include a combination of nucleobase side chains, i.e., purines and/or pyrimidines, and non-nucleobase side chains, such as non-nucleobase aromatic side chains, aliphatic side chains, and mixed aromatic/aliphatic side chains. In another general embodiment, the oligomers are effective to hybridize, by Watson-Crick base pairing, to one of the oligonucleotide oligomers in combinatorial library of random sequence oligonucleotides;
The oligomers in the library may also have different sequences of linkages, or be composed of the same linkages.
One preferred linkage is a 3-atom carba ate or 3-atom phosphorodiamidate linkage.
The oligomers may also include branched structures, in which one or more of the subunit structures forming an oligomer is linked to multiple subunits.
The oligomers in the library may be formed on a plurality of particles, such as macroporous particles, where each particle has a surface coating of molecules containing one of the base-sequences in the library. The oligomer molecules are preferably attached to the particle through cleavable linkages, e.g., chemically or photolytically cleavable linkages.
Alternatively, or in addition, the particles may be acroreticular particles having selected sizes in the 40- 200 μm range, where the oligomers are coupled to the particles through cleavable linkages.
Alternatively, or in addition, the oligomer molecules on each particle may represent a family of different-length oligomers having a common sequence from one oligomer end, but different termination subunit structures at the opposite oligomer end.
In another aspect, the invention includes a method of generating an oligomer compound capable of interacting specifically with a selected macromolecular ligand. The method includes contacting the receptor with a combinatorial library of oligomers of the type described above, isolating oligomer molecules that binds specifically to the receptor, and determining the sequence of bases in the isolated oligomer molecules.
Where the oligomers are designed to hybridize, by Watson-Crick base pairing, to complementary-sequence oligonucleotides in a combinatorial oligonucleotide library, the determining step includes reacting the isolated oligomers with a combinatorial library of oligonucleotides, under conditions effective to produce hybridization between the isolated oligomer molecules and complementary-base oligonucleotides, and determining the sequence of the oligonucleotides hybridized to the isolated oligomer molecules.
Where the combinatorial library is formed on a plurality of particles, the particle containing the desired binding molecules is isolated, e.g., by binding to a solid support, and oligomers on the particles are then sequenced, e.g., by release of the oligomers and micro mass spectrometry of the released oligomers. Alternatively, particle(s) having surface-bound receptor may be identified by reacting the particles with fluorescent-labeled anti-receptor antibodies, or by exploiting the greater density of the particles with surface-bound receptor. Also disclosed is a polymer composition assembled predominantly of morpholino subunit structures of the form:
Figure imgf000009_0001
where (i) the structures are linked together by linkages one to four atoms long joining the morpholino nitrogen of one subunit structure to the 4' cyclic carbon of an adjacent subunit structure, and X, is a purine or pyrimidine side chain, a non-nucleobase aromatic side chain, an aliphatic side chain, and/or a mixed aromatic/aliphatic side chain.
In a related aspect, the invention includes polymer composition assembled predominantly from morpholino subunit structures of the form:
Figure imgf000010_0001
where (i) the structures are linked together by linkages one to four atoms long joining the morpholino nitrogen of one subunit structure to the 4' cyclic carbon of an adjacent subunit structure, and X, is a purine or pyrimidine side chain, a non-nucleobase aromatic side chain, an aliphatic side chain, and/or a mixed aromatic/aliphatic side chain. These and other objects and features of the invention will become more fully appreciated when the following detailed description of the invention is read in conjunction with the accompanying drawings.
Brief Description of the Drawings
Fig. 1 shows a subunit of an oligomer formed of morpholino subunit structures joined by linkages L;
Fig. 2 shows a morpholino subunit structure used in the Fig. 1 oligomer; Fig. 3 illustrates the conversion of a ribonucleotide to a morpholino subunit structure;
Fig. 4 shows the conversion of glucose to a morpholino subunit structure;
Figs. 5A-5E shows representative X, purine and pyrimidine nucleobase side chains (3A) , modified nucleobase side chains (3B) ; aromatic side chains (3C) , aliphatic side chains (3D, and mixed aromatic/aliphatic side chains (3E), where the X, side chains are shown attached to the 1' morpholino ring position in Fig. 1;
Fig. 6 shows stereoche ical options for X, and linkage atoms Y in a morpholino subunit structure; Fig. 7 illustrates a variety of activated subunit structures useful in forming the oligomers of the invention;
Fig. 8 illustrate compounds which may be converted to morpholino subunit structures during oligomer assembly; Figs. 9A and 9B illustrate methods for the conversion of ribose and glucose compounds, respectively, to morpholino subunit structures during oligomer assembly;
Fig. 10 illustrates orientation about the Xj bond in morpholino subunit structures; Fig. 11 illustrates rotational freedom about the amide linkage in selected tertiary amine linkages;
Figs. 12A and 12B show representative one-atom linkages in oligomers of the invention;
Figs. 13A and 13B illustrates the syntheses of oligomers having one-atom linkages between morpholino subunit structures;
Fig. 14 shows representative two-atom linkages in oligomers of the invention;
Fig. 15 shows representative three-atom linkages in oligomers of the invention;
Fig. 16 shows representative four-atom linkages in oligomers of the invention;
Fig. 17 shows a portion of a branched oligomer formed in accordance with another embodiment of the invention; Fig. 18 illustrates the synthesis of the branched portion of the oligomer shown in Fig. 17;
Figs. 19A-19C show three different cleavable linkers used in attaching a morpholino oligomer to a tether bound to a particle surface; Fig. 20 shows a portion of a bead having a surface coating of same-sequence oligomer molecules; Fig. 21 illustrates a portion of a bead surface having a family of same-sequence, different-length oligomer molecules;
Fig. 22 illustrates a solid-phase method for isolating a particle carrying a surface coating of oligomer molecules that bind to a receptor attached to a solid support; and
Figs. 23A-23D illustrate various solution-phase methods for selecting particles carrying a surface coating of oligomer molecules that bind to a receptor attached to a solid support (23A) , by first binding receptor to a particle having the desired oligomer sequence (23B) , and identifying particle(s) having bound receptor by further reacting the particle with fluorescent-labeled anti- receptor antibody (23C) , or by separating particle with bound receptor on the basis of its increased density (23D) .
Detailed Description of the Invention I. Definitions Unless otherwise stated, the terms below have the following meanings:
A "morpholino subunit structure" refers to a morpholino structure of the form:
where X; is a side chain.
Figure imgf000012_0001
A "side chain" refers to one of several different X- groups that may be carried on a morpholino subunit structure,
A "subunit" in an oligomer includes a subunit structure and one of its associated linkages to an adjacent subunit structure. That is, the oligomer is composed of linked subunits, which in turn are composed of subunit structures and associated linkages. An "oligomer" refers to a polymer composed of typically between about 4- 15 subunits. The oligomers of the present inventions are formed of morpholino subunit structures that are linked together by linkages of one to four atoms long joining the morpholino nitrogen of one subunit structure to the 4' cyclic carbon of an adjacent subunit structure. Although morpholino subunit structures are the predominant subunit form in the oligomers, other subunit structures may also be employed.
The "sequence of side chains" in an oligomer refers to the sequence of individual side chains on successive subunit structures in an oligomer, on progressing from one end of the oligomer to the other.
The "sequence of linkages" in an oligomer refers to the sequence of individual linkages linking successive subunit structures in an oligomer, on progressing from one end of the oligomer to the other.
A "combinatorial library of oligomers" refers to a library of oligomer molecules containing a large number, typically between 103 and 107 different-sequence oligomers, typically defined by a different sequence of side chains, or a combination of different sequences of side chains and linkages. Each sequence in a library is preferably represented by a plurality, e.g. , 10lu-1012 molecules of the same sequence. A "branched oligomer" refers to an oligomer having one or more morpholino subunit structures that are covalently attached to a linkage that itself directly links two additional morpholino subunit structures in the oligomer. The sequence of side chains in a branched oligomer refers to the sequence of side chains in the longest chain of the oligomer, with branched side chains being indicated in parenthesis at the linkage position to which the branch is joined. Th s, an oligomer sequence of the form: X1X2X3X4(X4.1X4.2)X5X6 refers to an eightmer having the linear sequence of sidechains X,X2X3X4X5X6, and a branched sequence of side chains X4.)X4.2 on a two-subunit chain attached to the linkage between the fourth and fifth subunit structures in the linear chain.
A "nucleobase" side chain is a purine or pyrimidine side chain attached to the morpholino moiety through the N9 of the purine or the Nl of the pyrimidine.
A "non-nucleobase aromatic" side chain is a substituted or unsubstituted aromatic side chain that is not a purine or pyrimidine.
An "aliphatic" side chain refers to a side chain having the general structure -(CH2)m-X where m=l-5 and X is H, an unbranched or branched alkane, alkene or alkyne, OH, SH, an amine, a halide, an aldehyde, an acid, an amide, or an ester group.
A "mixed aromatic/aliphatic" side chain is an aromatic side chain substituted with an aliphatic side chain.
A "receptor" is a macromolecule capable of specifically interacting with ligand molecule, including oligomers of the inventions. Binding of the ligand to the receptor is typically characterized by a high binding affinity, i.e., Km>10s, and is intended to affect, e.g., inhibit, the function of the receptor in its normal biological setting. The receptor is also referred to herein as a target structure.
II. Morpholino Subunit Structures
The invention includes, in one aspect, a combinatorial library of oligomers having the general form shown in Fig. 1. The oligomers are formed from morpholino subunit structures of the form shown in Fig. 2, where the subunit structures are linked together by linkages L one to four atoms long joining the morpholino nitrogen of one subunit structure to the 4' cyclic carbon of an adjacent subunit structure. The { groups or side chains in the oligomers are nucleobase or non-nucleobase X groups, as will be described below.
Each morpholino subunit structure contains a morpholino backbone moiety, which allows linking the subunit structure to other subunit structures in a defined order, and a side chain X'. These morpholino subunit structures have the general structure shown in Fig. 2, where X;, the side chain, is hydrogen or an organic substituent, which may be in a protected form; Y, which may be in an activated or protected form, is a group which allows coupling of the morpholino subunit to the morpholino nitrogen or Z group of another morpholino subunit, or other structure; Z is hydrogen, a protective group, or other group, which may be in an activated or protected form, which is suitable for coupling to the Y group of another morpholino subunit or other structure; and, X and Y substituents have defined stereochemical orientations.
A. Preparing Subunit Structures
Morpholino subunit structures can be prepared from ribonucleosides and related substituted furanosides, as illustrated in Fig. 3 and described in Example 1, and from substituted glucose and related hexopyranosideε, as illustrated in Fig. 4 and described in Example 2.
A variety of side chains, X, contribute to the structural diversity achievable with this class of oligomers, which in turn facilitates the selection of oligomer species with desirable biological activities. Figs. 5A-5E illustrate representative types of side chains of morpholino subunits which can be prepared from natural products and simple chemical reagents. Fig. 5A shows representative nucleobase side chains. Example 3 describes synthetic routes to such structures. Fig. 5B shows a number of modified nucleobase side chains modified by addition of R groups at various ring positions, as indicated. Here R is preferably an aliphatic group, such as methyl. Example 4 describes synthetic routes to nucleobases modified at one or more such sites.
Fig. 5C shows representative, aromatic, non-nucleobase side chains. Here X is OH or OR, where R is a lower alkyl, or a primary, secondary or tertiary amine. Y and Z may be any of a variety of small groups, such as CN, halogen, N02, OH, alkoxy, aldehyde, and amine groups. Examples 5A-5E disclose methods for preparing morpholino subunit structures with exemplary non-nucleobase aromatic side chains.
Also contemplated are morpholino subunit structures with aliphatic side chains, as shown in Fig. 5D, where the R groups may be branched or unbranched alkanes, alkenes, or alkynes. Exemplary morpholino subunits having these types of side chains are described in Examples 5F-5I. Finally, the side chains may be mixed aromatic/aliphatic groups, such as shown in Fig. 5E.
B. Stereochemical Control of X and Y
The stereochemistry of the X side chain about the 1' carbon of the morpholino moiety can be selected to be either alpha or beta, and the stereochemistry of the Y group about the 4' carbon of the morpholino moiety can also be selected to be either alpha or beta, as illustrated in Fig. 6. Basic synthetic strategies for achieving these selected stereochemical options are illustrated in Example 6.
Morpholino oligomers are assembled predominantly by linking the Y group of one morpholino subunit structure to the morpholino nitrogen or Z group of another morpholino subunit structure (Fig. 2) , where one of these groups is nucleophilic and the other is electrophilic. The resulting intersubunit linkage, L, should be stable to conditions of synthesis and any required deprotection steps, as well as stable under the conditions of use.
A preferred assembly method is to use subunit structures in which the nucleophilic moiety is in a protected form (often protected with a trityl group) , and the electrophilic moiety is in an activated form, or is activated in situ just before or during the coupling step. Fig. 7 illustrates a number of representative morpholino subunits so configured for oligomer assembly, and Example 7 describes their preparation.
C. Conversion of Subunits to Morpholino Subunit Structures During Oligomer Assembly
In addition to oligomer assembly by coupling of preformed morpholino subunit structures, morpholino oligomers can also be assembled by a method in which the morpholino backbone moieties are formed in the course of oligomer assembly. Fig. 8 illustrates a number of representative compounds suitable for this purpose, and Example 8 describes their synthesis. Key structural characteristics of the backbone moiety of any such compound include a primary aliphatic amine moiety and two or more vicinal hydroxyls.
II. Oligomer Assembly
This section describes methods for preparing morpholino oligomers of the type used in the invention, and the spatial and geometric considerations important in polymer construction.
A. Side Chain Rotational Freedom
The diversity of spatial arrangements of the side chains in a library of morpholino oligomers can be increased appreciably by use of nucleobase and similar side chains which are structured so as to control their orientation about the bond between the side chain and the 1' atom of the morpholino backbone moiety. Based on NMR studies conducted in support of the invention, the morpholino backbone moiety exists predominantly in a chair conformation, with the X and Y groups positioned equatorial.
As indicated in Fig. 10, pyrimidines and related side chains which contain a bulky group at the 2 position and a hydrogen at the 6 position exist almost exclusively in the anti conformation about the X-l' bond. In contrast, purines and related side chains which contain a hydrogen at the 8 position can exist in either the syn or anti conformation about the X-l' bond. Further, purines and related side chains which contain a bulky group at the 8 position exist predominantly in the syn conformation about the X-l' bond.
B. Oligomer Linkage Rotomers
In selecting suitable intersubunit linkage types, a key objective is to prepare an oligomer library containing a collection of molecules, each of which has a definable spatial arrangement of side chains. In this regard, certain linkage constraints need to be considered. For example, if a bond has a high barrier to rotation, resulting in two distinct rotomers, and both rotomers are present at significant concentrations, then a given molecular specie containing such linkages would be expected to contain 2" distinct, but slowly interconverting conformations, where n is the number of rotomer-generating restricted-rotation bonds in that oligomer. This results in a diverse collection of rotomers, only one of which has the desired spatial arrangement of side chains.
Even if the desired rotomer can be isolated, except in special cases it will slowly interconvert to form the original mixture of rotomers. In this context, tertiary amides and related groups containing a carbonyl linked to a nitrogen containing two alkyl groups are well known to exhibit two distinct rotomer forms which interconvert only very slowly at physiological temperatures. For instance, amides containing the dialkyl nitrogen of proline have been reported to have a T,/2 of rotation of many hours at 37°C, and the temperature of coalescence (Tc) , determined by nuclear magnetic resonance, has been found to be 114°C. To illustrate the impact of such rotomers on the spatial arrangement of side chains in polymeric structures, it is the slow interconversion of the tertiary amide of proline in polypeptides which is largely responsible for the failure of many proteins to spontaneously renature after heat denaturation.
In view of the above considerations, intersubunit linkages containing tertiary amides might seem to be undesirable for morpholino oligomers destined for biological applications. However, in experiments carried out in support of the present invention, it has been discovered that in the special case of a carbonyl linked to the ring nitrogen of morpholino subunits, there is a relatively low barrier to rotation about this particular tertiary amide linkage, evidenced by the low Tc values for the amide-linked morpholino structures shown in Fig. 11.
Accordingly, tertiary amide intersubunit linkages to the ring nitrogen of the morpholino backbone moiety are now known to be acceptable linkages for a variety of morpholino oligomers. Novel intersubunit linkages of this type, which heretofore appeared to be unacceptable on the basis of previously available information, are illustrated in structure 1 of Fig. 12, structure 4 of Fig. 14, structure 2 of Fig. 15, and structure 2 of Fig. 16.
C. Forming Oligomers with One-Atom Linkages One-atom-length linkages between morpholino subunits afford oligomer structures with little conformational freedom, which, in turn, minimizes the entropy cost of binding between such oligomers and suitable target structures. Fig. 12 shows two one-atom-length intersubunit linkages.
Methods for joining morpholino subunits to form these one-atom-length intersubunit linkages are illustrated in Fig. 13 and described in Example 9. Alternatively, oligomers containing one-atom linkages may be constructed by converting the last-added subunit to a morpholino group during oligomer synthesis, as illustrated in Fig. 9 for ribose and glucose subunits. The methods of synthesis are detailed in Example 10. D. Forming Oligomers with Two-Atom Linkages Two-atom-length linkages afford oligomer structures with greater conformational freedom than those with one- atom linkages. Exemplary two-atom linkages, shown in Fig. 14, can be formed by the general methods illustrated in Fig. 13 and described in Example 9, or by the general method illustrated in Fig. 9 and described Example 10.
Additional methods of synthesis of oligomers from morpholino subunits are also described in co-owned U.S. Patent No. 5,235,033, and 5,185,444, which are incorporated herein by reference.
E. Forming Oligomers with Three-Atom Linkages
Fig. 15 illustrates and Example 11 describes methods of forming representative three-atom-length linkages between morpholino subunits. Additional methods are described in co-owned U.S. Patent Nos. 5,235,033 and 5,185,444. Such linkages properly space and position suitable nucleobase side chains for Watson/Crick binding to complementary single-stranded oligonucleotides, and to suitable complementary morpholino oligomers. Further, incorporation of a relatively rigid carbamate or thiocarbamate intersubunit linkage (structure 1 of Fig. 15) largely precludes stacking of adjacent nucleobase side chains in aqueous solution, resulting in substantial hydrophobic character for such nucleobase-containing oligomers. In contrast, incorporation of relatively flexible sulfonyl, and particularly phosphoryl linkages (structures 3, 4, and 5 of Fig. 15) affords good stacking of adjacent nucleobase side chains in aqueous solution, resulting in generally good water solubility for many such nucleobase-containing oligomers.
F. Forming Oligomers with Four-Atom Linkages Still greater spacing of the side chains in a morpholino oligomer is afforded by four-atom-length linkages between subunits. Representative four-atom-length intersubunit linkages are shown in Fig. 16. Methods of forming such linkages are described in Example 12.
It will be appreciated that non-morpholino subunits can be introduced into the morpholino-subunit oligomers, either in linear or branched portions thereof, by selecting subunit structures having suitable donor and acceptor groups, and incorporating these subunits into the oligomer by the general coupling methods described herein.
G. Forming Oligomers with Branches
Utilization of one or more branches in an oligomer can substantially increase the spatial diversity of its side chains relative to unbranched oligomers. One or more branches in an oligomer also serves to increase structural complexity by positioning a greater number of side chains in a small area, resulting in an increased likelihood of multiple interactions with a suitable target structure. Fig. 17 shows a portion of a morpholino-subunit oligomer having a branch linkage at which a 1-N subunit branch extends from a dominant linear portion of the oligomer (the longest linear chain in the oligomer) .
The branch oligomers may be formed by a variety of methods, typically by employing a branched structure which provides two nitrogens, each of which can be reacted with an activated subunit, as illustrated in Fig. 18. Example 13 describes the preparation of several such in-line type branches. Example 14 describes the synthesis of branched oligomers with hub branches. Example 15 describes the covalent joining of branched ends.
IV. Oligomer Libraries
This section describes the preparation and properties of combinatorial libraries of oligomers of the type described above. In general the libraries are constructed to contain oligomers having a large number of different sidechain sequences and, optionally, linkage sequences. Preferably, the oligomers making up the library include subunit structures with at least three, and typically 5-20 different side chains, and at least about 1,000 different side chain sequences. Preferably the library contains 104 to 107 different sequences, which may include different sidechainε and different linkages.
Each different-sequence specie in the library preferably exists in multiple copies, preferably IO10 or more where microsequencing is employed to determine oligomer sequence. Subunits with the same X side chain but different Y and/or Z groups constitute different subunits, since changing the Y or Z moiety generally alters the relative spatial arrangement of the side chain in the oligomer. Further, subunits with the same X side chain and the same Y and Z, but with differing stereochemistry about the X and/or Y groups also constitute different subunits since changing the stereochemistry generally affords a substantial alteration of the spatial arrangement of the side chain in the oligomer. As a consequence, hundreds of different subunits can be readily prepared, in contrast to the four nucleotide subunits of enzymatically-prepared oligonucleotides and the 20 amino acids of biologically- generated peptides.
Combinatorial libraries of the type used in the invention may be formed by a variety of solution-phase or solid-phase methods in which subunits are added stepwise to growing oligomers, until a desired oligomer size is reached, as outlined below.
A. Solid-Phase Particle Library
In one preferred method, the library is formed by solid-phase synthetic methods in which beads containing different-sequence oligomers that form the library are alternately mixed and separated, with one of a selected number of subunits being added to each group of separated beads at each step. Each bead in the resultant library contains only one oligomer specie, allowing a single bead, once identified as containing the desired binding oligomer sequence, to provide oligomer for sequence identification.
One preferred particle or bead for use in library construction is a macroporous bead having a density of between 1 and 1.3, and a size of about 20-200 μm. With reference to Fig. 20, the particle, which is shown fragmentarily at 30, is preferably derivatized with a separator chain or tether, such as tether 32, having a cleavable linkage 34 adjacent its distal or free end, such as detailed in Example 16.
Highly crosslinked macroporous polystyrene particles (buoyant density 1.05 g/cm3) are particularly suited for use in preparing such oligomer-particles, and commercially available polystyrene particles with amine, hydroxyl, or carboxyl moieties covering their surfaces provide suitable sites for linking tethers and dyes or fluorescent groups.
Polyethylene glycols and polypropylene glycols, preferably with average molecular weights in the range of 400 to 6000, serve as effective tethers. Use of higher molecular weight tethers ( > 1000 MW) typically afford oligomer-particles with higher target binding capacities in the typical case where the target structure is relatively large, for example proteins, which generally range from 30 to 100 angstroms in diameter.
The selectively cleavable anchor between the tether and the oligomer should be stable to conditions used for subunit coupling, deprotection of termini, deprotection of side chains, and the aqueous conditions used for assessment of target binding. The linker should also be easily and selectively cleavable under simple conditions. Three linkages which satisfy these criteria are: disulfide (cleavable with mercaptoethanol) ; derivatives of 4- hydroxymethyl-3-nitro-benzoic acid (cleavable with 350 n light) ; and vicinal alcohols (cleavable with periodate) , as illustrated in Figs. 19A-19C. Macroporous particles, each containing many femptomoles to a few picomoles of functional sites on its surfaces, and preferably having a buoyant density appreciably less than that of the target structure, are reacted to add to the surface a water soluble tether ending in a selectively cleavable anchor. Remaining sites on the particle surfaces may be reacted with a suitable dye or fluorescent group, or dye or fluorescent material may be incorporated within the particle matrix during its polymerization. Such label is desirable to improve visualization of the oligomer-particles in the course of assessing for target binding.
A preparation of particles, containing at least several times as many particles as there will be oligomer species in the library, is next distributed into equal portions, where the number of portions is typically the same as the number of different subunits in the set of subunits to be used for assembly of the variable portion of the oligomers in the oligomer library. Each portion of particles is than reacted with a different subunit of the subunit set, such as subunit structure 36 in Fig. 20. After coupling, all portions of particles are combined, mixed thoroughly, washed, and treated to deprotect the oligomer termini. This subunit addition cycle, comprising distribution of particles into separate portions, coupling each portion with a different subunit, recombining, mixing, washing, and deprotection of the oligomer termini, is repeated until the desired number of subunits have been added to give a complete library of oligomers covalently bound to the particles.
The collection of oligomer-particles are next treated to remove protective groups on the side chains, and then washed, after which they are ready for use. Example 16 describes representative procedures for preparing such oligomer-particles. One particle in a completed library is illustrated in Fig. 20. The particle, shown fragmentarily at 38, contains a plurality of oligomer molecules, such as molecules 40, each having the oligomer sequence ABCDEFGH, representing the sequence of eight different subunit side chains. As shown, each oligomer molecules is attached to the particle through a tether, such as tether 42, containing a cleavable linker, such as linker 44. Methods for forming library beads of the type just described are given in Example 16.
B- Preparing Oligomer Sequence Families In many applications, it may be desirable to prepare a library of oligomer families, where each family consists of different-length, but same-sequence oligomer molecules attached to the same particle. That is, the molecules all have the same sequence, beginning from one oligomer end, but contain different numbers of subunits, typically including molecules that contain from 1 to N subunits, where the largest oligomer contains N subunits. One exemplary particle in a completed library is illustrated in Fig. 21. The particle, shown fragmentarily at 46, contains a plurality of oligomer molecules, such as molecules 48, each having a portion of the sequence ABCDEFGH (including some molecules containing the entire sequence ABCDEFGH) , of an oligomer having this side chain sequence. As above, the oligomer molecules are each attached to the particle through a tether, such as tether 50, containing a cleavable linkage, such as linkage 52. Two general methods for forming bead libraries of the type just will now be described and are detailed in Example 17.
In one method, when coupling a given subunit with a particular portion of particles a mixture of activated subunits is used wherein a defined fraction in the mixture (50% to 90%) contains a protective group which, after coupling, can be cleaved to allow coupling of a subsequent subunit in the next subunit addition cycle. The remaining fraction of subunit in the mixture (10% to 50%) is capped with a group which precludes coupling in subsequent subunit addition cycles. By this method each oligomer-particle will contain a family of oligomer species, this family comprising capped oligomers ranging from 1 to N-l subunits, and an uncapped oligomer of N subunits.
If it is desirable to have the cap present during subsequent use of these particles for assessment of target binding, an acetyl cap is convenient. If it is desirable to remove the cap prior to use in the target binding assessment, a trifluoroacetate cap can be used. This group is removed during the treatment with ammonium hydroxide typically used for deprotecting side chains. In using this method of generating families of oligomers on a single particle, when branched oligomers are prepared, the method can lead to ambiguities in sequence information generated in the final mass spectral analysis. Such ambiguities arise because truncation can occur independently in each of the branches. A strategy to remove most, and often all of this sequence ambiguity is to incorporate a dual-mass cap in those oligomers which are truncated in the first- synthesized branch. One representative dual-mass scheme which is easily assessed in the mass spectral sequencing step entails utilizing a mixture of acetyl and benzoyl capped subunits in the subunit mixtures used for the first- synthesized branch of a branched oligomer, while using just the acetyl cap for subunit mixtures used for all other subunits additions. This affords a mass series in which each oligomer truncated in the first-synthesized branch is distinguished by dual masses, separated by 62 mass units. Another dual-mass scheme entails using a mixture of acetyl and trifluoroacetyl capped subunits for the first- synthesized branch, and just trifluoroacetyl capped subunits for subunit mixtures used for all other subunit additions. After assembly of the oligomer library is completed, the trifluoroacetyl moieties are cleaved by treatment with ammonia. This affords a mass series in which each oligomer truncated in the first-synthesized branch is distinguished by dual masses, separated by 42 mass units.
An alternative method for generating oligomer- particles containing families of different-length, same sequence oligomers has been developed for morpholino oligomers. In this approach (which does not utilize mixtures of capped and protected subunits) , the protective group on the chain termini which is to be cleaved at the end of each subunit addition cycle is a trityl group on the ring nitrogen of a morpholino subunit. Trityl cleavage is carried out with dichloromethane solutions which contain > 5% formic acid (v/v) . This formic acid treatment is effective to formulate the terminal morpholino nitrogen at a relatively constant rate for a given concentration of formic acid. For example, 7% by vol formic acid in dichloromethane formylates morpholino chain termini at a rate of 2.5%/hr at 20°C. Therefore, by simply exposing the particles containing nascent morpholino oligomers to a suitable formic acid deprotection solution for a selected period of time one can achieve truncation of a desired percent of chain termini. When concentrated ammonium hydroxide, neat or as a 1:1 v/v mixture with dimethylformamide, is used for deprotecting the side chains, these formyl moieties are cleaved from the truncated chains, leaving the terminal morpholino nitrogen in the free base form. For branched oligomers, it is desirable to utilize the dual mass capping strategy described above for the first-synthesized branch, and this controlled formylation method for all other subunit additions.
V. Selecting Specific-Sequence Oligomer Molecules
The combinatorial libraries described above are used to select one or more oligomer species in the library that demonstrate a specific interaction with a selected receptor. The receptor is any biological receptor of interest, that is, one for which it is desired to identify a oligomer (ligand) that binds specifically to the receptor, to affect the functioning of the receptor in its normal physiological setting. For example, the receptor may be an enzyme, where the oligomer is able to bind to the active site of the enzyme or otherwise inhibit the action of the enzyme on a normal substrate. In another general embodiment, the receptor may be a cell receptor protein, such as an ion channel or other transport receptor protein, or a receptor site for a hormone or other cell effector, or a receptor site for binding of pathogenic bacteria or viruses to a cell surface. The receptor protein may be associated with isolated cells with culture cells, with biological membrane particles isolated from tissues, with cells which are transformed to produce the receptor recombinantly, or with isolated cell receptors. Receptor proteins of this type, and expressed or isolated in a variety of forms, have been described in the literature, such as that cited above. In a related embodiment, the receptor is an antibody or antibody fragment, where it is desired to identify an "artificial" epitope ligand that binds specifically and with high affinity to the antibody.
In a typical application, the library of oligomers is screened for oligomer (ligand) molecules that bind specifically and with high affinity, e.g., with a binding constant KB greater than 106M, to the receptor. In one embodiment, illustrated in Fig. 22, receptor molecules, such as molecules 54, are attached to a solid support 56. Attachment may be by way of covalent or noncovalent attachment of an isolated receptor to the surface. Alternatively, the solid surface may be cells having surface-bound receptor, or the cells themselves may be anchored on a solid support. Methods for attaching proteins or cells to a solid support are well known.
In the selection method the support is contacted with the library oligomers, i.e., the different-sequence oligomer molecules making up the oligomer library, under conditions that allow binding of only one or a few oligomer species to the receptor. The binding conditions, e.g., salt concentration, pH and/or temperature may be selectively varied, according to standard methods, to ensure that only the highest-affinity oligomer species are bound to the receptor.
In the method illustrated in Fig. 22, the library is constructed as above to include a library of particles, each containing multiple copies of the same-sequence oligomer. The particles are reacted with support-bound receptors under conditions which promote binding to the solid surface of library particles, indicated at 58, that carry high-affinity ligands, such as oligomers 60, for the receptor.
Following this binding, the solid surface is washed to remove unbound or less tightly bound particles, and the one or more remaining bound particles are then analyzed, according to methods described below, to determine the sequence of the high-affinity oligomers.
Figs. 22A-22D illustrate various solution-phase methods for identifying desired library oligomer sequence(s). Here a library particle 62 carrying molecules, such as molecules 64, having one of the library sequences is reacted with the receptor 66 in solution phase, under conditions which lead to receptor binding to high-affinity library particles, as illustrated in Fig. 23B. The particles with bound receptor may be further reacted with reported-labeled antibody 68 specific against the receptor molecules, to label the desired library particle(ε) with a suitable reporter, such as a fluoreεcent label, aε indicated in Fig. 23C. The labeled particles may be removed by micromanipulation, e.g., under fluorescent microscopy, or using standard cell sorting methods to isolated reporter-labeled particles.
Alternatively, the particle density may be so selected that binding of receptor protein to the particles increases the particle denεity sufficiently to separate receptor- bound particles on the basis of differential density, as illustrated in Fig. 23D. The figure shows a receptor-bound particle being separated by centrifugation or particle settling in a medium 70 whoεe denεity is intermediate between the denεity of particles 72 that do not contain bond receptor, and those, such aε particle 62, that do.
A preferred type of particle for density separation which has desired density and solvent-reεistance properties is macroporous polystyrene particles in the size range of 20 to 200 microns in diameter. Such macroporous particles, which are used for ion exchange chromatography, can be obtained which have large surface to mass ratios, suitable pore sizes (in the range of 400 to 1000 angstroms) , and which have surfaces containing covalently linked amine, hydroxyl, or carboxyl groups, which provide convenient sites for anchoring oligomers.
Other methods of isolating library particles having desired receptor-binding properties are also contemplated. For example, in the case of an antibody receptor, the bivalent nature of the antibody could be used to crosslink particles having high-binding ligands on their surfaces.
Alternatively, where the receptor is carried on cell εurface, the library particles, such as polymeric particles having particle sizes in the 0.5-2 μm range, are reacted with the cells under conditions that promote ligand- εpecific receptor surface binding, followed by one or more cell washes, to remove unbound particles, and release of bound particle(s) from the washed cells.
VI . Determination of Oligomer Seguence
Once a library oligomer having a desired interaction, e.g., binding interaction, with a receptor is identified, the oligomer molecules, it must be sequenced to determine the sequence of side chains. This may be done in accordance with various sequencing methods, several of which are given below, and in Example 18. A. Oligonucleotide Amplification
Aε indicated above, the oligomer library may be formed of oligomer molecules having (i) nucleobase side chains and (ii) intersubunit linkages that allow Watson-Crick baεe pairing between the nucleobases the bases of complementary- base sequence oligonucleotides.
In this embodiment, the isolated oligomer molecules, whether in εolution phaεe or carried on a particle, are reacted with a combinatorial library of oligonucleotideε, under hybridization conditionε that permit complementary εtrand hybridization between the selected oligomer molecules and same-sequence oligonucleotide molecules.
The bound oligonucleotide molecules are then released, made double stranded, amplified, e.g., by polymerase chain reaction, and sequenced according to standard methods. The sequence obtained corresponds then to the side-chain sequence of the isolated oligomer molecules.
Both the library oligomer molecules and the random- sequence oligonucleotides may have known-sequence oligonucleotide end segments to enhance hybridization between the two. If the oligomers are designed to contain a mixture of nucleobases and either modified nucleobases or non-nucleobase sidechains, the stringency of the hybridization conditions may be reduced, to allow some non- pairing with oligomer bases. Sequencing the bound oligonucleotides would be effective to reconstruct the oligomer εequence in εome, but not all, εubunit poεitions.
B. Isolated Particle Sequencing In the embodiment in which the library oligomers are contained on particles, with each particle containing only one oligomer sequence, the isolated particles are treated to release the attached oligomer molecules, and the release molecules are sequenced, e.g., by micro maεs spectrometry, εuch as detailed in Example 17 below. Preferably, each particle provides sufficient oligomer material for microsequencing, to avoid the problem of sequencing mixed- sequence oligomers derived from different beads.
In a modification of this approach, the library particles are prepared to contain a family of different- length, same-sequence oligomer molecules, as described above. After cleavage of the family of oligomers from an isolated particle surface, sinapinic acid iε added and the material iε placed under reduced pressure to remove volatile material, and then inεerted into a maεs spectrometer, preferably a laser-desorption time-or-flight mass spectrometer. By this means, when the oligomer- particles are asεembled aε described above, the mass spectrum permits ready determination of the exact masε of each subunit, as well as the order of said subunits in each oligomer specie of the family of oligomers. This procedure even affords exact structureε for properly aεεembled branched oligomerε. Once the εequence haε been determined for the family of N oligomerε εpecies from a single particle, oligomers having that εequence, and εizeε ranges from 1 to N subunits, may be prepared to determine the oligomer length that affords higheεt binding affinity, or which provideε the best compromise between high binding affinity and length.
C. Solution-Phase Iterative-Search Method
In those cases where it is desirable to test oligomers free in solution, instead of attached to the surface of a particle, oligomer libraries can be prepared as described earlier, but cleaved from the support before testing. When testing is carried out with oligomer free in solution, one can asseεs for a broader range of activities than just target binding, such aε inhibition or activation of enzymes, blocking of binding of ligands, etc. Screening of these oligomers free in solution, along with an iterative selection and synthesis procesε for the systematic identification of oligomers having a desired biological activity can be carried out by methods modeled after those reported by Houghten, et al . (Nature 354 84 (1991)) .
From the foregoing, it can be appreciated how various objects and features of the invention are met. The combinatorial library is easy to synthesis by stepwise solution-phaεe or εolid-phaεe methodε, with the morpholino εubunit εtructureε making up the oligomerε being preformed or formed during εtepwise synthesis. The ability to construct εubunit structures with a wide range or nucleobase, modified nucleobase, aromatic, aliphatic, and mixed base side chains allows the construction of libraries having virtually any desired degree of complexity. The poεsible complexity of the libraries is further enhanced by the stereochemical variations, and variations in linkages that are possible, as well as the ability to construct branched oligomers.
The oligomerε may be readily screened for a desired interaction with a selected receptor, e.g., according to binding affinity. The invention provides a variety of methods for isolating library particleε containing deεired oligomer ligandε, aε well aε εimple methodε for determining oligomer εequenceε.
The following examples illustrate variouε εynthetic procedureε for preparing oligomerε uεeful in the invention. The examples are intended to illustrate, but not limit the scope of the invention.
Materialε Unless otherwise indicated, chemicals are purchased from Aldrich Chemical Co. Abbreviations used: Tr = trityl (triphenylmethyl) ; DMT = 4, 4'-dimethoxytrityl; CBz (phenylmethyl) oxycarbonyl ; Boc = ( 1 , 1- dimethyl ) ethyloxycarbonyl ; FMOC = ( 9 - fluoreny Imethy 1 ) oxycarbonyl ; TBDMS = tert- butyldimethylsilyl; TBDPS = tert-butyldiphenylsilyl, Ac = acetate; Bz = benzoate, DBU = 1, 8-diazabicyclo[5.4.0]undec- 7-ene, NMP = l-methyl-2-pyrolidinone. Referenced Methods The following references discloεe variouε synthetic procedureε referred to in the exampleε, and are incorporated herein by reference: Allevi, et al . , J. Chem. Soc, Perkin Tranε 1:1275 (1981) .
Araki, et al . , Tetrahedron Lett. 29:351 (1988) . Armitage, et al . , J. Chem. Soc, Perkin Tranε 1:680 (1972) . Belloεta and Czernecki, J. Chem. Soc, Chem. Commun. , 199 (1989) .
Benεeler and McLaughlin, Synthesis, 46 (1986) . Carpino, et al . , J. Chem Soc, Chem. Commun. 358 (1978) . Carpino and Han, J. Org. Chem. 22:3404 (1972).
Chow and Daniεhefsky, J. Org. Chem. 5_5:4211 (1990). Cook, et al . , J. Amer. Chem. Soc, 98.: 1492 (1976) . Czernecki and Ville, J. Org. Chem. 54.:610 (1989). Heikkila and Chattopadhyaya, Acta Chem. Scand. B37:263 (1983) .
Hiεkey and Adams, J. Amer. Chem. Soc. 22:3969 (1965) . Holy, et al . , Collect. Chezh. Chem. Common. 42:2246 (1977) .
Kδεter, et al . , Tetrahedron 4_0:1031 (1984) . Knieb-Cordonier, et al . , Int. J. Peptide Protein Res. 25:527 (1990) .
Krauε and Molina, J. Org. Chem. 5_3:752 (1988) . Kruse, et al . , Tetrahedron Lett., 885 (1977). Lichtenhaler, et al . , Tetrahedron Lett. 24:2141 (1974).
Martin and Lai, J. Org. Chem. 25:5188 (1990). Maercker, Org. React. 2Λ-270 (1965) .
Niedballa and Vorbrϋggen, J. Org. Chem. 39: 3654 (1974) . Pischel and Wagner, Arch. Pharm (Weinheim) 300:602 (1967) .
Posner, Org. React. 2: 53 (1975). Rammler and Khorana, J. Amer . Chem . Soc , 84 : 3112
(1962) .
Sakakibari, et al . , Carjb. Res . 9_5:291 (1981).
Southon and Pfleiderer, Chem . Ber . 111:996 (1978) . Srivastava and Nagpal, Experentia 2--.:220 (1970).
Stork and Isobe, J. Amer . Chem Soc , 2:6260 (1975).
Tronchet, et al . , Nucl . Nucl . , 12:615 (1993) .
Vorbrugen, et al . , Justus Liebigs, Ann . Chem . 988
(1975) . Winkley and Robins, J. Org . Chem . 22:2822 (1968) .
Wittenberg, Z., Chem . 4.:303 (1964) .
Yamamato, et al . , J. Chem . Soc , Perkin Trans 1:306
(1980) .
Yanagisawa and Kanazaki, Heterocycles 2.5:105 (1993) .
Example 1
Preparation of Morpholino Subunitε from Substituted Ribofuranoεides
A. General Procedure for Protection of the R Group l. Protection of amino groups on heteroaromatic rings. The ribofuranoside (1 mol) is suspended in acetonitrile (2.5 L) and hexamethyldisilazane (5 mol) is added. The solution is refluxed until solution is complete and the solvents then are removed by distillation. Residual hexamethyldisilazane is removed by addition of xylene (IL) and removal by diεtillation. The residue is dissolved in pyridine (2.5 L) and treated with trimethylchlorosilane (5 mol) . After the solution is stirred for 15 minutes, an acid chloride or chloroformate or similar acylating agent (5 mol) iε added and the solution is maintained at room temperature for 3-24 hours. The reaction is cooled in an ice bath and water (500 ml) iε added. After stirring for 5 minutes cone ammonia (500 ml) is added, and the reaction is εtirred for 15 minutes. The solution iε evaporated to near dryneεs and the residue iε poured into water (10 L) . The product iε isolated by filtration. Representative examples of ribo uransoideε and the corresponding acylating agents are cytidine and benzoyl chloride; adenosine and benzoyl chloride; guanoεine and the eεter formed from 1-hydroxybenzotriazole and phenylacetyl chloride (Benεeler and McLaughlin) . Alternatively, the FMOC group may be introduced by the method of Heikkila and Chattopadhyaya.
2. Protection of aliphatic or carbocyclic aromatic amines. Amino groupε are protected by conversion to the trifluoroacetamide by treatment with p-nitrophenyl trifluoroacetate or trifluoroacetic anhydride, or by conversion to the 2-trimethylsilylethyl carbamate by the method of Carpino or the FMOC group by the method of Carpino and Han. 3. Protection of thiols. The mercapto group iε reacted by the method of Armitage, et al , to produce the S- diεulfide.
4. Protection of alcoholε. Alcohols may be protected by reaction with benzoyl chloride or a substituted benzoyl chloride, eg, anisoyl chloride, in pyridine to form the ester. Alternatively, the hydroxyl group is silylated with t-butyldiphenylεilyl chloride and imidazole in DMF.
B. General Procedure for Formation of the Morpholino Ring
1. Using ammonia. The furanoεide (1 mole) is oxidized in methanol (4L) at room temperature by the addition of sodium periodate (1.1 mol) in 400 mL of warm water with vigorous stirring and exclusion of light. After the oxidation is complete, the reaction is filtered to remove sodium iodate and the filtrate treated with ammonium biborate (1.2 equivalents) . After stirring for 30 minutes, the mixture is treated with εodium cyanoborohydride (1 mol) followed by 6N hydrochloric acid until a pH = 4.5 iε obtained. The reaction iε allowed to εit at zero degrees C overnight and then evaporated. Aε an alternative, p-toluenesulfonic acid (or other arylsulfonic acid) may be used in place of 6N HCl in the reduction step. In certain cases a crystalline salt of the morpholino derivative and the sulfonic acid is obtained which may be filtered off and used in the next step. This method is especially effective for morpholino derivatives of uridine, N-4 benzoylcytidine and N-2 phenylacetylguanosine.
2. Using primary amines. The ribofuranoside iε oxidized with periodate as in the example above, and the filtered dialdehyde treated with 1.2 moles of a primary amine. Two amines which are satiεfactory for thiε purpose are 4-methoxyaniline and 4-methoxybenzyl amine. After stirring for 30 minutes, the mixture is treated with sodium cyanoborohydride (1 mol) followed by 6N hydrochloric acid until a pH = 4.5 is obtained. The reaction is allowed to sit at room temperature overnight and the product N-aryl or N-alkyl morpholino subunit is filtered from solution.
C. General Procedure for Protection of the Morpholino Ring Nitrogen
The crude residue, or sulfonate εalt, from the morpholino ring εyntheεis is suεpended in DMF (2L) and treated with triethylamine (10 moleε) and evaporated to near dryneεε. The reεidue iε again suspended in DMF (2L) and treated with triethylamine (4 moles) and trityl chloride (2 moles) while the temperature is maintained at 10 degrees C. The reaction is vigorously εtirred for 15 inuteε at room temperature, then quenched by the addition of piperidine (1 mole) . After 5 minutes, the reaction is poured into 20L of a one to one water/satd NaCL solution. The solids are collected, washed with water, and dissolved in 2L of 20% methanol/chlorofor . To thiε is added 2L of 20% isopropanol/chloroform and the mixture washed conεecutively with water, 5% εodium bicarbonate, and brine. The organic layer iε dried over εodium εulfate, filtered, and evaporated to provide crude N-tritylmorpholino subunit. The εubunit may be purified by silica gel chromatography.
Aε alternatives, base senεitive amine protecting groups may be incorporated, for example, 9- fluorenylmethylcarbonyl (using FMOC chloride in pyridine/DMF and quenching with water) .
D. General Procedure for the Removal of Alkyl and Aryl Groups from the Morpholino Nitrogen of Morpholino Subunitε
For morpholino εubunitε poεεeεεing benzylic groups at the morpholino nitrogen, the compound is hydrogenated over
Pd catalyst in methanol of ethanol/DMF mixtures. The εecondary amine produced may be protected as in the general Example.
For morpholino subunits posεeεsing either 4- ethoxyphenyl or 4-methoxybenzyl groups at the morpholino nitrogen, the compound is diεεolved in methanol or methanol/DMF mixture containing 4 molar equivalentε of acetic acid and 2 molar equivalentε of εodium acetate. Cerric ammonium nitrate (2 molar equivalentε) iε added and the reaction εtirred at room temperature for 1-24 hours. After evaporation of the solventε the morpholino nitrogen may be protected aε in the general Example.
Example 2
Preparation of Morpholino Subunitε from Substituted Hexopyranoεides
A. General Procedure for Protection of the R Group 1. Protection of amino groups on heteroaromatic rings. Protection iε done aε in Example 1A1.
2. Protection of aliphatic or carbocyclic aromatic amines. Protection iε done as in Example 1A2.
3. Protection of thiols. Protection iε done as in Example 1A3.
4. Protection of alcohols. Protection is done as in Example 1A4. B. General Procedure for Formation of the Morpholino
Ring The morpholino ring is constructed as in Example IB with the sole exception that 2.2 moles of sodium periodate are used in the oxidation step.
C General Procedure for Protection of the Morpholino Ring Nitrogen
The morpholino ring nitrogen is protected as in Example IC.
D. General procedure for the removal of alkyl and aryl groupε from the morpholino nitrogen of morpholino εubunitε. The nitrogen iε deprotected as in Example ID.
Example 3 Preparation of Subunits with Nucleobase Side Chains The example illustrate the uεe of the D-εugarε. The enantiomeric subunits may be obtained by employing the corresponding L-sugars.
A. Uracil as Nucleobase
1. Uridine was converted into the morpholino subunit 32.2b (Xi=uracil-l-yl) by the general procedure.
2. Uracil is biε-trimethylεilylated according to the procedure of Niedballa and Vorbruggen. Uracil iε diεεolved in benzene, and added to 1, 2 , 3 ,4 , 6-penta-O- acetyl-β-D-glucopyranoεe 33.1b (Xi=/5-OAc) (Niedballa and Vorbruggen) in 1,2 dichloroethane followed by tin tetrachloride in 1, 2-dichloroethane according to the method of Vorbruggen and Niedballa to provide the 1- (2, 3,4,6- tetra-O-acetyl- -D-glucopyranoεyl)uracil 33.1b (Xi= β- uracil-1-yl) . Following methanolyεis with sodium ethoxide in methanol the 1-(B-D-glucopyranoεyl)uracil 33.1a (Xi= β- uracil-l-yl) iε obtained. Thiε iε converted into the morpholino εubunit 32.2b (Xi= β-uracil-1-yl) by the general procedure. B. Thymine as Nucleobaεe
1. Ribothymidine 32.1a (Xi=/3-thymin-l-yl) is prepared by the method of Tronchet, et al . It is converted into the morpholino subunit 32.2b (Xi=β-thymin-l-yl) by the general procedure.
2. Thymine is silylated by the general procedure of Wittenberg and reacted aε for uracil in the Example 3a2 above to prepare the morpholino T derivative 32.2b (Xi=β- thymin-1-yl) . A wide variety of other 5-εubεtituted uracilε (halo, alkynyl, alkyl, alkenyl, nitro) may be prepared in thiε manner. In some caseε the use of acetonitrile in the Hilbert-Johnson reaction is advantageous.
C. N4-benzoylcytosine as Nucleobase
1. Cytidine was converted into the morpholino εubunit 32.2b (Xi=β-N4-benzoylcytidin-l-yl) by the general procedure.
2. The l-(2,3,4 , 6-tetra-0-acety1-/3-D- glucopyranosyl) uracil from Example 3A2 is treated with phosphoruε pentasulfide in benzene to provide the 4- thiouracil derivative. Reaction with triethylamine and dimethyl sulfate produce the S-alkylated species which is converted into 1-( -D-glucopyranosyl) cytosine 33.1a ( Xi=β- cytidin-1-yl) by treatment with methanolic ammonia. Following protection of the heterocyclic amine this iε converted into the morpholino subunit 32.2b (Xi=/3-N4- benzoylcytidin-1-yl) by the general procedure.
3. The l-(jδ-D-glucopyranosyl)uracil from Example 3A2 is treated with hexmethyldisilazane by the method of
Vorbruggen, et al . Following protection of the heterocyclic amine this iε converted into the morpholino subunit by the general procedure.
4. Cytoεine iε εilylated by the general method of Wittenberg. It iε reacted with 1, 2 , 3 , 4 , 6-penta-O- acetyl-β-D-glucopyranose in 1,2 dichloroethane followed by tin tetrachloride in 1, 2-dichloroethane (or acetonitrile) according to the method of Vorbruggen and Niedballa to provide the 1 - ( 2 , 3 , 4 , 6 -tetra -0-acety 1 - β -D- glucopyranosyl) cytosine 33.1b (Xi=β-cytidin-l-yl) . Following methanolysis with sodium methoxide in methanol the 1- ( -D-glucopyranosyl)cytosine is obtained. Following protection of the heterocyclic amine this is converted into the morpholino εubunit 32.2b (Xi=β-N4-benzoylcytidin-l-yl) by the general procedure.
D. N4-Benzoyladenine aε Nucleobaεe
1. Adenoεine waε converted into the morpholino εubunit 32.2b (Xi=3-N6-benzoyladenin-l-yl) by the general procedure.
2. N-6-Benzoyl-9-(2,3,4,6-tetra-O-acetyl-β-D- glucopyranoεyl) adenine (Lichtenhaler, et al . ) iε treated with 2:1 ammonium hydroxide/DMF at 45 degreeε C for 15 hourε to give 9- (/3-D-glucopyranoεyl)adenine 33.1a (Xi= β- adenin-9-yl) . The amino group iε protected aε in the general Example and the morpholino εubunit 32.2b (Xi= -N4- benzoyladenin-9-yl) produced by the general procedure for hexopyranoεides. A more direct method for the conversion of the glucoside into the morpholino subunit employs the selective O-deacylation procedure of Rammler and Khorana on
N-6-Benzoyl-9- ( 2 , 3 , 4 , 6-tetra-O-acetyl-jS-D- glucopyranosyl) adenine to give N-6-Benzoyl-9- (β-O- glucopyranoεyl) adenine which iε converted into the morpholino εubunit by the general procedure.
E. Hvpoxanthine as Nucleobase 1. Inosine waε converted into the morpholino εubunit 32.2b (Xi= β-hypoxanthin-9-yl) by the general procedure for ribofuranosides.
2. Inosine is silylated by the general procedure of Wittenberg. It is reacted with 1, 2 , 3 ,4 , 6-penta-O- acetyl-β-D-glucopyranose in 1,2 dichloroethane followed by tin tetrachloride in 1, 2-dichloroethane (or acetonitrile) to prepare 9 - ( 2 , 3 , 4 , 6 -tetra -O - a cety 1 - β -D- glucopyranosyl) hypoxanthine 33.1b (Xi= β-hypoxanthin-9-yl) . Methanolyεiε of the esters and application of the standard procedure for morpholino ring syntheεiε produce the εubunit 32.2b (Xi= /3-hypoxanthin-9-yl) .
F. N2-Phenylacetγlguanine aε Nucleobaεe
1. Guanoεine was converted into the morpholino subunit 32.2b (Xi= j3-N-2-phenylacetylguanin-9-yl) by the general procedure for ribofuranosideε. 2. N-2-Acety1-9-(2,3,4, 6-tetra-0-acetyl-j3-D- glucopyranoεyl)guanine (Lichtenhaler, et al . ) waε treated with 2:1 ammonium hydroxide/DMF at 45 degrees C for 15 hours. The amino group is protected aε in the general Example and the morpholino subunit 32.2b (Xi= β-N-2- phenylacetylguanin-9-yl) produced by the general procedure for hexopyranosides.
Example 4 Preparation Subunitε with Modified Nucleobaεe Side Chains A variety of pyrimidines, purines, and their analogε may be converted into the corresponding ribofuranosideε and hexopyranoεides by the methods of Niedballa and Vorbruggen and by the methodε of Lichtenhaler, et al . Theεe may be further processed to morpholino subunitε aε per the exampleε below.
A. 6-Methyluracil as Side Chain 6-Methyluridine (Winkley and Morris) is converted into the N-tritylated morpholino subunit by the general procedure to give 32.2b (Xi= β-6-methyluracil-l-yl) .
B. N3.6-Dimethyluracil as Side Chain
Treatment of 32.2b (Xi= β-6-methyluracil-l-yl) from
Example 4A with methyl iodide and DBU in DMF affords the N- 3 methylated derivative 32.2b (Xi= β-N3 , 6-dimethyluracil-l- yi). C. 6-Methylcytosine as Side Chain
1. 6-Methylcytidine (Winkley and Robins) is converted into the morpholino subunit 32.2b (Xi= β-6- methylcytosin-1-yl) by the general procedure. 2. Treatment of 32.2b (Xi= β-6-methyluracil-l- yl) from Example 4A with TBDMS-Cl in pyridine followed by triisopropylbenzenesulfonyl chloride in methylene chloride containing triethylamine provides the 0-4 sulfonated specieε which iε converted into 32.2b (Xi= 0-N4-benzoyl-6- methylcytosin-1-yl) by treatment with ammonia in DMF followed by protection of the base by the standard procedure and silyl cleavage.
D. N4.6-Dimethγlcytosine as Side Chain Treatment of 32.2b (Xi= 0-6-methyluracil-l-yl) from Example 4A with TBDMS-Cl in pyidine followed by triisopropylbenzenesulfonyl chloride in methylene chloride containing triethylamine provide the 0-4 sulfonated species which is converted into 32.2b (Xi= j8-N4-benzoyl-N4, 6- dimethylcytoεin-1-yl) by treatment with methylamine in DMF followed by protection of the baεe by the εtandard procedure and εilyl cleavage.
E. N6 ,N6-dimethyladenine aε Side Chain Inosine waε converted into the N-tritylated morpholino εubunit 32.2b (Xi= hypoxanthin-9-yl) by the general procedure. Following converεion into the 5-t- butyldimethylsilyl ether using TBDMS-Cl in pyridine, treatment with triisopropylbenzenesulfonyl chloride in methylene chloride containing triethylamine provide the 0-6 εulfonated εpecieε which iε converted into 32.2b (Xi= β- N6,N6-dimethyladenin-9-yl) by treatment with dimethylamine in DMF and εilyl cleavage.
F. 8-Methylhypoxanthine aε Side Chain
8-Methylhypoxanthine (Koppel and Robinε) iε εilylated by the general procedure of Wittenberg and converted into 8 -methy l -9 - ( 2 , 3 , 5-Tr i -O- benz oy 1 -beta -D- r i bo f ur a nosy 1 ) hy poxan th i ne 32.1b (Xi= β-8- methylhypoxanthin-9-yl) by the method of Lichtenhaler, et al . This product is converted into the morpholino subunit 32.2b(Xi= β-8-methylhypoxanthin-9-yl) produced by the general procedure for ribofuanoεides.
G. 8-Methylhypoxanthine as Side Chain
The hypoxanthine morpholino subunit from Example 3E iε treated with 1.1 equivalentε of εodium hydride in DMF followed by methyl iodide to produce the 1,8- dimethylhypoxanthine morpholino subunit 32.2b (β-Nl- methylhypoxanthin-9-yl) . The use of other alkyl groups allowε the formation of other 1-alkyated hypoxanthine εubunitε.
H. Nl , 8-Dimethylhypoxanthine as Side Chain
The 8-methylhypoxanthine morpholino εubunit from
Example 4F iε treated with 1.1 equivalents of sodium hydride in DMF followed by methyl iodide to produce the
1, 8-dimethylhypoxanthine morpholino subunit 32.2b (0-Nl,8- dimethylhypoxanthin-9-yl) .
I . 8-Bromo-N2-phenylacetylguanine as Side Chain The guanosine is bro inated by stirring with N- bromoεuccinimide in DMF at room temperature by the method of Srivaεtava and Nagpal. This is converted into the morpholino εubunit 32.2b (Xi= 3-8-bromo-N2- phenylacetylguanin-9-yl) by protection of the amine, morpholino ring synthesis and tritylation as per the general procedures. The 8-bromoadenine and 8- bromohypoxanthine species may be prepared similarly.
J. 8-Methylthio-N2-phenylacetylguanine as Side Chain The 8-bromoguanine derivatives in Example 41 are converted into the 8-methylthio species by reaction with sodium thiomethoxide in DMF. The 8-bromoadenine and 8- bromohypoxanthine specieε may be εi ilarly converted.
Example 5 Preparation of Subunits with Non-Nucleobase Side Chains
A. Methyl 4 (5) -methylimidazole-5(4) -carboxylate as Side Chain
Methyl 4 (5) -methylimidazole-5 (4) -carboxylate is silylated and reacted with an equimolar amount of 1,2,3,4, 6-penta-0-acetyl-3-D-glucopyranose by the method of Cook, et al . , using at least 1.44 mole of stannic chloride per mole sugar yields the acetylated sugar. Methanolysis with εodium methoxide in methanol provideε methyl 5-methyl- 1- (0-D-glucopyranoεyl) imidazole-4-carboxylate 33. la (Xi= 4- methoxycarbonyl-5-methylimadzol-l-yl. Thiε may be converted into the morpholino subunit 32.2b (Xi= β-4- methoxycarbonyl-5-methylimadzol-l-yl) by the standard procedure.
B. 2-Qxo-l .2-dihyropyridin-l-yl aε Side Chain
The pyridone ribofuranoεide 32.1a (Xi= β-2-oxo-l, 2- dihyropyridin-1-yl) (Pischel and Wagner) iε converted into the corresponding morpholino subunit 32.2b (Xi= β-2-oxo- 1, 2-dihyropyridin-l-yl) by the standard procedureε.
C 2-Qxo-l.2-dihyropyrimidin-l-yl aε Side Chain The pyrimidone ribofuranoside 32.1a (Xi= β-2-oxo-l, 2- dihyropyrimidin-1-yl) (Holy, et al ) is converted into the corresponding morpholino subunit 32.2b (Xi= β-2-oxo-l, 2- dihyropyrimidin-1-yl) by the standard procedureε.
D. Benzimidazole aε Side Chain
The benzimidazole containing ribofuranoεide 32.1a (Xi= ιδ-benzimidazol-1-yl) prepared by the method of Southon and Pfleiderer iε converted into the morpholino subunit 32.2b (Xi= β-benzimidazol-1-yl) by the standard procedure.
E. Phenyl as Side Chain The methods below may be used to prepare a wide variety of aryl subεtituted morpholino subunits.
1. 34.1a (Xi= C6H5) The C-phenyl glycoside 33.1a (Xi= jδ-phenyl) prepared by the method of Czernecki and Ville is converted into the morpholino subunit 32.2b (Xi= β-phenyl) by the general procedure.
2. 34.2a (Xi= CήHs) 3 , 4 , 6-Tri-O-benzyl-l, 2- anhydro-β-D-mannopyranoεe waε reacted with lithium diphenyl cuprate (Posner) uεing the procedure of Belloεta and Czernecki. The phenyl mannopyranoεide 33.3d (Xi= -phenyl) is hydrogenated to remove the benzyl groups and converted into the morpholino subunit by the εtandard procedure to provide 34.2a (Xi= α-phenyl) .
3. 34.3a (Xi= C6HS) This iε made from L-mannoεe by the procedure in 4E2.
4. 34.4a (Xi= C6H5) This is made from L-glucose by the procedure in 4E1.
F. Alkyl aε Side Chain The methods below may be used to prepare a wide variety of alkyl or aralkyl (for example, benzyl or phenethyl) subεtituted morpholino subunits.
1. 34.la (Xi= CH,) The -methyl glycoside 33.1b (Xi= jS-methyl) prepared by the method of Bellosta and Czernecki iε converted into the morpholino εubunit 32.2b (Xi= β-methyl) by the general procedure.
2. 34.2a (Xi= CH,) 3 , 4 , 6-Tri-O-benzyl-l, 2- anhydro-β-D-mannopyranoεe was reacted with lithium dimethyl cuprate (Posner) using the procedure of Bellosta and Czernecki. The methyl mannopyranoside 33.3d (Xi= α-ethyl) iε hydrogenated to remove the benzyl groupε and converted into the morpholino εubunit by the εtandard procedure to provide 34.2a (Xi= α-methyl) .
3. 34.3a (Xi= CH,) Thiε is made from L-mannose by the procedure in 4E2.
4. 34.4a (Xi= CH,) This is made from L-glucose by the procedure in 4E1. G. Aliphatic Side Chainε Bearing Hydroxy Groups 1. Hydroxymethyl a. 34.1a (Xi= CH2OTBDPS) : The vinyl glucopyranoside 33. Id (Xi= -ethenyl) , prepared by the method of Kraus and Molina iε ozonolyzed in a mixture of methanol and ethyl acetate and after removal of the ozone the reaction is quenched with sodium borohydride in methanol to provide the alcohol 33. Id (Xi= β-CH2OH) . Thiε iε converted into the t-butyldiphenylεilyl ether by the general procedure. Catalytic hydrogenation removeε the benzyl protecting groupε and the molecule iε converted into the morpholino subunit 34.1a [32.2b] (Xi= jβ-CH?OTBDPS) by the general procedure. b. 34.2a (Xi= CH?OTBDPS) : 3,4,6-Tri-O- benzyl-1, 2-anhydro-β-D-mannopyranoεe iε reacted with lithium divinyl cuprate (Poεner) (REF) using the procedure of Bellosta and Czernecki. The vinyl mannopyranoside 33.3d (Xi= α-ethenyl) iε further treated aε per the procedure in Example 4Gla to provide 34.2a (Xi= CH2OTBDPS) . c 34.3a (Xi= CH2OTBDPS) : The alcohol 33. Id
(Xi= β-CH2OH) prepared aε in Example 4Gla is converted into the t-butyldiphenylsilyl ether by the general procedure. Catalytic hydrogenation removeε the benzyl groupε. The glucoεide is converted to the "α-morpholino" subunit 34.3a (Xi= CH2OTBDPS) by the procedure in Summerton, et al (US patent, 5,235,033) . This compound may also be prepared by application of the procedureε in Example 4Glb to L-mannose. d. 34.4a (Xi= CH2OTBDPS) : The hydroxymethyl glucopyranoside 33. Id (Xi= |3-CH2OH) prepared as in Example 4Gla is reacted with trimethylacetyl chloride in pyridine. Catalytic hydrogenation removes the benzyl protecting groups and the molecule is converted into the morpholino εubunit 32.2b (Xi= 0-CH2OCO-C(CH,) ,) by the general procedure. The free alcohol iε εilylated according to the general procedure and the product iε treated with lithium aluminum hydride in THF to prepare the free alcohol 34.4a (Xi= CH,OTBDPS) . This compound may also be obtained by application of the procedures in Example 4Gla to L-glucoεe. 2. Hydroxyethyl a. 34.1 (Y= CH2OH, Xi= CH2CH2OTBDPS) : The tetrabenzylated hydroxyethyl derivative 33. Id (Xi= β-
CH2CH2OH) prepared by the method of Allevi, et al , iε protected aε the t-butyldiphenylsilyl ether by the general procedure, the benzyl groups removed by catalytic hydrogenation over Pd on charcoal, and the morpholino ring formed by the general procedure. Alternatively, the vinyl glucopyranoside 33. Id (Xi= β-ethenyl) from Example 4Gla is treated with borane-THF followed by alkaline hydroperoxide to yield the tetrabenzylated starting material. b. 34.2 (Y= CH2OH, Xi= CH2CH2OTBDPS) : The tetrabenzylated hydroxyethyl derivative 33. id (Xi= α-
CH2CH?OH) , prepared by the method of Allevi, et al , is protected aε the t-butyldiphenylsilyl ether by the general procedure, the benzyl groups removed by catalytic hydrogenation over Pd on charcoal, and the morpholino ring formed by the general procedure. Alternatively, the vinyl mannopyranoεide 33.3d (Xi= α-ethenyl) from Example 4Glb iε reacted with εodium hydride in DMF with benzyl chloride, then treated with borane-THF followed by alkaline hydroperxide to yield the 33. Id (Xi= αCH2CH2OH) . This is protected as the t-butyldiphenylsilyl ether by the general procedure, the benzyl groups removed by catalytic hydrogenation over Pd on charcoal, and the morpholino ring formed by the general procedure. c 34.3 (Y= CH2OH, Xi= CH2CH2OTBDPS) : Is prepared from L-glucose or L-mannose by the methodε in
Example 4G2b. d. 34.4 (Y= CH,0H, Xi= CH,CH,OTBDPS) : Is prepared from L-glucoεe by the methodε in Example 4G2a.
3. Hydroxypropyl a. 34.1 (Y= CH,OH, Xi= CH2CH2CH2OTBDPS) : Xanthate 32.1 (R,,R,= iεopropylidene, R_,= benzoyl, Xi= O-CS- SCH (Araki, et al . ) is reacted with methyl acrylate in the presence of tributyltin hydride and 2,2'- azobis (isobutyronitrile) as initiator to produce the C- riboside eεter 32.1 (R2,R,= iεopropylidene, R,= benzoyl, Xi= CH,CH2C02CH,) . Treatment with methanolic HCl gave the free triol which waε converted into the morpholino εubunit 32.2b (Xi= ιβ-CH2CH2C02CH,) by the εtandard procedure. Protection of the hydroxy group aε the benzyloxymethyl ether (Stork and Isobe) followed by treatment with lithium aluminum hydride in THF, then silylation aε in the εtandard procedure, and catalytic hydrogenation provideε the deεired protected alcohol 34.1 (Y= CH20H, Xi= CH2CH2CH2OTBDPS) . b. 34.2 (Y= CH2OH, Xi= CH2CH2CH2OTBDPS) : Eεter 33.1b (Xi= α-CH2CH2C02CH,) (Adlington, et al . ) iε reacted with methanolic HCl to give the free tetraol which was converted into the morpholino subunit 32.2b (Xi= α- CH2CH2C02CH,) by the standard procedure. Protection of the hydroxy group aε the benzyloxymethyl ether (Stork and Iεobe) followed by treatment with lithium aluminum hydride in THF, then εilylation as in the standard procedure, and catalytic hydrogenation provides the desired protected alcohol 34.2 (Y= CH2OH, Xi= CH,CH,CH?OTBDPS) . c. 34.3 (Y= CH2OH, Xi= CH2CH2CH2OTBDPS) : Is prepared from L-glucose by the methodε in Example 4G3b. d. 34.4 (Y= CH2OH, Xi= CH2CH2CH,OTBDPS) : Iε prepared from L-riboεe by the methodε in Example 4G3a.
4. Homologous ω-hvdroxyalkyl Derivatives
Higher order alcohols 34.1-34.4 (Y= CH20H, Xi= CH2[CH2]n CH2OTBDPS) may be made by the following procedure from lower order alcohols: The hydroxymethyl group of 34.1-34.4 (Y=
CH2OH, Xi= [CH2]nOTBDPS) is protected as the benzyloxymethyl ether by the method of Stork and Isobe, then the TBDPS group is removed with tetrabutylammoniu fluoride. The alcohol iε converted into a tosylate and reacted with εodiodiethylmalonate in DMSO. The ester is εaponified, acidified and decarboxylated. Following treatment with trityl chloride in DMF to replace any trityl cleaved in the proceεε, the acid iε reduced with lithium aluminum hydride in THF, the alcohol silylated by the standard procedure to provide 34.1-34.4 (Y= CH2OH, Xi= [CH2]n+2OTBDPS) .
5. Other Alcohol Containing Side Chains The hydroxyymethyl group of 34.1-34.4 (Y= CH2OH, Xi= [CH2]πOTBDPS) iε protected aε the benzyloxymethyl ether by the method of Stork and Iεobe, then the TBDPS group iε removed with tetrabutylammoniu fluoride. The alcohol iε converted into an aldehyde with diisopropylcarbodiimide in DMSO containing a small amount of pyridinium methaneεulfonate . The aldehyde may be reacted with any of a large variety of Grignard or organolithium reagentε to provide εecondary alcohols. These may be silylated by the general procedure and the hydroxymethyl freed by hydrogenolyεiε. The εecondary alcoholε may by oxidized to ketoneε which may be reacted again with any of a large variety of Grignard or organolithium reagentε to provide tertiary alcoholε. Theεe typically do not require protection and the final εubunit may be prepared by hydrogenolyεiε.
H. Aliphatic Side Chainε Containing Carbon-Carbon Double Bondε
The hydroxyymethyl group of 34.1-34.4 (Y= CH2OH, Xi=
[CH,]n0TBDPS) iε protected aε the benzoate eεter then the
TBDPS group iε removed with tetrabutylammonium fluoride.
The alcohol iε converted into the aldehyde with diisopropylcarbodiimide in DMSO containing a small amount of pyridinium methaneεulfonate. The aldehyde may be reacted with any of a large variety of Wittig reagentε (Maercker) to produce alkeneε. For example, reaction of 34.1 (Y= CH2OBz, Xi= CHO) with isopropylidene t r i p h e n y l p h o s p h o r a n e ( p r e p a r e d f r om iεopropyltriphenylphoεphonium bromide and butyllithium in THF) provideε the alkene 34.1 (Y= CH20Bz , Xi= CH=C(CH3),) . This is converted into the morpholino εubunit 34.1 (Y= CH2OH, Xi= CH=C(CH,),) by εaponification.
Similarly, reaction with benzylidene t r i ph e ny l ph o εph o r a n e ( pr ep a r e d f r om benzyltriphenylphoεphonium chloride and butyllithium in THF) followed by saponification provides the morpholino εubunit 34.1 (Y= CH2OH, Xi= CH=CHPhenyl) , the isomers of which may be separated by εilica gel chromatography.
Subunitε 34.2-34.4 with aliphatic εide chainε containing carbon-carbon double bonds are prepared in a similar fashion.
I . Aliphatic Side Chains Containing Carboxylic Acids and Esterε Alcohol 34.1 (Y= CH,OH, Xi= [CH,]„OTBDPS) iε treated with 80% acetic acid in water followed by reaction with benzyl chloroformate to provide the carbamate 34.1c (Xi=
[CH2]nOTBDPS) . The alcohol iε protected aε the benzyloxymethyl ether by the method of Stork and Iεobe, then the TBDPS group is removed with tetrabutylammonium fluoride. The hydroxymethyl group is converted into a carboxyl by oxidation with potassium permanganate or pyridinium dichromate. The acids are protected by conversion into the eεter by treatment with diiεopropylcarbodiimide, 4-dimethylaminopyridine and either methyl alcohol or 2-(phenylsulfonyl) ethyl alcohol in dichloromethane. Treatment with hydrogen and Pd on charcoal followed by tritylation of the morpholino nitrogen prepares the morpholino εubunitε. Similar procedureε may be performed on the acidε 34.1- 34.4 (Y= CH2OH, Xi= [CH2]nOTBDPS) to prepare the correεponding acid. Other alcoholε may be employed to produce a large variety of esters.
J. Aliphatic Side Chains Containing Carboxylic Acid
Amines
The acids prepared in part I above are reacted with diisopropylcarbodiimide and morpholino in dichloromethane to produce the morpholino amide. Conversion to the subunit follows hydrogenolytic cleavage of the carba ate and acetal with Pd on charcoal. Other amides may be prepared by use of ammonia or other amines.
K. Aliphatic Side Chains Containing A ineε
1. From alcohol derivativeε. The hydroxyymethyl group of 34.1-34.4 (Y= CH2OH, Xi= [CH,]nOTBDPS) is protected as the benzyloxymethyl ether by the method of Stork and Isobe, then the TBDPS group is removed with tetrabutylammonium fluoride. The alcohol iε converted into an aldehyde with diiεopropylcarbodiimide in DMSO containing a εmall amount of pyridinium methaneεulfonate. The alcohol iε treated with triphenylphoεphine, εodium or lithium azide and carbon tetrabromide in DMF to produce the azide by the method of Yamamato, et al . Catalytic reduction with Pd on charcoal in the preεence of ammonia provides the amine and frees the alcohol. The amine is protected aε the general procedure. 2. From alcoholε via oxidation to the aldehyde and reductive amination. The hydroxyymethyl group of 34.1- 34.4 (Y= CHOH, Xi= [CH2]n0TBDPS) is protected aε the benzyloxymethyl ether by the method of Stork and Iεobe, then the TBDPS group iε removed with tetrabutylammonium fluoride. The alcohol is converted into an aldehyde with diisopropylcarbodiimide in DMSO containing a εmall amount of pyridinium methaneεulfonate. The aldehyde iε treated with a large excess of the appropriate amine in methanol at pH=6 in the presence of sodium cyanoborohydride. The resulting amine is protected aε in the general Exampleε and the acetal cleaved by hydrogenolyεis.
Additionally, the ketones prepared in Example 4G5 may be employed aε starting materialε for the production of more amineε species.
Preparation of Thiol Derivatives The hydroxyymethyl group of 34.1-34.4 (Y= CH2OH, xi= [CH2]nOTBDPS) is protected aε the benzoate eεter then the TBDPS group iε removed with tetrabutylammonium fluoride. The alcohol is converted into the tosylate by treatment with p-toluenesulfonyl chloride in pyridine. The tosylate group iε displaced with thiourea to give the thiol which is protected by converεion into the S-ethyl diεulfide by the general method. The benzoate group iε removed by εaponification.
M. Hydrogen as Side Chain
1. (S) -4-Trityl-2-hydroxymethylmorpholino 32.2b (Xi= H) iε prepared from the (S) -4-tert-butoxycarbonyl-2- hydroxymethylmorpholino prepared by Yanagiεawa and Kanazaki, by cleavage of the Boc group in 50% trifluoroacteic acid in dichloromethane followed by retritylation by the general method.
2. (R) -4-Trityl-2-hydroxymethylmorpholine 32.2b (Xi= H) iε prepared from the (R) -4-tert-butoxycarbonyl-2- hydroxymethyl orpholine prepared by Yanagisawa and Kanazaki, by cleavage of the Boc group in 50% trifluoroacteic acid in dichloromethane followed by retritylation by the general method.
Example 6
Synthetic Strategies for Stereochemical Control of R and Y Groupε of Morpholino Subunitε
Exampleε 3 and 4 above generally illuεtrate the preparation of morpholino εubunits with nucleobase or modified nucleobase side chains with groupε R and Y in figure 6 both in the β poεition (figure 34.1) . Thiε deriveε principally from the uεe of D-glucoεe or D- galactoεe or D-riboεe and their derivatives aε precurεorε. For the preparation of the enantiomeric εubunitε, that iε, morpholino εubunits with groups R and Y in figure 6 both in the α position (specieε 34.4), correεponding L-εugarε are employed. For the preparation of morpholino εubunits with nucleobaεe or modified nucleobaεe side chains with groups Y in figure 6 in the β position, and group R in the α position (species 34.3) , it is preferred to use the method of Chow and Danishefεky. In thiε procedure εilylated nucleobases and modified nucleobaseε are reacted with 3,4, 6-tri-O-TBDMS-l,2-anhydro-β-D-mannopyranose to give the O-TBDMS-α-D-glycoεideε which are converted into the morpholino εubunits 34.3 following desilylation with tertabutylammonium fluoride. For the preparation of morpholino subunitε with nucleobaεe or modified nucleobase side chains with groups Y in figure 6 in the α position, and group R in the β position (species 34.4) , it iε preferred to uεe the method of Chow and Daniεhefεky. In thiε procedure silylated nucleobaseε and modified nucleobaseε are reacted with 3 ,4, 6-tri-O-TBDMS-l, 2-anhydro- β-L-mannopyranoεe to give the O-TBDMS-α-L-glycoεideε which are converted into the morpholino εubunits 34.4 following desilylation with tertabutylammonium fluoride.
Example 7
Preparartion of Morpholino Subunitε with Representative Y and Z
A. 7.1 (Xi= 0-N4-benzoylcytoεin-l-yl) The alcohol 32.2b (Xi= 0-N4-benzoylcytoεin-l-yl) iε oxidized to the aldehyde 7.1 (Xi= jS-N4-benzoylcytoεin-l-yl) with diiεopropyl carbodiimide in DMSO containing a εmall amount of pyridinium methaneεulfonate.
B. 7.2 (X= OH. Xi= β-N4-benzoylcvtoεin-l-yl)
The aldehyde from Example 7A iε oxidized with potaεεium permanganate in acetone or t- butanol/dioxane/water buffered with magneεium εulfate to the acid 7.2 (X= OH, Xi= β-N4-benzoylcytosin-l-yl) . Higher yields may be obtained if the trityl group in the alcohol 32.2b (Xi= β-N4-benzoylcytosin-l-yl) is replaced with a CBz group. Oxidation with permanganate, hydrogenolysis of the CBz group, and retritylation prepare the acid needed for activation.
C. 7.2 (X= O-p-nitrophenyl . Xi= β-N4-benzoylcytoεin- i-yi)
The acid from Example 7B iε reacted with p-nitrophenol and diiεopropyl carbodiimide in dichloromethane to produce the ester 7.2 (X= O-p-nitrophenyl, Xi= β-N4-benzoylcytoεin- 1-yl) εuitable for coupling reactionε.
D. 7.2 (X= imidazol-1-yl. Xi- g-N4-benzoylcytoεin-l-
-£11 Reaction of the acid with carbonyl diimidazole produceε the imidazolide 7.2 (X= imidazol-1-yl, Xi= β-N4- benzoylcytoεin-1-yl) suitable for coupling reactions.
E. 7.3 (X= Cl. Xi= β-N6-benzoyladenin-l-yl)
The alcohol 32.2b (Xi= β-N6-benzoyladenin-l-yl) is converted into the tosylate using tosyl chloride and pyridine. This is reacted with thiourea in methanol to provide the thiol deriviative. This may be oxidized to the sulfonic acid using potassium permanganate in acetone or t- butanol/dioxane/water buffered with magnesium sulfate. Higher yields in the oxidation are obtained if the trityl group is replaced by the benzyloxycarbonyl group. The sulfonic acid is isolated as its triethylamonium salt by extraction into chloroform from water saturated with triethylamine hydrochloride. The salts of sulfonic acids can be easily chromatographed on silica gel using triethylamine/methanol/chloroform ixtureε if the εilica iε first pre-eluted with 2% triethylamine in chloroform. Retritylation may be efected by hydrogenolysiε with Pd on charcoal to remove the carba ate followed by tritylation by the general procedure. For activation, ten mmole of the triethylamine εalt of εulfonate subunit is diεεolved in 10 ml of dichloromethane and then 40 mmole of pyridine iε added. Thiε solution is chilled for 15 minuteε on a bed of dry ice and then 11 mmole of phoεgene (20% in Toluene) iε εlowly added while the solution iε rapidly stirred. After addition the solution is allowed to come to room temperature and then washed with aqueouε NaHCO,, dried, and chromatographed on εilica gel eluting with a mixture of chloroform and acetone to give the desired sulfonyl chloride 7.3 (X= Cl, Xi= j8-N6-benzoyladenin-l-yl) .
F. 7.4 (X= OH. Xi= α-methyl) The alcohol 32.2b (Xi= α-methyl) is oxidized to the aldehyde 7.1 (Xi= α-methyl) with diiεopropyl carbodiimide in DMSO containing a εmall amount of pyridinium methanesulfonate. This is reacted with 2 , 6-dithianylidene- triphenylphosphorane by the method of Kruse, et al . The resulting ketenedithioacetal iε converted into the carboxylic acid by hydrolyεis with mercuric chloride in wet acetonitrile to give the subunit 7.4 (X= OH, Xi= α-methyl), which can be chromatographed on silica gel using triethylamine/methanol/chloroform mixtures if the εilica iε firεt pre-eluted with 2% triethylamine in chloroform.
G. 7.4 (X= O-p-nitrophenyl. Xi= α-methyl)
The acid εalt from the previous example is activated by treatment with diiεopropylcarbodiimide in dichloromethane containing p-nitrophenol containing 1 equivalent of pyridinium p-tolueneεulfonate.
H. 7.5 (X= OH, Xi= α-methyl).
Benzyl α-bromoacetate iε reacted with triphenylphoεphine and the phoεphonium salt product is reacted with sodium hydroxide to produce the ylid. Thiε is reacted with aldehyde 7.1 (Xi= α-methyl) , produced from alcohol 32.2b Xi= α-methyl) as in Example 7A, to give the unsaturated ester. Treatment with hydrogen and Pd on charcoal yields the acid 7.5 (X= OH, Xi= α-methyl), which can be chromatographed on silica gel using triethylamine/methanol/chloroform mixtures if the silica is first pre-eluted with 2% triethylamine in chloroform.
I • 7.5 (X= O-p-nitrophenyl . Xi= α-methyl) The acid salt from the previous example is activated by treatment with diisopropylcarbodiimide in dichloromethane containing p-nitrophenol containing 1 equivalent of pyridinium p-tolueneεulfonate.
J- 7.6 (X= O-p-nitrophenyl. Y= 0. Xi= β-N2- phenylacetylguanin-9-γl)
Dry, N-protected, 5'-hydroxyl morpholino subunit 32.2b
(Xι= j -N2-phenylacetylguanin-9-yl) (1 mmol), is treated with bis- (p-nitrophenyl) carbonate (BNPC) and triethylamine (TEA) in DMF under anhydrous conditionε. The εolution iε stirred for three hours, then evaporated to dryness. The residue is dissolved in chloroform and chromatographed on εilica gel eluting with a chloroform/methanol mixture to give activated εubunit.
K. 7.6 (X= imidazol-1-yl. Y= S. Xi= β-N2- phenylacetylguanin-9-γl)
Dry, N-protected, 5'-hydroxyl morpholino εubunit 32.2b
(Xi= j6-N2-phenylacetylguanin-9-yl) iε treated with thiocarbonyldiimidazole in pyridine at room temperature for 12 hours. Water is added to quench the reagentε, the εolventε evaporated and the residue is diεεolved in chloroform and chromatographed on εilica gel eluting with an a chloroform/methanol mixture to give activated εubunit.
L. 7.7 (X= Cl. Xi= β-CH?CH,OTBDPS)
An N-tritylated morpholino subunit 32.2b (Xi= β- CH2CH-,OTBDPS) is detritylated by treatment with 2% dichloroacetic acid in dichloromethane followed by addition to ether to precipitate the product salt. The crude salt is diεεolved in dichloromethane/pyridine and treated with 3 equivalents of dimethoxytrityl chloride. The solventε are evaporated and the reεidue taken up in 1:1 methanol/acetic acid to cleave the DMT group on the nitrogen. The solvents are removed, the residue disεolved in dichloromethane, waεhed with water, εodium bicarb εolution and brine. The εolution iε dried over εodium sulfate, filtered and evaporated to give a residue which iε purified by chromatography on εilica gel eluting with a chloroform/methanol mixture. The free morphline is sulfated by treatment with SO,/pyridine complex (with excess pyridine) in dimethylformamide (DMF) . It should be mentioned that the saltε of εulfamic acidε can be eaεily chromatographed on εil ica gel using triethylamine/methanol/chloroform mixtures if the silica iε first pre-eluted with 2% triethylamine in chloroform. For activation, ten mmole of the triethylamine salt of εulfated εubunit iε diεεolved in 10 ml of dichloromethane and then 40 mmole of pyridine iε added. This solution iε chilled for 15 minuteε on a bed of dry ice and then 11 mmole of phoεgene (20% in Toluene) iε εlowly added while the εolution iε rapidly εtirred. After addition the solution is allowed to come to room temperature and then washed with aqueous NaHCO,, dried, and chromatographed on silica gel eluting with a mixture of chloroform and acetone to give the deεired εulfamoyl chloride 7.7 (X= Cl, Xi= CH2CH20TBDPS) .
M. 7.8 (R'= H. X= Cl. Xi= θ-uracil-1-yl) The alcohol derivative 32.2b (Xi= -uracil-1-yl) iε treated with triphenylphoεphine, εodium azide and carbon tetrabromide in DMF to produce the azide by the method of Yamamato, et al . Thiε may be reduced by either triphenylphoεphine and ammonia, or catalytic hydrogenation over Pd and charcoal. The amine iε sulfated by treatment with SO,/pyridine complex (with excess pyridine) in dimethylformamide (DMF) . It should be mentioned that the saltε of εulfamic acidε can be easily chromatographed on silica gel using triethylamine/methanol/chloroform mixtureε if the silica iε firεt pre-eluted with 2% triethylamine in chloroform.
For activation, ten mmole of the triethylamine εalt of εulfated εubunit iε diεεolved in 10 ml of dichloromethane and then 40 mmole of pyridine iε added. Thiε εolution iε chilled for 15 minuteε on a bed of dry ice and then 11 mmole of phoεgene (20% in Toluene) iε εlowly added while the εolution is rapidly stirred. After addition the solution is allowed to come to room temperature and then washed with aqueous NaHCO,, dried, and chromatographed on silica gel eluting with a mixture of chloroform and acetone to give the desired sulfamoyl chloride.
N. 7.8 (R'= CH.. X= Cl. Xi= fi-uracil-1-yl. The alcohol derivative 32.2b (Xi= β-uracil-1-yl) iε oxidized to the aldehyde with diiεopropyl carbodiimide in DMSO containing a εmall amount of pyridinium methaneεulfonate. The aldehyde may be reacted with metylamine in buffered (p-nitrophenol) methanol at pH = 7 in the presence of sodium cyanoborohydride to give the morpholine-2-methanamine derivative. The amine is sulfated by treatment with SO,/pyridine complex (with excess pyridine) in di ethylformamide (DMF) . It should be mentioned that the saltε of εulfamic acidε can be eaεily chromatographed on si l ica gel using triethylamine/methanol/chloroform mixtures if the silica is first pre-eluted with 2% triethylamine in chloroform.
For activation, ten mmole of the triethylamine salt of sulfated subunit is disεolved in 10 ml of dichloromethane and then 40 mmole of pyridine is added. This εolution iε chilled for 15 minuteε on a bed of dry ice and then 11 mmole of phoεgene (20% in Toluene) iε εlowly added while the solution is rapidly εtirred. After addition the solution iε allowed to come to room temperature and then waεhed with aqueouε NaHCO,, dried, and chromatographed on εilica gel eluting with a mixture of chloroform and acetone to give the desired sulfamoyl chloride. O. 7.9 (X= Cl. Y= O, Z= N(CH,),, Xi= g-phenyl One mmole of 5'-hydroxyl subunit 34.1a (Xi= -phenyl) , protected and tritylated on the morpholino nitrogen is disεolved in 5 ml of dichloromethane. Six mmole of N,N- diethylaniline and 2 mmole of dimethylaminodichlorophoε- phate (0P(C1)2N(CH,)2) iε added to the solution followed by the addition of 0.5 mmole of either N-methylimidazole, tetrazole, or 4-methoxypyridine-N-oxide. After the reac¬ tion is complete (assessed by thin layer chromatography) the reaction solution may be washed with aqueous NaH2P04. The activated subunit is isolated by chromatoqraphy on silica gel developed with acetone/chloroform or ethyl acetate/dichloromethane mixtures. Alternatively, the reaction mixture is placed on the top of a silica column and chor atographed without workup.
The dimethyla inodichlorophosphate uεed in the above procedure waε prepared aε follows: a suspenεion containing 0.1 mole of dimethylamine hydrochloride in 0.2 mole of phoεphorouε oxychloride waε refluxed for 12 hourε and then distilled (boiling point is 36°C at 0.5 mm Hg) .
P. 7.9 ( X= Cl. Y= S. Z= O-ethyl. Xi= β-phenyl) One mmole of 5'-hydroxyl εubunit 34.1a (Xi= j3-phenyl) iε reacted with ethyl dichlorothiophosphate according to the conditions in Example 70.
Q. 7.10 (X= p-nitrophenyl. Xi= β-N4-benzoylcytosin- -γi)
1. The N-tritylated morpholino εubunit derivative 32.2b (Xi= β-N4-benzoylcytoεin-l-yl) is detritylated using 2% acetic acid in 20% trifluoroethanol/dichloromethane. The reεulting secondary amine iε reacted with iεoamyl nitrite and the N-nitroεo εpecies reduced with hydrogen over Pd on charcoal or Zn in acetic acid. The amino group may be protected as the benzhydryl carbamate by the method of Hiskey and Adamε or aε the Boc carbamate uεing ditertbutyl dicarbonate. The alcohol is activated for coupling as the carbonate by reaction with biε-(p-nitrophenyl) carbonate to give 7.10 (X= p-nitrophenyl, Xi= β-N4-benzoylcytoεin-l-yl) . Other activated εpecies may be prepared using thiocarbonyldiimidazole or N,N-dimethylaminophoεphoryl chloride aε deεcribed in the preceeding exampleε.
2. Alternatively, ribofuranoεide 32.1a (Xi= β- N4-benzoylcytoεin-l-yl) iε reacted with periodate as in the general method for morpholino subunit synthesiε, but t- butylcarbazate iε εubεtituted for ammonia in the reductive ring cloεure εtep to give the 5'-free εubunit which may be activated aε in the example above.
R. 7.11 (X= OH. Xi= β-uracil-1-yl) The alcohol 32.2b (Xi= β-uracil-1-yl) (lmol) iε treated with an exceεε of εodium hydride in a DMF/THF mixture. Sodium chloroacetate (1 mol) is added and the solution stirred for 24 hours. The solution iε filtered in an inert atmoεphere, and excess of triethylammonium hydrochloride in DMF is added, the mixture filtered, and the εolvents removed by evaporation. The residue can be chromatographed on sil ica gel using triethylamine/methanol/chloroform mixtures if the silica is firεt pre-eluted with 2% triethylamine in chloroform.
s- 7.11 (X= O-p-nitrophenyl, Xi= β-uracil-1-yl) The acid εalt from the previouε example iε activated by treatment with diiεopropylcarbodiimide in dichloromethane containing p-nitrophenol containing 1 equivalent of pyridinium p-tolueneεulfonate.
T. 7.12 (X= O-p-nitrophenyl. Xi= ff-thvmin-1-γl)
1. The εubunit 32.2b (Xi= Xi= -thymin-1-yl) iε detritylated uεing 2% acetic acid in 20% trifluoroethanol/dichloromethane. The reεulting εecondary amine iε reacted with benzyl bromoacetate. The alcohol iε converted into the primary amine my the procedure in method 7M. The amine is tritylated by the general procedure, the benzyl ester cleaved by catalytic hydrogenolyεis in DMF/ethanol containing trieylamine. The acid is activated by treatment with diiεopropylcarbodiimide in dichloromethane containing p-nitrophenol and one equivalent of pyridinium toεylate.
2. Alternatively, ribothymidine (Tronchet) iε reacted with periodate aε in the general method for morpholino εubunit synthesiε, but glycine benzyl eεter iε substituted for ammonia in the reductive ring closure εtep to give the 5'-free subunit which may be further converted as in the example above.
Example 8 Representative Subunits Which are Converted to Morpholino Structures During Oligomer Aεsembly
A. 5'-Aminoribofuranosideε 8.1
Ribofuranoεideε may be converted into their 5'-amino derivatives by reaction with triphenylphosphine, sodium or lithium azide and carbon tetrabromide in DMF (Yamamato) , followed by reduction with either triphenyl phosphine/ammonia or with hydrogen over Pd on charcoal.
B. 6'-Aminohexopyranoεideε 8.4 Hexopyranosides may be converted into their 6'-amino derivatives by the procedure in Example 8A or by the following procedure. The glycoside is treated with dimethoxytrityl chloride in pyridine to selectively protect the primary alcohol. The remaining hydroxy groups are protected by reaction with t-butyldimethylsilyl chloride in DMF containing imidazole. The dimethoxytrityl group iε cleaved by treatment with zinc bromide in nitromethane at room temperature (Kόεter, et al ) . The free 6'-alcohol is converted into the 6'-amino derivative by reaction with triphenylphoεphine, εodium or lithium azide and carbon tetrabromide in DMF (Yamamato) , followed by reduction with either triphenyl phoεphine/ammonia or with hydrogen over Pd on charcoal. The εilyl groupε are removed by treatment with HF/pyridine of tetrabutylammonium fluoride in THF.
C. 5'-O-Aminoribofuranoεideε 8.2 Ribofuranoεideε may be converted into their 5'-0-amino derivatives by the following procedure. The glycoside is treated with dimethoxytrityl chloride in pyridine to selectively protect the primary alcohol. The remaining hydroxy groupε are protected by reaction with t- butyldimethylsilyl chloride in DMF containing imidazole. The dimethoxytrityl group is cleaved by treatment with zinc bromide in nitromethane at room temperature (Kόster, et al ) and the primary alcohol converted into the deεired aminoxy εpecies using N-hydroxyphthalimide by the procedure of Vasεuer, et al . The εilyl groupε are removed by treatment with HF/pyridine of tetrabutylammonium fluoride in THF.
D. 5'-0-Aminohexopyranosides 8.5
May be converted into their 6'-0-amino derivatives by the procedure for the ribofuranosideε in Example 8C.
Example 9
Coupling Morpholino Subunits to Form Representative One-Atom-Length Intersubunit Linkages and Two-Atom-Length Intersubunit Linkages
A. General
Whenever the morpholino nitrogen of a subunit, or the terminal subunit in an oligomer, contains an acid labile group such aε the trityl group, deprotection is performed with mild acid. Representative acid mixtures which are εuitable include 10% cyanoacetic acid in 4:1 dichloromethane/acetonitrile, 7% formic acid in dichloromethane, and 2.5% cyanoacetic acid in 7:93 trifluoroethanol/dichloro ethane. For molecules which contain a Boc or benzhydryl carbamate a 20-50% solution of trifluoroacetic acid in dichloromethane may by employed. The acid is removed by precipitation of the deprotected subunit in ether if the reaction iε done in homogeneouε solution, or by washing with the appropriate rinse solvent if solid phase methods are employed.
Whenever the morpholino nitrogen of a subunit, or the terminal subunit in an oligomer, contains a base labile group such as the FMOC group, deprotection is performed with mild base. Representative base reagents which are suitable include 1-10% DBU/DMF, 10% N- methylpyrrolidine/DMF, and 2-20% piperidine/DMF. The excess reagent, dibenzofulvene, and derived by productε are removed by precipitation of the deprotected εubunit in ether if the reaction iε done in homogeneous solution, or by waεhing with the appropriate rinεe solvent if solid phaεe methodε are employed.
Coupling to a morpholino εubunit requireε that the morpholino nitrogen be present in the uncharged state. This may be achieved as followε. A mild baεe εuch as triethylamine, diisopropylethyla ine, or diiεopropylaminoethanol (or itε ethers or esterε) is employed to neutralize residual charge produced in acidic deprotections and/or to maintain any unreacted morpholino nitrogen in the neutral εtate during the coupling reaction.
B. Coupling to Form Amide Linkageε
The nitrophenyl eεter formed in Example 7C, is dissolved in DMF or NMP (containing 0.2-0.4 molar of an appropriate base, εuch as methyl diisopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric species with an uncharged morpholino nitrogen produced as in Example 9A.
C. Coupling to Form an Amine Linkage
The aldehyde formed in Example 7A iε diεsolved in methanol, or DMF/methanol mix containing nitrophenol and sodium cyanoborohydride at pH = 6.5. This is mixed with the deprotected onomeric or oliogomeric species with an uncharged morpholino nitrogen produced as in Example 9A. 1. Formation of amide linkages. The nitrophenyl ester formed in Example 7G, is dissolved in DMF or NMP (containing 0.2-0.4 molar of an appropriate base, such as methyl diisopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric εpecies with an uncharged morpholino nitrogen produced as in Example 9A. )
Example 10 Method for Conversion of Non-Morpholino Subunit to Morpholino Subunit During Oligomer Asεembly
Oligomer may be aεεembled by conεtruction of the morpholino ring from a dialdehyde and a primary amine. The coupling iε performed aε follows. The 5'- aminoribofuranoside or 6'-aminohexopyranoside from Example 8 is protected on the amine with trityl as in the general procedure. The molecule is diεεolved or suspended in methanol and treated with periodate as per the general procedure in Examples 1 or 2. To the dialdehyde εo formed iε added a second 5'-aminoribofuranoside or 6'- aminohexopyranoεide followed by εodium cyanoborohydride and the pH iε maintained between 4.5 and 6.5.
A particularly advantageouε method for the εyntheεiε of oligomers by this method involveε fixing the the amino group of the firεt aminoglycoεide to a εolid support by a cleavable anchor, as in Example 16 below, and performing the oxidation and reductive amination εteps on the solid support.
Example 11
Coupling Morpholino Subunits to Form Representative Three-Atom-Length Intersubunit Linkageε
A. Formation of Amide Linkageε
The nitrophenyl eεter formed in Example 71, iε diεεolved in DMF or NMP (containing 0.2-0.4 molar of an appropriate baεe, εuch aε methyl diiεopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric εpecieε with an uncharged morpholino nitrogen produced as in Example 9A.
B. Formation of Carbamate Linkageε
Thiε linkage is prepared from the nitrophenyl carbonate formed in Example 7J and the morpholino- deprotected subunitε/oligomer formed aε in Example 9A. The coupling follows the method of Summerton and Weller (US patent 5,034,506)
C. Formation of Sulamide Linkages
This linkage is prepared from the εulfamoyl chlorideε produced in Exampleε 7M or 7N and the morpholino deprotected εubunitε/oligomer formed aε in Example 9A. The coupling follows the method of Summerton and Weller (US patent 5,034,506)
D. Formation of Phorodiamidate Linkages
Thiε linkage iε prepared from the phosphoryl chloride produced in Example 70 and the morpholino deprotected subunitε/oligomer formed aε in Example 9A. The coupling followε the method of Summerton and Weller (US patent
5,185,444)
Example 12
Coupling Morpholino Subunits to Form Representative Four-Atom-Length Intersubunit Linkages
A. Formation of Amide Linkages
1. The nitrophenyl ester formed in Example 7S, is diεεolved in DMF or NMP (containing 0.2-0.4 molar of an appropriate baεe, εuch aε methyl diisopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric species with an uncharged morpholino nitrogen produced as in Example 9A.
2. The nitrophenyl ester formed in Example 7T, is disεolved in DMF or NMP (containing 0.2-0.4 molar of an appropriate baεe, εuch aε methyl diisopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric εpecieε with an uncharged morpholino nitrogen produced aε in Example 9A.
B. Formation of Carbazateε
Thiε linkage iε prepared from the nitrophenyl carbonate formed in Example 7Q iε diεsolved in DMF or NMP (containing 0.2-0.4 molar of an appropriate base, such as methyl diiεopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the deprotected monomeric or oliogomeric εpecieε with an uncharged morpholino nitrogen produced aε in Example 9A.
Example 13
Preparation of In-Line Branches A. From Diethylenetriamine
The triamine is reacted with one equivalent of triamine and the terminally reacted monotritylated species isolated by chromatography on alumina. The diamine is now reacted with FMOC chloride, followed immediately by sulfation in pyridine with the sulfur trioxide/pyridine complex. It should be mentioned that the salts of the sulfamic acidε can be eaεily chromotographed on εilica gel uεing triethylamine/methanol/chloroform mixtureε if the εilica iε firεt pre-eluted with 2% triethylamine in chloroform. For activation, ten mmole of the triethylamine εalt of εulfated εubunit iε dissolved in 10 ml of dichloromethane and then 40 mmole of pyridine is added. Thiε εolution is chilled for 15 minutes on a bed of dry ice and then 11 mmole of phosgene (20$ in Toluene) iε εlowly added while the εolution iε rapidly εtirred. After addition the εolution iε allowed to come to room temperature and then washed with aqueouε NaHCO,, dried, and chromatographed on εilica gel eluting with a mixture of chloroform and acetone to give the desired sulfamoyl chloride. The sulfamate can be coupled to an amino group or morpholino amine in the same faεhion in which an activated εubunit may be coupled (Examples 9-12) . Following incorporation of the branching subunit, cleavage of the trityl group allows construction of the oligomeric brancheε by εequential coupling of εubunits. When the first branch is complete is capped and the molecule treated with 10% DBU/DMF to remove the FMOC group. The second branch may now be synthesized using by sequential coupling of subunits.
B. From 1.3-Diamino-2-Hvdroxγpropane The diamine is disεolved in DMF and treated with one equivalent of trityl chloride. The monotritylated εpecieε is εeparated by chromatography on εilica gel and then reacted with FMOC chloride to protect the remaining amino group. The alcohol is reacted with bis (p-nitrophenyl carbonate) in DMF containing triethylamine to produce the activated carbonate. The carbonate can be coupled to an amino group or morpholino amine in the same faεhion in which an activated εubunit may be coupled (Example 9-12) . Following incorporation of the branching εubunit, cleavage of the trityl group allowε construction of the oligomeric branch by sequential coupling of subunitε. When the first branch iε complete, it is capped and the molecule treated with 10% DBU/DMF to remove the FMOC group. The second branch may now be εyntheεized uεing by εequential coupling of subunits.
Example 14 Preparation of Hub Branches
A. Using 1 , 3.5-Benzenetricarboxylic Acid Amideε One mmol of 1 , 3 , 5-benzenetricarbonyl chloride in pyridine is reacted with 1 mmol of o-nitrobenzyl alcohol, followed by 1 mmol of p-nitrophenethyl alcohol, and the reaction quencehed with piperidine. The desired species containing one o-nitrobenzyl ester and one p-nitrophenethyl ester is isolated by chromatography on silica gel. The free piperazine iε coupled to activated εubunitε prepared in Example 7 uεing the methodε in Exampleε 9-12. After the coupling, the product iε purified on silica gel. Additional subunits may be introduced by detrityalation and repetition of the coupling. Following introduction of the final subunit, the chain is detritylated and capped with acetic anhydride. The nitrophenethyl eεter iε cleaved by treatment with 10% DBU/DMF. The free acid iε coupled with N-trityl piperazine prepared below uεing diiεopropylcarbodiimide in dichloromethane. Sububitε may be introduced by detritylation and coupling aε above. When this chain is finished it iε capped with acetic anhydride.
The o-nitrobenzyl eεter is cleaved by irradiation with 320 nm light. Following coupling with N-trityl piperazine as above, sububitε may be introduced by detritylation and coupling aε above.
B. Using 1, 3 , 5-Benzenetricarboxylic Acid One mmol of 1, 3 , 5-benzenetricarbonyl chloride in pyridine is reacted with 1 mmol of o-nitrobenzyl alcohol, followed by 1 mmol of p-nitrophenethyl alcohol, and the reaction quencehed with water. The desired species containing one o-nitrobenzyl ester and one p-nitrophenethyl eεter is isolated by chromatography on εilica gel. The free acid iε coupled to εubunitε or preformed oligomerε, at the free morpholino nitrogen (produced by detritylation and neutralization as described in Example 9) , uεing diiεopropylcarbodiimide in dichloromethane. The nitrophenethyl eεter iε cleaved by treatment with 10% DBU/DMF. The free acid iε coupled to εubunitε or preformed oligomers, at the free morpholino nitrogen, coupled with using diiεopropylcarbodiimide in dichloromethane. The o- nitrobenzyl eεter is cleaved by irradiation with 320 nm light. The free acid is coupled to εubunitε or preformed oligomerε, at the free morpholino nitrogen, uεing diiεopropylcarbodiimide in dichloromethane. It εhould be recognized that the acid may be employed in εolid phaεe synthesis by coupling to a growing chain on a solid εupport. The two eεters which may each be selectively deprotected are reacted εequentially with εubunits or oligomers.
C. From Piperazine
N-tritylpiperazine iε reacted with FMOC chloride. The trityl group iε removed by the method in Example 9, and the free piperazine nitrogen reacted with an activated εubunit by the method above. Aε many εubunits as desired may be introduced by the method in Example 14A above. Following end capping of thiε chain, the FMOC group iε cleaved uεing 10% DBU/DMF. The free piperazine nitrogen iε reacted with an activated subunit by the method above. As many εubunits as desired may be introduced by the method in Example 14A above.
Example 15 Joining Two Ends of an Oligomer by Covalent Linkage
Two chainε of a divergent branch are conεtructed so as to place subunits with Xi= [CH2]„-SS-ethyl at the termini. The disulfide is cleaved using dithiothreitol in mildy baεic aqueouε εolution. The oligomeric dithiol is separated from the reagents by passage over a column of chromatographic grade polypropylene and eluting with an acetonitrile in dilute aqueous acetic acid. The dilute solution is neutralized to pH = 8, and treated with iodine to produce the diεulfide.
Example 16 Preparation of Oligomer Library on a Solid Support A. Solid Support
The following εupportε are εuitable for solid phase syntheεiε of oligomerε: aminomethyl polyεtyrene reεin, 1% divinylbenzene croεεlinked, 200-400 mesh, 0.5-1.5 mmoles N per gram (Sigma Chemical CO. A1160) ; polyεtyrene reεin, 1% divinylbenzene crosεlinked, grafted with polyethylene glycol, primary amino terminated, 0.1-0.3 mmoles N per gram (TentaGel, Rapp Polymere, Germany) ; custom-εyntheεized macroporouε polyεtyrene, 8% divinylbenzene croεεlinked, functionalized with 1, 12-diaminododecane, with particle εizeε in the range of 50-80 micronε in diameter, and with pore εizes approximately 700 Λ.
B. Construction of Anchorε The following anchors are employed for solid phase oligomer syntheεiε:
1 . 10 mm o l o f b i s [ 2 -
(succinimidooxycarbonyloxy) ethyl] εulfone (Pierce, Rockford
IL) iε treated with 5 mmol of momotritylpiperazine (made as in the example below) and the product purified by silica chromatography or cryεtallization.
2. 2 , 2'-Thiodiethanol iε treated with an equimolar amount of biε(p-nitrophenyl) carbonate in DMF containing triethylamine. The monoeεterified εpecieε is purified by chromatography and reacted with an excess of monotritylpiperazine, formed by adding trityl chloride to a solution of excess piperazine in DMF. Thiε is converted to the nitrophenyl carbonate with a slight excess of as above biε(p-nitrophenyl) carbonate in DMF containing triethylamine.
3. 4-Hydroxymethyl-3-nitrobenzoic acid (Knieb- Cordonier, et al ) iε eεterifed with methanol and diiεopropylcarbodiimide in dichloromethane. The alcohol iε converted into the p-nitrophenylcarbonate by the method above and reacted with monotritylpiperazine. The eεter iε cleaved by εaponification and converted into the p- nitrophenyl eεter by treatment with p-nitrophenol and diiεopropylcarbodiimide in dichloromethane.
C. Conεtruction of Tethers
Polyethylene glycol 4600 iε converted into itε mono-p- nitrophenyl carbonate by reaction of 10 mmol of the PEG with 1 mmol of bis(p-nitrophenyl) carbonate in DMF containing triethylamine. To the solution iε add an exceεs of piperazine and the excesε reagents thoroughly removed by evaporation. The mixture is taken up in water, acidified and the amine is purified from the neutral PEG chains by ion exchange chromatography on Dowex-50. The amine iε converted into the N-trityl εpecieε by the εtandard procedure and then the alcohol iε converted to the nitrophenyl carbonate with a slight excess of bis(p- nitrophenyl) carbonate in DMF containing triethylamine.
D. Configuration of the Particle for Oligomer Asεerobly
1. Atttachment of the tether. The εolid εupport is placed in a column such as the 2 mL polypropylene Biorad
Bio-Spin Diεposable Chromatography Column, cat # 732-6008, whose frit has been replaced with a new frit (Isolab Quik- Sep Disc # D-4301) . The resin iε treated with DMF for 1-12 hourε, during which time it is placed in a aspirator vacuum to remove trapped air, and gently agitated to break up clumpε. The tether iε diεεolved in DMF or NMP (containing 0.2-0.4 molar of an appropriate base, such as triethylamine) at a concentration of about 0.05 molar and added to the εupport. Sufficient tether iε added εo aε to react 5-50% of the free amineε on the reεin surface. After 12-48 hours at 45 degrees C the solvents are drained and the resin washed with DMF.
2. Capping with dansyl chloride. The resin from the previous example is waεhed with dichloromethane and treated with a solution of 0.2 molar dansyl chloride in 20% tetramethylene sulfone in dichloromethane containing 0.4 molar of an appropriate amine such as diisopropylethylamine. After 30 minuteε at room temperature the reεin is drained and washed with DMF. 3. Attachment of the anchor. The trityl group iε removed from the end of the tether by three waεhings with 2% dichloroacetic acid in dichloromethane. The resin is washed with dichloromethane, then 5% diisopropylethylamine in dichloromethane. The anchor is diεεolved in DMF or NMP (containing 0.2-0.4 molar of an appropriate baεe, εuch aε methyl diiεopropylaminoethyl ether) at a concentration of about 0.2 molar, and mixed with the reεin containing the deprotected tether for 2-48 hourε at room temperature. The reεin iε thoroughly washed with DMF.
E. Solid Phase Syntheεiε of Oligomerε for Solution Phaεe Teεting
1. Coupling to produce an oligomer with only morpholino backbone type. Aminomethyl polystyrene resin is loaded with the anchor from Example 16B1 to achieve about 350 umol of trityl εpecies per gram resin. The following cycle is repeated. Suitable waεheε of dichloromethane, 25% iεopropanol/dichlromethane, or DMF are incorporated between the εtepε to remove exceεε reagentε and reaction byproducts. a. The protecting group is removed by an acidic reagent from Example 9A. b. The resin is neutralized with 5-20% diisopropylethylamine in dichloromethane. c. A mixture of activated subunits prepared in Example 7 is coupled to the end of the growing chain by the procedures defined in Exampleε 9-12. It iε critical, in order to achieve roughly equimolar amountε of the individual oligomerε, that the concentrationε of each activated subunit in the reaction be adjusted so that the rate of coupling for each εubunit will be aε nearly the same as posεible. The coupling rateε for the activated subunit are determined in solution, by reaction with a monomeric morpholino subunit. The appearance of coupling product as a function of time monitored by HPLC. A rate conεtant iε calculated and uεed to adjust the concentrations in the coupling mixture so that the rate of incorporation of each activated species in the mixture is the same. 2. Preparation of a mixed backbone oligomer. The method of Example 16E1 iε employed, but activated εubunits other than morpholino εpecieε are employed. For example, Boc-alanine may be converted into iε p-nitrophenyl ester using diisopropylcarbodiimide in dichloromethane. It is uεed aε an activated εubunit in the repetitive εteps outlined in the method of example 16E1. The oligomer so produced has a mixed morpholino-peptide backbone.
F. Deprotection of the Oligomers
Deprotection of the functional groups on the side chainε iε acheived aε followε. Silylated groupε are removed by treatment with either t-butylammonium fluoride in THF or pyridinium/HF complex in pyridine. Amideε may be cleaved by ammonolyεis with 2:1 cone ammonia/DMF. Phenylsulfonyl or FMOC carbamates are cleaved DBU/DMF treatment. Diεulfideε are converted into thiolε by treatment with mercaptoethanol or dithiothreitol in DMF or water containing triethylamine.
Example 17
Solid Phaεe Synthesis of Oligomerε for Oligomer Family Teεting Methodε
The method of Example 16E1 iε employed with the following differenceε. A macroporouε reεin is treated with tether, then anchor. Two additional εtepε, a and e below, are incorporated into each cycle to produce the following εequence:
A. The resin is diεtributed, in equal portionε, into a number of εynthesiε columnε that iε the same as the number of subunitε species desired to couple in step e.
B. The protecting group iε removed by an acidic reagent from Example 9A.
C. The reεin iε neutralized with 5-20% diiεopropylethylamine in dichloromethane.
D. Only a single activated subunit εpecieε iε coupled in each column.
E. The resin is recombined. For example, to prepare an oligomer family which consiεts of activated subunitε derived from the following εet of εubunitε:
1. 32.2b (Xi= (S-methyl) 2. 32.2b (Xi= jβ-uracil-1-yl)
3. 32.2b (Xi= j8-N4-benzoylcytosin-l-yl)
4. 32.2b (Xi= β-N6-benzoyladenin-l-l)
5. 32.2b (Xi= β-N2-phenylacetylguanin-l-yl) requireε that following incorporation of the anchor onto the reεin, the macroporous reεin iε divided into five equal portionε and placed in five columnε (Example 16D1) εuitable for εolid phase syntheεis.
The syntheεiε cycle iε then preformed with each column receiving a εingle activated εubunit εpecieε (prepared by the methodε in Example 7, from the εubunitε in the list above) for the coupling step. When the coupling step is finished, the resin is recombined and distributed into five new solid phase synthesiε columnε for the εecond εyntheεis cycle, where again, each column recieves a εingle activated εubunit εpecieε.
2. Incorporation of truncated species into the oligomer family. a. By use of partially pre-capped εubunitε. The five subunits specieε from Example 16F1 are converted into their acetamideε or trifluoroacetamides by removal of the trityl protecting group and reaction with either 5% acetic anhydride and 5% triethylamine in DMF for 5 minutes or with p-nitrophenyl trifluoroacetate in DMF.
These are then individually activated by the methods in Example 7 and individually mixed with the corresponding activated, but still tritylated, subunitε with the εame Xi group. The correct proportion of capped to tritylated εubunitε for a given εynthesis cycle in the conεtruction of a hexamer iε given in Table 1. The εyntheεiε iε then performed exactly as described in Example 16F1 with theεe five mixtureε of capped and tritylated activated subunit specieε. b. By capping during the synthesis. After the deprotection step of each coupling cycle, the resin containing the detritylated chain is treated with 7% formic acid in dichloromethane. The extent of formylation iε controlled by the length of the treatment. For example, to achieve a 2.5% converεion to formylated chainε requireε one hour with thiε reagent. As an alternative, the cleavage of trityl may be done with formic acid/dichloromethane mixtures aε deεcribed in example 9A. Inεtead of immediately waεhing the reεin after detritylation, to remove the acidic reagent, the reaction iε continued to promote the formylation of the morpholino nitrogen.
Example 18 Determination of Oligomer Sequence
A. Removal of Oligomers from a Selected Bead
The treament necessary to remove the oligomer from the resin dependε on the anchor:
1. Anchor from 16B1 iε cleaved by treatment with 10% DBU/DMF.
2. Anchor from 16B2 iε cleaved by treatment with mercaptoethanol or dithiothreitol in DMF or water containing triethylamine.
3. Anchor from 16B3 is cleaved by iradiation of the resin with light of 350 nm. Wavelengths shorter than
300 nm are are excluded by a pyrex filter.
B. Analysiε of the Oligomer by Maεε Spectrometry
A εingle bead, containing an oligomer family, and εorted by the procedureε deεcribed above, iε waεhed by the methodε deεcribed above to remove protein. The anchor iε then cleaved by the method in Example 16H uεing 2 uL of reaction solution. The reaction mixture is combined with a mixture of εinapinic acid and aqueouε acetonitrile (4 partε) . The εolution iε then introduced onto the probe of a Matrix Aεsisted Laser Desorption Time Of Flight (MALDE- TOF) masε εpectrometer. The compoεition and εequence of the oligomer is determined by the molecular weights of the peaks of the full-length molecule and the truncated specieε.
Example 19
Denεity Gradient Separation of Oligomer-Library Particleε
Librarieε of oligomerε are formed on the particles in accordance with the examples above. The oligomer-particles preferably contain an intense dye or fluoreεcent material to facilitate viεualization of individual particleε. Each particleε iε preferably prepared to contain a εingle family of N-εubunit oligomer εpecieε, and together the collection of particleε in a given preparation contain the full library of oligomer specieε. To utilize εuch a library of oligomer-particles for detection of target binding by one or more component oligomer specieε and for determining the εequence of an oligomer family containing an oligomer which exhibitε εaid target binding, the oligomer-particle library preparation iε mixed with a suitable concentration of target in a solution having a denεity greater than that of the oligomer-particle, but leεε than that of an oligomer-particle/target complex. Sucroεe εolutionε are generally convenient for this purpose. After gentle mixing for a period of time sufficient to allow binding of target to any particle-bound oligomer which has a εuitable affinity for εaid target, the εolution iε allowed to εtand for a period of time, whereupon any oligomer-particle/target complex which formε will settle to the bottom of the container. If the particles are quite small (e.g., 20 to 30 microns in diameter) or the buoyant density differential between the εolution and the oligomer-particle/target is small, then centrifugation can be used to εpeed the εettling of complexed particleε. Alternatively, the oligomer-particle preparation iε mixed with a εuitable concentration of target in a solution containing a density-gradient-forming component, such as metrizamide, Centrifugation in an ultracentrifuge then generally rapidly εeparateε oligomer-particleε from any oligomer-particle/target complex which may have formed.
Although the invention haε been deεcribed with reference to εpecifc synthetic, and εequencing methodε, it will be appreciated that variouε changeε and modification can be made without departing from the invention.

Claims

7 /IT r CLAIMED:
1. A combinatorial library of oligomerε formed of morpholino εubunit εtructureε of the form:
Figure imgf000079_0001
where (i) the εtructureε are linked together by linkageε one to four atoms long joining the morpholino nitrogen of one subunit to the 4' cyclic carbon of an adjacent subunit, and X, iε a εide chain selected from the group consiεting of purineε, pyrimidineε, non-nucleobaεe aromatic side chains, aliphatic εide chains, and mixed aromatic/aliphatic moieties, where at least 3 of the side chains X, are variable, and the library includeε at least about 1,000 different side chain sequence oligomers.
2. The compoεition of claim 1, wherein oligomer linkages in the library include one-atom linkageε of the form:
Figure imgf000079_0002
3. The composition of claim 1, wherein oligomer linkages in the library include carbony1-containing linkages of the form:
Figure imgf000080_0001
4. The composition of claim 1, wherein oligomer X, in the library include side chains εelected from the group consisting of purines and pyrimidineε, and side chainε selected from the group consisting of a non-nucleobase aromatic moieties, aliphatic moietieε, and mixed aromatic/aliphatic moietieε.
5. The compoεition of claim 1, wherein εaid oligomerε are effective to hybridize, by Watεon-Crick baεe pairing to random-εequence oligonucleotideε.
6. The compoεition of claim 1, wherein εaid oligomers have different sequences of linkages.
7. The composition of claim 1, wherein the linkages are selected from the group consiεting of 3-atom carbamate and 3-atom phoεphorodiamidate.
The composition ot claim 1, wherein the oligomers include at least one branched subunit joined to a linkage in the oligomer.
9. The composition of claim 1, wherein the combinatorial library is formed on a plurality of particles, each particle having a surface coating of molecules containing one of the base-εequences in the library.
10. The composition of claim 9, wherein the oligomer molecules on each particle are carried on dendritic polymers attached to the particles and coupled to the oligomers through cleavable linkageε.
11. The compoεition of claim 9, wherein the particles are macroreticular particles having selected sizeε in the 40-200 μm range, and the oligomerε are coupled to the particles through cleavable linkages.
12. A method of generating a compound capable of interacting specifically with a selected macromolecular ligand, comprising
(a) contacting the receptor with a combinatorial library of oligomers formed of morpholino subunit structureε of the form:
Figure imgf000081_0001
where (i) the εtructureε are linked together by linkageε one to four ato ε long joining the morpholino nitrogen of one εubunit to the 4' cyclic carbon of an adjacent subunit, and X is a side chain selected from the group consisting of purines, pyri Ldines, non-nucleobase aromatic side chains, aliphatic side chains, and mixed aromatic/aliphatic side chains, where at least 3 of the bases X, are variable, and the library includes at leaεt about 1,000 different baεe sequence oligomers,
(b) isolating oligomer moleculeε that bindε specifically to the receptor, and
(c) determining the sequence of baεes in the iεolated oligomer moleculeε.
13. The method of claim 12, wherein oligomer linkageε in the library include one-atom linkageε of the form:
Figure imgf000082_0001
14. The method of claim 12, wherein oligomer linkages in the library include amide-containing linkages of the form:
Figure imgf000082_0002
15. The method of claim 12, wherein oligomer side chainε in the library include some side chainε selected from the group consiεting of purines and pyrimidineε, and εome side chainε εelected from the group conεiεting of a non-nucleobase aromatic side chains, aliphatic side chainε, and mixed aromatic/aliphatic εide chains.
If.. The method ot cl im 1 ? , wherein said oligomers are designed to hybridize, by Watson-Crick base pairing, to random-sequence oligonucleotides, and said determining includes reacting the isolated oligomers with a combinatorial library of oligonucleotides, under conditions effective to produce hybridization between the isolated oligomer molecules and complementary-base oligonucleotides, and determining the sequence of the oligonucleotides hybridized to the isolated oligomer moleculeε.
17. The method of claim 12, wherein the combinatorial library is formed on a plurality of particles, each particle having a surface coating of molecules containing one of the side chain-εequences in the library, said isolating includes isolating a particle having surface- bound receptor, and said determining includes determining the sequence of bases of the molecules on the isolated particle.
18. The method of claim 17, wherein said isolating includes contacting particles having εurface-bound receptor with a solid εurface having surface-bound anti-receptor molecules effective to bind specifically to the receptor, and isolating particles bound to the solid surface.
19. The method of claim 18, wherein the oligomer molecules on each bead are carried on dendritic polymers attached to the particles and coupled to the oligomers through cleavable linkages.
20. The method of claim 19, wherein said determining includeε analyzing the baεe sequence of the isolated oligomers by mass spectro etry.
21. The method of claim 12, for use in generating an oligomer effective to bind selectively to an known antibody, wherein each oligomer torming the library is bLvalent, and said isolating includes immunoprecipitating antibody-bound oligomerε from a εolution of the library oligomerε.
22. An oligomer compoεition comprised of morpholino subunit εtructures of the form:
Figure imgf000084_0001
where (i) the εtructureε are linked together by linkages one to four atoms long joining the morpholino nitrogen of one subunit to the 4' cyclic carbon of an adjacent subunit, and X, is a side chain selected from the group consiεting of purineε, pyrimidineε, non-nucleobaεe aromatic εide chainε, aliphatic εide chains, and mixed aromatic/aliphatic moieties, where at leaεt 3 of the side chains X, are variable.
23. An oligomer compoεition compriεed of morpholino subunit structureε of the form:
Figure imgf000084_0002
Figure imgf000084_0003
where (i) the structu Areε are linked together by linkageε one to four atomε long joining the morpholino nitrogen of one εubunit to the 4' cyclic carbon of an adjacent εubunit, and X, is a side chain selected from the group consisting of purines, pyrimidines, non-nucleobase aromatic side chains, aliphatic side chains, and mixed aromatic/aliphatic moieties, where at least 3 ot the side chains Xt are variable.
24. The composition of claim 23, wherein X, iε a purine or pyrimidine Watson-Crick base-pairing moiety.
PCT/US1995/006041 1994-05-11 1995-05-11 Morpholino-subunit combinatorial library and method WO1995031459A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24385/95A AU2438595A (en) 1994-05-11 1995-05-11 Morpholino-subunit combinatorial library and method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/242,159 US5506337A (en) 1985-03-15 1994-05-11 Morpholino-subunit combinatorial library and method
US08/242,159 1994-05-11

Publications (1)

Publication Number Publication Date
WO1995031459A1 true WO1995031459A1 (en) 1995-11-23

Family

ID=22913681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/006041 WO1995031459A1 (en) 1994-05-11 1995-05-11 Morpholino-subunit combinatorial library and method

Country Status (3)

Country Link
US (2) US5506337A (en)
AU (1) AU2438595A (en)
WO (1) WO1995031459A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009509A3 (en) * 2000-07-31 2003-05-15 Universty Of Minessota Inhibition of gene expression using polynucleotide analogues
US6867349B2 (en) 2000-07-31 2005-03-15 Regents Of The University Of Minnesota Inhibition of gene expression using polynucleotide analogues

Families Citing this family (569)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
JPH09500625A (en) 1993-07-09 1997-01-21 スミスクライン・ビーチャム・コーポレイション Cyclic semi-random peptide library
US5856083A (en) * 1994-05-06 1999-01-05 Pharmacopeia, Inc. Lawn assay for compounds that affect enzyme activity or bind to target molecules
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
US20030099945A1 (en) * 1994-09-20 2003-05-29 Invenux, Inc. Parallel selex
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040161777A1 (en) * 1996-06-06 2004-08-19 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5731438A (en) * 1996-08-01 1998-03-24 Isis Pharmaceuticals, Inc. N-(aminoalkyl)-and/or N-(amidoalkyl)-dinitrogen heterocycles
US6617114B1 (en) 1996-10-31 2003-09-09 Karo Bio Ab Identification of drug complementary combinatorial libraries
US6262269B1 (en) 1997-02-04 2001-07-17 Trega Biosciences, Inc. 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
US6893815B1 (en) * 1997-06-30 2005-05-17 Isis Pharmaceuticals, Inc. Nucleobase heterocyclic combinatorialization
US7252950B1 (en) 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
US6190920B1 (en) 1997-11-12 2001-02-20 The Regents Of The University Of California Method for detecting enzyme catalyzed cyclization
AU3198899A (en) * 1998-03-20 1999-10-11 Rockefeller University, The Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof
JP2002522747A (en) 1998-04-14 2002-07-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Assays for detecting microtubule depolymerization inhibitors
US6872537B1 (en) 1998-04-14 2005-03-29 Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US6699969B1 (en) 1998-04-14 2004-03-02 The Regents Of The University Of California Assays for the detection of microtubule depolymerization inhibitors
US7402400B2 (en) 2001-07-03 2008-07-22 Regents Of The University Of California Mammalian sweet taste receptors
US7018846B1 (en) 1998-08-10 2006-03-28 Science & Technology Corporation @ Unm Display of receptors and analysis of binding interactions and drug libraries
US7189519B2 (en) * 1998-08-10 2007-03-13 Stc.Unm Bead-based detection of ligand-GPCR-G protein complexes
DE69942782D1 (en) 1998-11-27 2010-10-28 Ucb Sa Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2000045167A2 (en) * 1999-01-29 2000-08-03 Avi Biopharma, Inc. Non-invasive method for detecting target rna
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
DE60039601D1 (en) * 1999-05-24 2008-09-04 Avi Biopharma Inc ANTISENSE AGAINST C-MYC FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE
US6649358B1 (en) 1999-06-01 2003-11-18 Caliper Technologies Corp. Microscale assays and microfluidic devices for transporter, gradient induced, and binding activities
US6362342B1 (en) 1999-06-29 2002-03-26 Lion Bioscience Ag Triazole compounds and methods of making same
US6515122B1 (en) 1999-09-24 2003-02-04 Lion Bioscience Ag Tetracyclic benzimidazole derivatives and combinatorial libraries thereof
JP2004536082A (en) * 1999-10-22 2004-12-02 グラクソ グループ リミテッド In vivo imaging
EP1950306A1 (en) 1999-11-17 2008-07-30 Mendel Biotechnology, Inc. Environmental stress tolerance genes
AU1765601A (en) 1999-11-17 2001-05-30 Luc Adam Plant biochemistry-related genes
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US8642284B1 (en) 1999-12-15 2014-02-04 Massachusetts Institute Of Technology Methods for identifying agents that alter NAD-dependent deacetylation activity of a SIR2 protein
US7452664B2 (en) * 1999-12-15 2008-11-18 Massachusetts Institute Of Technology Methods for identifying agents which alter histone protein acetylation
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
WO2001083740A2 (en) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Splice-region antisense composition and method
AU2001271873A1 (en) 2000-07-06 2002-01-21 Avi Biopharma, Inc. Transforming growth factor beta (TGF-beta) blocking agent-treated stem cell composition and method
WO2002015675A1 (en) 2000-08-22 2002-02-28 Mendel Biotechnology, Inc. Genes for modifying plant traits iv
JP5305553B2 (en) 2000-10-12 2013-10-02 ユニバーシティー オブ ロチェスター Composition for inhibiting the growth of cancer cells
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7572575B2 (en) * 2000-12-13 2009-08-11 Massachusetts Institute Of Technology SIR2 activity
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
IL158000A0 (en) * 2001-03-19 2004-03-28 Harvard College Evolving new molecular function
DE60213771T2 (en) 2001-03-30 2007-08-16 The University of Massachusetts, Worcester MORPHOLINE IMAGING AND THERAPY
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US20040219632A1 (en) * 2001-04-20 2004-11-04 Robert Margolskee T1r3 a novel taste receptor
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
DE60228477D1 (en) 2001-05-08 2008-10-02 Darwin Molecular Corp PROCESS FOR REGULATING THE IMMUNE FUNCTION IN PRIMATES USING THE FOXP3 PROTEIN
DK1402024T3 (en) 2001-06-20 2007-12-27 Nuevolution As Method for synthesizing a template molecule
CA2451317C (en) 2001-06-26 2016-03-29 Senomyx, Inc. T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
IL159640A0 (en) 2001-07-10 2004-06-01 Senomyx Inc Use of specific t2r taste receptors to identify compounds that block bitter taste
AU2002329647A1 (en) * 2001-07-26 2003-02-24 University Of Utah Research Foundation In vitro assays for inhibitors of hiv capsid conformational changes and for hiv capsid formation
JP2005522187A (en) * 2001-10-12 2005-07-28 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア サン ディエゴ Gastrointestinal chemosensory receptors
US20030224353A1 (en) * 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
JP2005507660A (en) 2001-10-16 2005-03-24 アビ バイオファーマ， インコーポレイテッド Antisense antiviral agents and methods for the treatment of ssRNA virus infections
EP1442137A4 (en) * 2001-11-07 2005-08-31 Applera Corp Universal nucleotides for nucleic acid analysis
AU2002362013B2 (en) 2001-11-21 2008-04-24 Applied Biosystems, Llc. Digital assay
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20030211538A1 (en) * 2001-12-03 2003-11-13 Ming Luo CAP-Gly domain structure and uses thereof
US7179907B2 (en) * 2001-12-18 2007-02-20 Bruce Eaton Antibiotic compounds
WO2003062395A2 (en) * 2002-01-18 2003-07-31 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
MXPA04007586A (en) 2002-02-06 2005-06-08 Vicor Technologies Inc Anti-infarction molecules.
AU2003213676A1 (en) * 2002-03-04 2003-09-22 Bristol-Myers Squibb Company Novel nucleic acid molecules and polypeptides encoding baboon tafi
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
AU2003257181A1 (en) 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20040214232A1 (en) * 2002-08-16 2004-10-28 Burke Martin D. Generation of skeletal diversity within a combinatorial library
JP4657919B2 (en) * 2002-08-19 2011-03-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Evolving new molecular functions
EP2270166A3 (en) 2002-09-18 2011-08-10 Mendel Biotechnology, Inc. Polynucleotides and polypeptides in plants
WO2004044132A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
CA2506243A1 (en) * 2002-11-19 2004-06-03 Amgen Inc. Amplified genes involved in cancer
EP2258724A1 (en) 2002-11-21 2010-12-08 Celltech R & D, Inc. Modulating immune responses using multimerized anti-CD83 antibodies
JP2006518997A (en) * 2003-01-21 2006-08-24 ブリストル−マイヤーズ　スクイブ　カンパニー Novel acyl coenzyme A: polynucleotide encoding monoacylglycerol acyltransferase-3 (MGAT3) and uses thereof
US7232659B1 (en) 2003-02-04 2007-06-19 Stc.Unm Multiplex analysis for high throughput discrimination of GPCR agonists and antagonists
US8017323B2 (en) 2003-03-26 2011-09-13 President And Fellows Of Harvard College Free reactant use in nucleic acid-templated synthesis
US7468418B2 (en) 2003-04-29 2008-12-23 Avi Biopharma., Inc. Compositions for enhancing transport of molecules into cells
WO2004112575A2 (en) * 2003-06-20 2004-12-29 Amgen Inc. Gene amplification and overexpression in cancer
WO2005002527A2 (en) * 2003-07-03 2005-01-13 Massachusetts Institute Of Technology Sirt1 modulation of adipogenesis and adipose function
NZ545747A (en) 2003-08-06 2010-06-25 Senomyx Inc T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
WO2005027833A2 (en) * 2003-09-12 2005-03-31 Avi Biopharma, Inc. Compound and method for treating androgen-independent prostate cancer
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20050244810A1 (en) * 2003-09-29 2005-11-03 Egan Josephine M Taste signaling in gastrointestinal cells
US7480382B2 (en) * 2003-09-30 2009-01-20 Microsoft Corporation Image file container
EP2369347A1 (en) 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
US20050164969A1 (en) * 2003-11-19 2005-07-28 Massachusetts Institute Of Technology Method of extending life span
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
WO2005072527A2 (en) * 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US20050226865A1 (en) 2004-04-02 2005-10-13 Regents Of The University Of California Methods and compositions for treating and preventing diseases associated with alphavbeta5 integrin
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
US7323347B2 (en) * 2004-05-27 2008-01-29 Sensata Technologies, Inc. Biosensor surface structures and methods
WO2005118864A2 (en) 2004-05-28 2005-12-15 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
AU2005252663B2 (en) * 2004-06-03 2011-07-07 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
CA2571243A1 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
US7807816B2 (en) 2004-06-28 2010-10-05 University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
PT1766012E (en) 2004-07-02 2011-09-05 Avi Biopharma Inc Antisense antibacterial method and compound
AU2005277648B2 (en) * 2004-08-20 2011-12-22 Buck Institute For Age Research Small molecules that replace or agonize p53 function
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US20060228726A1 (en) * 2005-01-06 2006-10-12 Martin Patrick K Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
US20060153745A1 (en) * 2005-01-11 2006-07-13 Applera Corporation Fluid processing device for oligonucleotide synthesis and analysis
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
US7338775B1 (en) 2005-02-09 2008-03-04 Myriad Genetics, Inc. Enzyme assay and use thereof
US20100196509A1 (en) 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
AU2006230563B8 (en) 2005-03-31 2010-06-17 Agensys, Inc. Antibodies and related molecules that bind to 161P2F10B proteins
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
US8076090B2 (en) 2005-04-05 2011-12-13 Corning Incorporated Label free biosensors and cells
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
US20070099830A1 (en) 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
ES2431315T3 (en) 2005-05-19 2013-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Functional epitopes of the Streptococcus pneumoniae PsaA antigen and uses thereof
US20090130666A1 (en) * 2005-05-27 2009-05-21 Applera Corporation Cytometric system including nucleic acid sequence amplification, and method
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
EP1915161B1 (en) 2005-07-13 2017-04-26 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007011722A2 (en) 2005-07-15 2007-01-25 President And Fellows Of Harvard College Reaction discovery system
HUE042197T2 (en) 2005-07-19 2019-06-28 Stemgen S P A Inhibition of the tumorigenic potential of tumor stem cells by lif
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
US20070072247A1 (en) * 2005-08-31 2007-03-29 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
WO2007030691A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
EP1937278B1 (en) * 2005-09-08 2012-07-25 AVI BioPharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US20070059713A1 (en) * 2005-09-09 2007-03-15 Lee Jun E SSB-DNA polymerase fusion proteins
US7781209B2 (en) 2005-09-25 2010-08-24 Multispan, Inc. GPCR-expressing cell lines
US8906609B1 (en) 2005-09-26 2014-12-09 Arrowhead Center, Inc. Label-free biomolecule sensor based on surface charge modulated ionic conductance
EP2402435A3 (en) 2005-10-14 2012-03-28 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
MX2007015931A (en) 2005-10-20 2008-04-22 Senomyx Inc Chimeric human sweet-umami and umami-sweet taste receptors.
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
JP2009514535A (en) * 2005-11-03 2009-04-09 レッドポイント バイオ コーポレイション High-throughput screening assay for TRPM5 ion channel
CA2628238A1 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
EP1976567B1 (en) 2005-12-28 2020-05-13 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
US20070172842A1 (en) * 2006-01-25 2007-07-26 Andreas Braun Methods for isolating and identifying novel target-specific structuremers for use in the biological sciences
WO2007103529A2 (en) * 2006-03-07 2007-09-13 Avi Biopharma, Inc. Antisense antiviral compound and method for treating arenavirus infection
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
CA2646597A1 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and ly6 e: targets for cancer diagnosis and therapy
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
KR101387563B1 (en) 2006-04-21 2014-04-25 세노믹스, 인코포레이티드 Comestible compositions comprising high potency savory flavorants, and processes for producing them
CN101421419B (en) 2006-05-02 2012-08-29 学校法人帝京大学 Method for screening of substance capable of increasing glutathione
PT2735568T (en) * 2006-05-10 2017-11-14 Avi Biopharma Inc Oligonucleotide analogs having cationic intersubunit linkages
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20070265215A1 (en) * 2006-05-11 2007-11-15 Iversen Patrick L Antisense restenosis composition and method
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
JP2009539844A (en) * 2006-06-06 2009-11-19 マサチューセッツ・インスティテュート・オブ・テクノロジー SIRT1 and LXR cholesterol regulatory complex and methods of use
DE602006012460D1 (en) 2006-06-07 2010-04-08 Nutrinova Gmbh Method for screening substances that modulate the activity of Gpcrs
EP2035831B1 (en) 2006-06-30 2013-08-14 Applied Biosystems, LLC Methods of analyzing binding interactions
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US7674594B2 (en) * 2006-07-27 2010-03-09 Redpoint Bio Corporation Screening assay for inhibitors of TRPA1 activation by a lower alkyl phenol
JP2009545317A (en) 2006-08-01 2009-12-24 アプライド バイオシステムズ， エルエルシー Analyte and nucleic acid detection
WO2008022035A2 (en) * 2006-08-10 2008-02-21 The Scripps Research Institute Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
WO2008019394A2 (en) * 2006-08-11 2008-02-14 The Government Of The United States Of America As Represented By The Secretary, Dept Of Health And Human Services Methods for treatment and diagnosis of psychiatric disorders
WO2008023840A2 (en) 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
EP2679998A1 (en) 2006-09-06 2014-01-01 The Regents of the University of California Molecular diagnosis and classification of malignant melanoma
AU2007297535C1 (en) 2006-09-21 2017-11-23 University Of Florida Research Foundation, Inc. Compositions and methods related to protein displacement therapy for myotonic distrophy
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
US20100062000A1 (en) * 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
US20080187928A1 (en) * 2006-12-29 2008-08-07 The Salk Institute For Biological Studies Methods for enhancing exercise performance
US9101671B2 (en) 2007-01-03 2015-08-11 Sanford-Burnham Medical Research Institute Methods and compositions related to clot binding compounds
WO2008098182A1 (en) 2007-02-08 2008-08-14 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
US20080229436A1 (en) * 2007-03-15 2008-09-18 Board Of Trustees Of The University Of Arkansas Methods for identifying modulators of lifespan and resistance to oxidative stress
US20080269065A1 (en) * 2007-04-30 2008-10-30 Syntrix Biosystems, Inc. Conformationally Constrained Analytical Probes
WO2009023059A2 (en) 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
AU2008262391A1 (en) * 2007-06-06 2008-12-18 Avi Biopharma, Inc. Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
US20090099066A1 (en) 2007-06-29 2009-04-16 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
ES2477294T3 (en) 2007-08-13 2014-07-16 Baxter International Inc IVIG modulation of chemokines for the treatment of multiple sclerosis, Alzheimer's disease and Parkinson's disease
EP2195656A4 (en) 2007-08-21 2011-10-19 Senomyx Inc Human t2r bitterness receptors and uses thereof
WO2009028158A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
US7875452B2 (en) * 2007-10-01 2011-01-25 Redpoint Bio Corporation Non-desensitizing mutant of the transient receptor potential TRPM5 ion channel
CA2697992C (en) 2007-10-04 2017-08-22 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
CA2703165A1 (en) 2007-10-22 2009-04-30 The Regents Of The University Of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi Use of tam receptor inhibitors as antimicrobials
US20090171078A1 (en) * 2007-11-20 2009-07-02 Applied Biosystems Inc. Method of sequencing nucleic acids using elaborated nucleotide phosphorotiolate compounds
US8017338B2 (en) * 2007-11-20 2011-09-13 Life Technologies Corporation Reversible di-nucleotide terminator sequencing
US7989608B2 (en) * 2007-12-28 2011-08-02 Avi Biopharma Inc. Immunomodulatory agents and methods of use
WO2009100037A1 (en) * 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
AU2009221778A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
ES2690554T3 (en) 2008-03-17 2018-11-21 The Scripps Research Institute Combined chemical and genetic approaches for the generation of induced pluripotent stem cells
CN102083850B (en) 2008-04-21 2015-08-12 加利福尼亚大学董事会 Selectivity high-affinity polydentate ligand and preparation method thereof
US20120058105A1 (en) 2008-06-27 2012-03-08 Martin Kean Chong Ng Method of treatment of vascular complications
CA2735710A1 (en) 2008-08-04 2010-02-11 Glen N. Barber Sting (stimulator of interferon genes), a regulator of innate immune responses
WO2010019963A2 (en) * 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
AU2009298879A1 (en) 2008-09-23 2010-04-08 President And Fellows Of Harvard College SIRT4 and uses thereof
US8153606B2 (en) * 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
US8334372B2 (en) 2008-10-15 2012-12-18 Isis Pharmaceuticals, Inc. Modulation of factor 11 expression
KR20230025924A (en) 2008-10-24 2023-02-23 사렙타 쎄러퓨틱스 인코퍼레이티드 Multiple exon skipping compositions for dmd
CA2779958A1 (en) 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
EP2687609B1 (en) 2008-11-10 2017-01-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for treating solid tumor
WO2010065617A1 (en) 2008-12-02 2010-06-10 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
BRPI0922345B1 (en) 2008-12-03 2022-03-22 The Scripps Research Institute Compound, in vitro methods for stabilizing an isolated animal cell and for maintaining cell survival, and, composition
ES2629630T3 (en) 2008-12-04 2017-08-11 Curna, Inc. Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO
EP2370582B1 (en) 2008-12-04 2017-05-10 CuRNA, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
US8927511B2 (en) * 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
EP2370175A2 (en) * 2008-12-16 2011-10-05 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
EP2373784B1 (en) 2008-12-17 2017-10-25 The Scripps Research Institute Generation and maintenance of stem cells
US8592386B2 (en) * 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
ES2560107T3 (en) 2009-02-12 2016-02-17 Curna, Inc. Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF
CA2755409C (en) 2009-03-16 2019-04-30 Joseph Collard Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
JP5904935B2 (en) 2009-03-17 2016-04-20 クルナ・インコーポレーテッド Treatment of DLK1-related diseases by suppression of natural antisense transcripts against Delta-like 1 homolog (DLK1)
US20100240069A1 (en) * 2009-03-18 2010-09-23 Boehringer Ingelheim International Gmbh Drug Discovery Assay for Modulators of HIF-Prolyl Hydroxylase Activity
US20100240065A1 (en) * 2009-03-18 2010-09-23 Boehringer Ingelheim International Gmbh Prolyl Hydroxylase Compositions and Methods of Use Thereof
TW201039841A (en) 2009-03-27 2010-11-16 Gojo Ind Inc Compositions and methods for screening and using compounds antagonizing spore-surface interactions
KR101722541B1 (en) 2009-05-06 2017-04-04 큐알엔에이, 인크. Treatment of tristetraproline(ttp) related diseases by inhibition of natural antisense transcript to ttp
CN102459596B (en) 2009-05-06 2016-09-07 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
CA2761248C (en) 2009-05-08 2023-03-14 Joseph Collard Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
ES2664590T3 (en) 2009-05-18 2018-04-20 Curna, Inc. Treatment of diseases related to reprogramming factors by inhibition of the natural antisense transcript to a reprogramming factor
US8895527B2 (en) 2009-05-22 2014-11-25 Curna, Inc. Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
WO2010138806A2 (en) 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US9200276B2 (en) 2009-06-01 2015-12-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
JP5944311B2 (en) 2009-06-16 2016-07-05 クルナ・インコーポレーテッド Treatment of collagen gene-related diseases by suppression of natural antisense transcripts against collagen genes
US8951981B2 (en) 2009-06-16 2015-02-10 Curna, Inc. Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
JP6073133B2 (en) 2009-06-24 2017-02-01 クルナ・インコーポレーテッド Treatment of TNFR2-related diseases by suppression of natural antisense transcripts against tumor necrosis factor receptor 2 (TNFR2)
EP2446037B1 (en) 2009-06-26 2016-04-20 CuRNA, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
WO2011011366A2 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011011775A1 (en) 2009-07-24 2011-01-27 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb5 integrin
CN102762731B (en) 2009-08-05 2018-06-22 库尔纳公司 By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS)
CN104313027B (en) 2009-08-11 2018-11-20 库尔纳公司 By inhibiting the natural antisense transcript of adiponectin (ADIPOQ) to treat adiponectin (ADIPOQ) related disease
US9914745B2 (en) 2009-08-14 2018-03-13 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
CA2771102C (en) 2009-08-14 2019-10-15 The Regents Of The University Of California Methods of diagnosing and treating autism
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
WO2011022638A1 (en) 2009-08-20 2011-02-24 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
KR101805213B1 (en) 2009-08-21 2017-12-06 큐알엔에이, 인크. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
WO2011031482A2 (en) 2009-08-25 2011-03-17 Curna, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
CN102791861B (en) 2009-09-25 2018-08-07 库尔纳公司 FLG relevant diseases are treated by adjusting expression and the activity of Filaggrin (FLG)
JP2013507365A (en) 2009-10-07 2013-03-04 サンフォード−バーナム メディカル リサーチ インスティテュート Methods and compositions for clot-binding lipid compounds
EP2499249B1 (en) 2009-11-12 2018-08-08 The University Of Western Australia Antisense molecules and methods for treating pathologies
US8697858B2 (en) 2009-11-13 2014-04-15 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
AU2010321885B2 (en) 2009-11-20 2015-12-24 The Regents Of The University Of California Epithelial membrane protein-2 (EMP2) and proliferative vitreoretinopathy (PVR)
ES2661813T3 (en) 2009-12-16 2018-04-04 Curna, Inc. Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene
EP2512497A1 (en) 2009-12-18 2012-10-24 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
JP5934106B2 (en) 2009-12-23 2016-06-15 カッパーアールエヌエー，インコーポレイテッド Treatment of HGF-related diseases by inhibition of natural antisense transcripts against hepatocyte growth factor (HGF)
CA2782375C (en) 2009-12-23 2023-10-31 Opko Curna, Llc Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
EP2519634B1 (en) 2009-12-29 2016-06-01 CuRNA, Inc. TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
WO2011082281A2 (en) 2009-12-31 2011-07-07 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
KR101878501B1 (en) 2010-01-04 2018-08-07 큐알엔에이, 인크. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
KR101853509B1 (en) 2010-01-06 2018-04-30 큐알엔에이, 인크. Treatment of Pancreatic Developmental Gene Related Diseases By Inhibition of Natural Antisense Transcript to A Pancreatic Developmental Gene
ES2664866T3 (en) 2010-01-11 2018-04-23 Curna, Inc. Treatment of diseases related to sex hormone binding globulin (shbg) by inhibition of the natural antisense transcript to shbg
WO2011091435A2 (en) 2010-01-25 2011-07-28 Mount Sinai School Of Medicine Methods of treating liver disease
CN102782135A (en) 2010-01-25 2012-11-14 库尔纳公司 Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
WO2011113015A2 (en) 2010-03-12 2011-09-15 Avi Biopharma, Inc. Antisense modulation of nuclear hormone receptors
KR101877065B1 (en) 2010-04-02 2018-07-10 큐알엔에이, 인크. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
CN102858979B (en) 2010-04-09 2018-01-26 库尔纳公司 FGF21 relevant diseases are treated by suppressing the natural antisense transcript of FGF2 1 (FGF21)
JP6066900B2 (en) 2010-04-26 2017-01-25 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of cysteinyl tRNA synthetase
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
CA2797271C (en) 2010-04-28 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
WO2011139854A2 (en) 2010-04-29 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CA2797277C (en) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CN103140233B (en) 2010-05-03 2017-04-05 Atyr 医药公司 Treatment, diagnosis and the discovery of antibody compositions related to the protein fragments of methionyl-tRNA synthetase
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
CN102985103A (en) 2010-05-04 2013-03-20 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
CA3090304A1 (en) 2010-05-13 2011-11-17 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
TWI586356B (en) 2010-05-14 2017-06-11 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
JP6396656B2 (en) 2010-05-14 2018-09-26 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of phenylalanyl βtRNA synthetase
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
WO2011149843A1 (en) 2010-05-24 2011-12-01 Mendel Biotechnology Inc. Novel reporter constructs for compound screening
RU2620978C2 (en) 2010-05-26 2017-05-30 Курна, Инк. Treatment of diseases associated with methionine sulfoxide reductase a (msra), by msra natural antisense transcript inhibition
NO2576783T3 (en) 2010-05-26 2018-04-28
CN103096913B (en) 2010-05-27 2017-07-18 Atyr 医药公司 Treatment, diagnosis and the innovation of antibody compositions related to the protein fragments of glutaminyl tRNA synzyme is found
KR101981705B1 (en) 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
JP6023705B2 (en) 2010-06-23 2016-11-09 カッパーアールエヌエー，インコーポレイテッド Treatment of SCNA-related diseases by inhibition of natural antisense transcripts on sodium channels, voltage-gated, alpha subunit (SCNA)
JP6116479B2 (en) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of glycyl-tRNA synthetase
US8980860B2 (en) 2010-07-14 2015-03-17 Curna, Inc. Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
US8648053B2 (en) 2010-10-20 2014-02-11 Rosalind Franklin University Of Medicine And Science Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
CA2815212A1 (en) 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
US20120122769A1 (en) 2010-11-12 2012-05-17 Avi Biopharma, Inc. Antisense antibacterial compounds and methods
CA3077910A1 (en) 2010-11-17 2012-05-24 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
WO2012074855A2 (en) 2010-11-22 2012-06-07 The Regents Of The University Of California Methods of identifying a cellular nascent rna transcript
KR102010598B1 (en) 2010-11-23 2019-08-13 큐알엔에이, 인크. Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
WO2012087965A2 (en) 2010-12-22 2012-06-28 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
CN103501793A (en) 2011-02-08 2014-01-08 夏洛特-梅克伦堡医院(商业用名:卡罗来纳保健系统) Antisense oligonucleotides
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
ES2716865T3 (en) 2011-02-18 2019-06-17 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells to a myelinating cell target
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
EP2691105B1 (en) 2011-03-28 2018-07-11 University of Utah Research Foundation Methods and compositions related to inhibition of viral entry
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
WO2012151324A1 (en) 2011-05-02 2012-11-08 Isis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with usher syndrome
CN103619356B (en) 2011-05-05 2017-09-12 萨勒普塔医疗公司 Peptide oligonucleotide conjugates
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
JP6188686B2 (en) 2011-06-09 2017-08-30 カッパーアールエヌエー，インコーポレイテッド Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN)
WO2012170945A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
CA2840614A1 (en) 2011-06-29 2013-01-03 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
WO2013012752A2 (en) 2011-07-15 2013-01-24 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
JP6014904B2 (en) 2011-07-29 2016-10-26 国立大学法人徳島大学 ERAP1-derived peptides and uses thereof
CN108272782B (en) 2011-09-06 2021-04-23 库尔纳公司 Use of small molecules in preparation of medicine for treating Dravet syndrome or generalized epilepsy with febrile convulsion adjunctive disease
US9801948B2 (en) 2011-09-21 2017-10-31 Yale University Antimicrobial compositions and methods of use thereof
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
CN104039739A (en) 2011-11-18 2014-09-10 萨勒普塔医疗公司 Functionally-modified oligonucleotides and subunits thereof
CA2857664A1 (en) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides targeting within the smn2 pre-mrna for use ininduced exon inclusion in spinal muscle atrophy
JP6317675B2 (en) 2011-11-30 2018-04-25 サレプタ セラピューティクス， インコーポレイテッド Oligonucleotides for treating prolonged repeat disease
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
US9895451B2 (en) 2011-12-02 2018-02-20 Yale University Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
EP2788487B1 (en) 2011-12-08 2018-04-04 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
JP2015500345A (en) 2011-12-16 2015-01-05 トランスポサジェン・バイオファーマシューティカルズ・インコーポレイテッドＴｒａｎｓｐｏｓａｇｅｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． TRPC4 modulator used for the treatment or prevention of pain
WO2013096837A1 (en) 2011-12-22 2013-06-27 Isis Pharmaceuticals, Inc. Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression
US20150025231A1 (en) 2012-01-11 2015-01-22 Cold Spring Harbor Laboratory Compositions and methods for modulation of ikbkap splicing
WO2013120003A1 (en) 2012-02-08 2013-08-15 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
WO2013123305A1 (en) 2012-02-16 2013-08-22 The Penn State Research Foundation Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
WO2013138456A1 (en) 2012-03-14 2013-09-19 University Of Central Florida Research Foundation, Inc. Lim kinasemodulating agents for neurofibromatoses therapy and methods for screening for same
CN110438125A (en) 2012-03-15 2019-11-12 科纳公司 By inhibiting the natural antisense transcript of brain derived neurotrophic factor (BDNF) to treat BDNF related disease
WO2013142514A1 (en) 2012-03-19 2013-09-26 Isis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
CN104411831B (en) 2012-03-20 2020-08-11 萨勒普塔医疗公司 Boronic acid conjugates of oligonucleotide analogs
EP2831231A1 (en) 2012-03-30 2015-02-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013151771A1 (en) 2012-04-05 2013-10-10 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
US9612235B2 (en) 2012-04-05 2017-04-04 Koch Biological Solutions, Llc Herbicidal compound screening
CN104520315A (en) 2012-04-24 2015-04-15 迈阿密大学 PERFORIN 2 defense against invasive and multidrug resistant pathogens
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
WO2013177248A2 (en) 2012-05-22 2013-11-28 Isis Pharmaceuticals, Inc. Modulation of enhancer rna mediated gene expression
WO2013180815A1 (en) * 2012-05-30 2013-12-05 University Of Tennessee Research Foundation Compounds for amide-forming reactions
US9487780B2 (en) 2012-06-01 2016-11-08 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
WO2013181665A1 (en) 2012-06-01 2013-12-05 Isis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
EP2855425A4 (en) 2012-06-04 2016-05-18 Scripps Research Inst Novel phenyl glyoxal probes
LT3461895T (en) 2012-06-25 2020-09-10 Ionis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
EP3184121A3 (en) 2012-07-25 2017-09-27 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
US20150297629A1 (en) 2012-07-27 2015-10-22 Isis Pharmaceuticals, Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
AR092658A1 (en) 2012-09-25 2015-04-29 Genzyme Corp OLIGONUCLEOTIDOS ANTISENTIDO MORFOLINO UNITED TO PEPTIDE FOR THE TREATMENT OF MYOTONIC DYSTROPHY
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
WO2014059364A1 (en) 2012-10-11 2014-04-17 Isis Pharmaceuticals, Inc. Methods of treating kennedy's disease
EP4144845B1 (en) 2012-10-12 2024-04-24 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
WO2014059356A2 (en) 2012-10-12 2014-04-17 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014066864A2 (en) 2012-10-26 2014-05-01 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
MX2015008035A (en) 2012-12-20 2016-03-17 Sarepta Therapeutics Inc Improved exon skipping compositions for treating muscular dystrophy.
US9856474B2 (en) 2013-01-16 2018-01-02 Iowa State University Research Foundation, Inc. Deep intronic target for splicing correction on spinal muscular atrophy gene
DK2954323T3 (en) 2013-02-07 2020-07-20 Univ California Use of translation profiling to identify target molecules for therapeutic treatment
KR102169899B1 (en) 2013-02-14 2020-10-26 아이오니스 파마수티컬즈, 인코포레이티드 Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
US10251906B2 (en) 2013-03-12 2019-04-09 University Of Utah Research Foundation Compositions and methods for inducing apoptosis
JP6449231B2 (en) 2013-03-14 2019-01-09 サレプタ セラピューティクス， インコーポレイテッド Exon skipping composition for treating muscular dystrophy
BR112015022156A2 (en) 2013-03-14 2017-11-14 Isis Pharmaceuticals Inc compositions and methods for modulating tau expression
EP2970964B8 (en) 2013-03-14 2019-03-06 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US9428537B2 (en) 2013-03-15 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University tRNA derived small RNAs (tsRNAs) involved in cell viability
EA201591792A1 (en) 2013-03-15 2016-02-29 Сарепта Терапьютикс, Инк. IMPROVED COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DISTROPHIA
EP2986717A1 (en) 2013-04-19 2016-02-24 The Regents of The University of California Lone star virus
US9127276B2 (en) 2013-05-01 2015-09-08 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2014189142A1 (en) 2013-05-24 2014-11-27 味の素株式会社 Morpholino oligonucleotide manufacturing method
EP3656386A1 (en) 2013-06-21 2020-05-27 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
WO2015002971A2 (en) 2013-07-02 2015-01-08 Isis Pharmaceuticals, Inc. Modulators of growth hormone receptor
US10077236B2 (en) 2013-07-15 2018-09-18 The Regents Of The University Of California Azacyclic constrained analogs of FTY720
TWI657819B (en) 2013-07-19 2019-05-01 美商Ionis製藥公司 Compositions for modulating tau expression
TW201536329A (en) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
CA2921839A1 (en) 2013-08-28 2015-03-05 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (pkk) expression
EP3041935A1 (en) 2013-09-05 2016-07-13 Sage Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
EP3808338A1 (en) 2013-09-11 2021-04-21 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
US10059947B2 (en) 2013-09-11 2018-08-28 Synthena Ag Nucleic acids and methods for the treatment of Pompe disease
PL3043827T3 (en) 2013-09-13 2020-03-31 Ionis Pharmaceuticals, Inc. Modulators of complement factor b
US9708360B2 (en) 2013-09-30 2017-07-18 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
US9644037B2 (en) 2013-10-18 2017-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
EP3750997A1 (en) 2013-12-02 2020-12-16 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CA2933590C (en) 2013-12-11 2023-10-03 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
CN111394355A (en) 2013-12-24 2020-07-10 Ionis制药公司 Modulation of angiopoietin-like 3 expression
EP3114214B1 (en) 2014-03-04 2023-11-01 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
WO2015136509A2 (en) 2014-03-14 2015-09-17 Genesis Theranostix Korlatolt Felelossegu Tarsasag Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
CN106103717A (en) 2014-03-19 2016-11-09 Ionis制药公司 For regulating the compositions that ataxin 2 is expressed
SG11201608109TA (en) 2014-04-01 2016-10-28 Ionis Pharmaceuticals Inc Compositions for modulating sod-1 expression
KR102149571B1 (en) 2014-05-01 2020-08-31 아이오니스 파마수티컬즈, 인코포레이티드 Compositions and methods for modulating growth hormone receptor expression
KR102369736B1 (en) 2014-05-01 2022-03-02 아이오니스 파마수티컬즈, 인코포레이티드 Compositions and methods for modulating complement factor b expression
SI3137605T1 (en) 2014-05-01 2021-02-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
HUE052709T2 (en) 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
EP3620178A3 (en) 2014-05-16 2020-07-22 Oregon State University Antisense antibacterial compounds and methods
CA2948568A1 (en) 2014-05-19 2015-11-26 David Greenberg Antisense antibacterial compounds and methods
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US20170182189A1 (en) 2014-05-23 2017-06-29 Genzyme Corporation Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016054259A1 (en) 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2016061487A1 (en) 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
WO2016069694A2 (en) 2014-10-30 2016-05-06 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
WO2016081621A1 (en) 2014-11-18 2016-05-26 Yale University Formulations for targeted release of agents under low ph conditions and methods of use thereof
US10682422B2 (en) 2014-11-18 2020-06-16 Yale University Formulations for targeted release of agents under low pH conditions and methods of use thereof
WO2016086104A1 (en) 2014-11-25 2016-06-02 Ionis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016108930A2 (en) 2014-12-31 2016-07-07 Geller Bruce L Antisense antibacterial compounds and methods
US10793855B2 (en) 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
US10538763B2 (en) 2015-01-16 2020-01-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of DUX4
US9434947B2 (en) 2015-01-20 2016-09-06 Oregon Health & Science University Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
MX2017011010A (en) 2015-02-26 2017-10-20 Ionis Pharmaceuticals Inc Allele specific modulators of p23h rhodopsin.
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
MA41795A (en) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
WO2016164746A1 (en) 2015-04-08 2016-10-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
KR102258516B1 (en) 2015-04-16 2021-05-31 아이오니스 파마수티컬즈, 인코포레이티드 Compositions for modulating c9orf72 expression
CN107921092B (en) 2015-05-19 2022-04-08 萨勒普塔医疗公司 Peptide oligonucleotide conjugates
WO2016195982A2 (en) 2015-06-01 2016-12-08 The Penn State Research Foundation Hepatitis b virus capsid assembly
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
US10851423B2 (en) 2015-06-22 2020-12-01 Proteovista Llc SNP arrays
WO2016207313A1 (en) 2015-06-24 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for detecting protein-protein interactions
US11414657B2 (en) 2015-06-29 2022-08-16 Ionis Pharmaceuticals, Inc. Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
WO2017011276A1 (en) 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
AU2016312530A1 (en) 2015-08-24 2018-03-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
WO2017048620A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
CN108366990B (en) 2015-09-24 2021-09-03 加利福尼亚大学董事会 Synthetic sphingolipid molecules, drugs, methods of their synthesis and methods of treatment
RU2018113709A (en) 2015-09-24 2019-10-30 Айонис Фармасьютикалз, Инк. KRAS EXPRESSION MODULATORS
EP4285912A2 (en) 2015-09-25 2023-12-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating ataxin 3 expression
EP3653216A1 (en) 2015-09-30 2020-05-20 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
CN108271351B (en) 2015-10-08 2021-10-26 Ionis 制药公司 Compounds and methods for modulating angiotensinogen expression
EP3858993A1 (en) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
CN117737124A (en) 2015-10-16 2024-03-22 菲特治疗公司 Platform for inducing and maintaining ground state pluripotency
JP2018531605A (en) 2015-11-06 2018-11-01 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Regulation of apolipoprotein (a) expression
EP4119569A1 (en) 2015-11-06 2023-01-18 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds for use in therapy
US11058709B1 (en) 2015-12-04 2021-07-13 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
US20190030176A1 (en) 2015-12-15 2019-01-31 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA3010084A1 (en) 2015-12-23 2017-06-29 Oregon State University Antisense antibacterial compounds and methods
WO2017112888A1 (en) 2015-12-23 2017-06-29 David Greenberg Antisense antibacterial compounds and methods
CA3006599A1 (en) 2016-01-05 2017-07-13 Ionis Pharmaceuticals, Inc. Methods for reducing lrrk2 expression
WO2017147594A1 (en) 2016-02-26 2017-08-31 Yale University COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS
EP3423106B1 (en) 2016-03-01 2022-07-27 Alexion Pharmaceuticals, Inc. Biodegradable activated polymers for therapeutic delivery
CA3013797A1 (en) 2016-03-09 2017-09-14 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting pmp22 expression
US10961271B2 (en) 2016-03-16 2021-03-30 Ionis Pharmaceuticals, Inc. Methods of modulating KEAP1
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
US20190142856A1 (en) 2016-04-13 2019-05-16 Ionis Pharmaceuticals, Inc. Methods for reducing c9orf72 expression
KR102522059B1 (en) 2016-04-18 2023-04-14 사렙타 쎄러퓨틱스 인코퍼레이티드 Antisense oligomers and methods of their use to treat diseases associated with the acid alpha-glucosidase gene
NZ747685A (en) 2016-04-29 2023-05-26 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
CA3024178A1 (en) 2016-05-24 2017-12-14 Sarepta Therapeutics, Inc. Pharmaceutical composition comprising eteplirsen
MA45362A (en) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc PROCESSES FOR THE PREPARATION OF MORPHOLINO OLIGOMERS OF PHOSPHORODIAMIDATE
WO2017205879A2 (en) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
BR112018074270B1 (en) 2016-05-24 2021-02-02 Sarepta Therapeutics, Inc process for preparing oligomeric compounds as well as said compounds
CN109563114B (en) 2016-05-24 2022-08-12 萨勒普塔医疗公司 Process for preparing oligomers
MA45183A (en) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc PROCESSES FOR THE PREPARATION OF MORPHOLINO OLIGOMERS OF PHOSPHORODIAMIDATE
US10925973B2 (en) 2016-06-15 2021-02-23 University Of Utah Research Foundation Compositions and methods for using albumin-based nanomedicines
EP3471781A4 (en) 2016-06-17 2020-05-06 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
AU2017290231A1 (en) 2016-06-30 2019-02-07 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
IL264216B2 (en) 2016-07-15 2024-04-01 Ionis Pharmaceuticals Inc Compounds and methods for modulation of smn2
WO2018036503A1 (en) 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
AU2017330276B2 (en) 2016-09-20 2022-01-20 The Regents Of The University Of Colorado, A Body Corporate Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
JOP20190065A1 (en) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc Compounds and methods for reducing tau expression
EP3522898A4 (en) 2016-10-06 2020-05-27 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
JOP20190104A1 (en) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn3 expression
EP3548620A4 (en) 2016-12-02 2020-07-22 Cold Spring Harbor Laboratory Modulation of lnc05 expression
US20200085758A1 (en) 2016-12-16 2020-03-19 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
HUE060065T2 (en) 2016-12-19 2023-01-28 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
BR112019012647A2 (en) 2016-12-19 2019-11-19 Sarepta Therapeutics Inc exon jump oligomer conjugates for muscular dystrophy
CN110636866A (en) 2016-12-19 2019-12-31 萨勒普塔医疗公司 Exon skipping oligomer conjugates for muscular dystrophy
WO2018165564A1 (en) 2017-03-09 2018-09-13 Ionis Pharmaceuticals, Inc. Morpholino modified oligomeric compounds
US11771703B2 (en) 2017-03-17 2023-10-03 The Johns Hopkins University Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression
JOP20190215A1 (en) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc Modulators of pcsk9 expression
EP3612215A4 (en) 2017-04-20 2021-05-26 aTyr Pharma, Inc. Compositions and methods for treating lung inflammation
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
NL2019390B1 (en) 2017-08-04 2019-02-21 Univ Leiden Screening Method
WO2019032827A1 (en) 2017-08-09 2019-02-14 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
WO2019036613A1 (en) 2017-08-18 2019-02-21 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
EA201991450A1 (en) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
US20200248178A1 (en) 2017-09-28 2020-08-06 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
JP2020536057A (en) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド Combination therapy to treat muscular dystrophy
US20210145852A1 (en) 2017-09-28 2021-05-20 Sarepta Therapeutics, Inc. Combination Therapies for Treating Muscular Dystrophy
EP3692073A4 (en) 2017-10-03 2021-05-26 Cedars-Sinai Medical Center Methods for targeting the immune checkpoint pd1 pathway for treating pulmonary fibrosis
WO2019079637A2 (en) 2017-10-18 2019-04-25 Sarepta Therapeutics, Inc. Antisense oligomer compounds
TWI809004B (en) 2017-11-09 2023-07-21 美商Ionis製藥公司 Compounds and methods for reducing snca expression
US10953036B2 (en) 2017-11-20 2021-03-23 University Of Georgia Research Foundation, Inc. Compositions and methods of modulating HIF-2A to improve muscle generation and repair
US11725208B2 (en) 2017-12-14 2023-08-15 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
AU2019206731A1 (en) 2018-01-15 2020-07-30 Ionis Pharmaceuticals, Inc. Modulators of DNM2 expression
JP7317029B2 (en) 2018-02-12 2023-07-28 アイオーニス ファーマシューティカルズ， インコーポレーテッド Modified compounds and uses thereof
EP3759127A4 (en) 2018-03-02 2022-03-30 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-beta precursor protein
TW202000199A (en) 2018-03-02 2020-01-01 美商Ionis製藥公司 Modulators of IRF4 expression
CN112105625A (en) 2018-03-07 2020-12-18 赛诺菲 Nucleotide precursors, nucleotide analogs, and oligomeric compounds containing the same
WO2019183440A1 (en) 2018-03-22 2019-09-26 Ionis Pharmaceuticals, Inc. Methods for modulating fmr1 expression
CA3094020A1 (en) 2018-04-11 2019-10-17 Ionis Pharmaceuticals, Inc. Modulators of ezh2 expression
BR112020020957B1 (en) 2018-05-09 2022-05-10 Ionis Pharmaceuticals, Inc Oligomeric compounds, population and pharmaceutical composition thereof and their uses
AU2019266307A1 (en) 2018-05-09 2020-11-19 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ATXN3 expression
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP4219717A3 (en) 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
AU2019287635A1 (en) 2018-06-14 2020-12-17 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing STMN2 expression
SG11202011864XA (en) 2018-06-27 2020-12-30 Ionis Pharmaceuticals Inc Compounds and methods for reducing lrrk2 expression
WO2020023737A1 (en) 2018-07-25 2020-01-30 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn2 expression
US10857174B2 (en) 2018-07-27 2020-12-08 United States Government As Represented By The Department Of Veterans Affairs Morpholino oligonucleotides useful in cancer treatment
TW202020153A (en) 2018-07-27 2020-06-01 美商薩羅塔治療公司 Exon skipping oligomers for muscular dystrophy
EP3830278A4 (en) 2018-08-01 2022-05-25 University of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development
CN113329739A (en) 2018-08-20 2021-08-31 罗贡股份有限公司 Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathy
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
EP3620520A1 (en) 2018-09-10 2020-03-11 Universidad del Pais Vasco Novel target to treat a metabolic disease in an individual
TW202023573A (en) 2018-09-19 2020-07-01 美商Ionis製藥公司 Modulators of pnpla3 expression
WO2020087107A1 (en) 2018-10-31 2020-05-07 The University Of Sydney Compositions and methods for treating viral infections
US11325978B2 (en) 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
TW202028222A (en) 2018-11-14 2020-08-01 美商Ionis製藥公司 Modulators of foxp3 expression
TW202039840A (en) 2018-11-15 2020-11-01 美商伊奧尼斯醫藥公司 Modulators of irf5 expression
US20220025366A1 (en) 2018-11-21 2022-01-27 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing prion expression
EP3894558A1 (en) 2018-12-13 2021-10-20 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
CA3128093A1 (en) 2019-01-31 2020-08-06 Ionis Pharmaceuticals, Inc. Modulators of yap1 expression
WO2020157760A1 (en) 2019-01-31 2020-08-06 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
SG11202108450SA (en) 2019-02-27 2021-09-29 Ionis Pharmaceuticals Inc Modulators of malat1 expression
MA55515A (en) 2019-03-28 2022-02-09 Sarepta Therapeutics Inc METHODS OF TREATING MUSCULAR DYSTROPHY WITH CASIMERSEN
US20220228140A1 (en) 2019-03-29 2022-07-21 Mitsubishi Tanabe Pharma Corporation Compound, method and pharmaceutical composition for modulating expression of dux4
CN117431244A (en) 2019-03-29 2024-01-23 Ionis制药公司 Compounds and methods for modulating UBE3A-ATS
WO2020214763A1 (en) 2019-04-18 2020-10-22 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
WO2020243292A1 (en) 2019-05-28 2020-12-03 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing fus expression
JP2022536495A (en) 2019-06-19 2022-08-17 サレプタ セラピューティクス， インコーポレイテッド How to treat muscular dystrophy
WO2021021673A1 (en) 2019-07-26 2021-02-04 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gfap
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
CA3149421A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
EP4025582A1 (en) 2019-09-05 2022-07-13 Sanofi Oligonucleotides containing nucleotide analogs
WO2021074772A1 (en) 2019-10-14 2021-04-22 Astrazeneca Ab Modulators of pnpla3 expression
US20230057461A1 (en) 2020-01-27 2023-02-23 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021163281A1 (en) 2020-02-12 2021-08-19 Accutar Biotechnology Inc. Antisense oligonucleotides and their use for treating pendred syndrome
CR20220485A (en) 2020-02-28 2022-11-10 Ionis Pharmaceuticals Inc Compounds and methods for modulating smn2
EP4121534A1 (en) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
CA3181546A1 (en) 2020-05-01 2021-11-04 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating atxn1
US20230227824A1 (en) 2020-05-12 2023-07-20 Mitsubishi Tanabe Pharma Corporation Compound, method and pharmaceutical composition for regulating expression of ataxin 3
AU2021293780A1 (en) 2020-06-19 2023-02-02 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
WO2022006134A2 (en) 2020-06-29 2022-01-06 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating plp1
MX2023002480A (en) 2020-08-31 2023-05-18 Univ Yale Compositions and methods for delivery of nucleic acids to cells.
TW202227102A (en) 2020-09-22 2022-07-16 瑞典商阿斯特捷利康公司 Method of treating fatty liver disease
JP2023546199A (en) 2020-10-20 2023-11-01 サノフイ Novel ligands for asialoglycoprotein receptors
EP4136092A4 (en) 2020-11-18 2023-10-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
US20240002853A1 (en) 2020-11-23 2024-01-04 Alpha Anomeric Sas Nucleic acid duplexes
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
WO2022140535A1 (en) 2020-12-23 2022-06-30 Sarepta Therapeutics, Inc. Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
CA3216839A1 (en) 2021-04-30 2022-11-03 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
WO2022235929A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
AU2022293556A1 (en) 2021-06-18 2024-01-18 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ifnar1 expression
TW202333748A (en) 2021-07-19 2023-09-01 美商艾拉倫製藥股份有限公司 Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
WO2023034870A2 (en) 2021-09-01 2023-03-09 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing dmpk expression
WO2023034515A2 (en) 2021-09-03 2023-03-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
WO2023055774A1 (en) 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
WO2023086295A2 (en) 2021-11-10 2023-05-19 University Of Rochester Antisense oligonucleotides for modifying protein expression
WO2023086292A2 (en) 2021-11-10 2023-05-19 University Of Rochester Gata4-targeted therapeutics for treatment of cardiac hypertrophy
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023146807A1 (en) 2022-01-25 2023-08-03 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2023159189A1 (en) 2022-02-18 2023-08-24 Yale University Branched poly(amine-co-ester) polymers for more efficient nucleic expression
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
WO2023178230A1 (en) 2022-03-17 2023-09-21 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
WO2023205451A1 (en) 2022-04-22 2023-10-26 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
WO2024015924A2 (en) 2022-07-15 2024-01-18 Entrada Therapeutics, Inc. Hybrid oligonucleotides
WO2024050261A1 (en) 2022-08-29 2024-03-07 University Of Rochester Antisense oligonucleotide-based anti-fibrotic therapeutics
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123473A2 (en) * 1983-04-25 1984-10-31 Fujisawa Pharmaceutical Co., Ltd. Morpholine derivatives, processes for the preparation thereof, the use thereof and pharmaceutical compositions containing them
WO1986005519A1 (en) * 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
WO1991018898A1 (en) * 1990-06-01 1991-12-12 Nippon Shinyaku Co., Ltd. Nucleic acid homolog
WO1992021353A1 (en) * 1991-05-31 1992-12-10 Genta Incorporated Compositions and delivery systems for transdermal administration of neutral oligomers
US5378841A (en) * 1989-12-20 1995-01-03 Antivirals Inc. Alpha-morpholino ribonucleoside derivatives and polymers thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405938A (en) * 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5217866A (en) * 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5166315A (en) * 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
US5186444A (en) * 1991-04-11 1993-02-16 Heidelberg Harris Gmbh Method and device for assuring orderly web travel in a folder by punching holes in a paper width direction

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0123473A2 (en) * 1983-04-25 1984-10-31 Fujisawa Pharmaceutical Co., Ltd. Morpholine derivatives, processes for the preparation thereof, the use thereof and pharmaceutical compositions containing them
WO1986005519A1 (en) * 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
WO1986005518A1 (en) * 1985-03-15 1986-09-25 James Summerton Stereoregular polynucleotide-binding polymers
EP0639582A2 (en) * 1985-03-15 1995-02-22 Antivirals Inc. Polynucleotide assay reagent and method
US5378841A (en) * 1989-12-20 1995-01-03 Antivirals Inc. Alpha-morpholino ribonucleoside derivatives and polymers thereof
WO1991018898A1 (en) * 1990-06-01 1991-12-12 Nippon Shinyaku Co., Ltd. Nucleic acid homolog
WO1992021353A1 (en) * 1991-05-31 1992-12-10 Genta Incorporated Compositions and delivery systems for transdermal administration of neutral oligomers

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009509A3 (en) * 2000-07-31 2003-05-15 Universty Of Minessota Inhibition of gene expression using polynucleotide analogues
US6867349B2 (en) 2000-07-31 2005-03-15 Regents Of The University Of Minnesota Inhibition of gene expression using polynucleotide analogues

Also Published As

Publication number Publication date
AU2438595A (en) 1995-12-05
US5506337A (en) 1996-04-09
US5698685A (en) 1997-12-16

Similar Documents

Publication Publication Date Title
US5506337A (en) Morpholino-subunit combinatorial library and method
US5142047A (en) Uncharged polynucleotide-binding polymers
US5235033A (en) Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5217866A (en) Polynucleotide assay reagent and method
US5034506A (en) Uncharged morpholino-based polymers having achiral intersubunit linkages
US5635598A (en) Selectively cleavabe linners based on iminodiacetic acid esters for solid phase peptide synthesis
JP4065555B2 (en) Coded combinatorial chemistry library
EP0535155B1 (en) Libraries of modified peptides with protease resistance
ES2204921T3 (en) SOLID PHASE LIBRARIES CODED, TOPOLOGICALLY SECREGATED.
AU697920B2 (en) Soluble combinatorial libraries
US5470974A (en) Uncharged polynucleotide-binding polymers
US5378841A (en) Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5037882A (en) Synthesis of oligonucleotide analogs
JPH06506945A (en) peptide nucleic acid
AU678460B2 (en) Preparation and screening of diverse peptide (or other polymer) libraries
SK281490B6 (en) Bio-oligomer library, method of synthesis thereof, and method of determining sequence of bio-oligomer ligands
EP1206451A1 (en) Cyclopropylindole derivatives
CA2131620A1 (en) A dna transporter system and method of use
WO1993010161A1 (en) Polymer reversal on solid surfaces
CA2241222C (en) Linker arm for solid support oligonucleotide synthesis and process for production thereof
Rapp PEG grafted polystyrene tentacle polymers: Physicochemical properties and application in chemical synthesis
Lescrinier et al. DNA‐Binding Ligands from Peptide Libraries Containing Unnatural Amino Acids
Han et al. Investigations of azapeptides as mimetics of Leu-enkephalin
WO2006056009A1 (en) Peptides having adhesive properties for use in solid phase assay and chemical polymer synthesis regimes.
EP0832127A2 (en) Synthetic peptides and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA